<html xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List href="basagrisi_dosyalar/filelist.xml">
<title>BA&#350; A&#286;RISI</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:GrammarState>Clean</w:GrammarState>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h2
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h3
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:14.0pt;
	font-family:"Times New Roman";}
h4
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:14.2pt;
	margin-bottom:.0001pt;
	text-indent:-14.2pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h6
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:6;
	font-size:12.0pt;
	font-family:"Times New Roman";}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	color:maroon;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:8;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	color:maroon;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:14.2pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:9;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	color:maroon;
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:14.2pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:14.2pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	color:maroon;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
pre
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:151147570;
	mso-list-template-ids:-1766057142;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l1
	{mso-list-id:574752019;
	mso-list-template-ids:-961543084;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l2
	{mso-list-id:783115005;
	mso-list-template-ids:-1035803764;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l3
	{mso-list-id:1094400061;
	mso-list-template-ids:-1951514910;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l4
	{mso-list-id:1305356777;
	mso-list-template-ids:952301428;}
@list l4:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5
	{mso-list-id:2091149166;
	mso-list-template-ids:1977793152;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><b><span
lang=TR style='font-size:16.0pt;font-family:Tahoma;mso-ansi-language:TR'>BA&#350;A&#286;RISI
</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
14.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bet�l Baykan,
Halil Atilla &#304;driso&#287;lu</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Son g�ncelleme tarihi: 30.06.2009</span></p>

</div>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;nsanlar&#305; etkileyen
a&#287;r&#305;l&#305; durumlardan en yayg&#305;n olan&#305;
ba&#351;a&#287;r&#305;s&#305;d&#305;r. Ba&#351;a&#287;r&#305;s&#305; n�rolojik
hastal&#305;klar&#305;n yan&#305; s&#305;ra sistemik hastal&#305;klara&nbsp;da
e&#351;lik edebilen bir semptomdur. Ba&#351;a&#287;r&#305;s&#305;yla
hayat&#305; boyunca tan&#305;&#351;mam&#305;&#351; insan yok gibidir ve
toplumda en s&#305;k g�r�len belirtilerden bir tanesidir. Bir
�al&#305;&#351;mam&#305;za g�re yurdumuzda n�roloji polikliniklerine
ba&#351;vuran hastalar&#305;n toplam 2/3��n�n ba&#351;a&#287;r&#305;s&#305;
vard&#305;r ve 1/3�� sadece ba&#351;a&#287;r&#305;s&#305; i�in
ba&#351;vurmaktad&#305;r. Bu hastalar&#305;n en az 1/4 kadar&#305;nda
&#351;iddetli ve ciddi k&#305;s&#305;tl&#305;l&#305;k yapan migren oldu&#287;u
g�sterilmi&#351;tir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tan&#305;y&#305; kolayla&#351;t&#305;rmak i�in ve etyolojik
yakla&#351;&#305;mla ba&#351;a&#287;r&#305;s&#305;n&#305; daha iyi ele almak
i�in de&#287;i&#351;ik ba&#351;a&#287;r&#305;s&#305; tiplerini
s&#305;n&#305;flamak esast&#305;r. Ba&#351;a&#287;r&#305;s&#305;n&#305;n
etyolojisi, s&#305;kl&#305;&#287;&#305;, &#351;iddeti ve ya&#351;amsal
sonu�lar&#305; �ok b�y�k farkl&#305;l&#305;klar g�sterebilir ve
ba&#351;ar&#305;l&#305; bir tedavinin ilk basama&#287;&#305; do&#287;ru ve
�zg�n bir tan&#305;d&#305;r. Hastalar&#305;n �o&#287;u
ba&#351;a&#287;r&#305;lar&#305;n&#305;n altta yatan ciddi bir sorunun belirtisi
oldu&#287;undan korkar. Fakat �o&#287;unda iyi seyirli ancak uzun y&#305;llar
boyu ataklarla s�ren bir s�re� s�z konusudur. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>T�m d�nyada kullan&#305;lan ve genel kabul g�ren bir s&#305;n&#305;flamaya
sahip olmak t&#305;bb&#305;n her dal&#305; i�in �nemlidir.
Ba&#351;a&#287;r&#305;s&#305; bozukluklar&#305; hakk&#305;nda �ok fazla �n
yarg&#305; oldu&#287;undan bu durum ba&#351;a&#287;r&#305;s&#305; i�in
�zellikle do&#287;rudur. <i>Uluslararas&#305; Ba&#351;a&#287;r&#305;s&#305; </i>Derne&#287;i
<i>(International Headache Society IHS)</i> ilk olarak 1988 y&#305;l&#305;nda
ba&#351;a&#287;r&#305;lar&#305;n&#305; ayr&#305;nt&#305;l&#305; &#351;ekilde
s&#305;n&#305;flamaya y�nelik bir �al&#305;&#351;ma yapm&#305;&#351;t&#305;r.
Ba&#351;a&#287;r&#305;s&#305; tan&#305;s&#305;nda standart olu&#351;turan ve
�zellikle klinik ara&#351;t&#305;rmalarda kullan&#305;lmas&#305; ama�lanan bu
ilk s&#305;n&#305;flama sistemi t�m d�nyada yayg&#305;n bir bilimsel kabul
g�rm�&#351; ve 2004�de bir revizyonu yap&#305;lm&#305;&#351;t&#305;r. Her iki
s&#305;n&#305;flama T�rk�e de dahil olmak �zere yirmiden fazla dile �evrilmi&#351;
ve d�nyadaki doktorlar&#305;n �o&#287;u i�in ula&#351;&#305;labilir duruma
gelmi&#351;tir. &nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>IHS s&#305;n&#305;flama sisteminde ba&#351;a&#287;r&#305;lar&#305;
ba&#351;l&#305;ca iki geni&#351; grupta ele al&#305;nmaktad&#305;r: primer
ba&#351;a&#287;r&#305;s&#305; bozukluklar&#305; (1.-4. Kategoriler) ve sekonder
ba&#351;a&#287;r&#305;s&#305; bozukluklar&#305; (5.-12. Kategoriler) (<b>Tablo
1A ve B</b>). Sekonder ba&#351;a&#287;r&#305;s&#305; bozukluklar&#305;nda
ba&#351;a&#287;r&#305;s&#305; beyin t�m�r�, inme veya metabolik bozukluk gibi
bir ba&#351;ka hastal&#305;&#287;a ba&#287;l&#305;d&#305;r ve IHS kriterleri bu
grup ba&#351;a&#287;r&#305;lar&#305;n&#305; etyolojik nedenlerine dayanarak
s&#305;n&#305;flayan bir kriterler sistemi sa&#287;lamaktad&#305;r. Primer
ba&#351;a&#287;r&#305;s&#305;nda ise altta yatan saptanabilir ba&#351;ka bir
neden yoktur ve IHS kriterleri ba&#351;a&#287;r&#305;lar&#305;n&#305; belirti
�zelliklerine g�re s&#305;n&#305;flayan tan&#305;mlay&#305;c&#305; bir sistem
ortaya koymu&#351;tur. IHS kriterleri D�nya Sa&#287;l&#305;k �rg�t� (WHO)
taraf&#305;ndan kabul g�rm�&#351; ve bu sistemin ana hatlar&#305;
Uluslararas&#305; Hastal&#305;k S&#305;n&#305;flamas&#305;�na (ICD-10) da
al&#305;nm&#305;&#351;t&#305;r.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>IHS s&#305;n&#305;flamas&#305;n&#305; bu b�l�m�n s&#305;n&#305;rlar&#305;
i�inde t�m�yle ele almak m�mk�n olmad&#305;&#287;&#305;ndan �nce tan&#305;sal
yakla&#351;&#305;m, ard&#305;ndan baz&#305; s&#305;k
kar&#351;&#305;la&#351;&#305;lan primer ba&#351;a&#287;r&#305;lar&#305; b�l�m
i�inde k&#305;saca tart&#305;&#351;&#305;lacakt&#305;r; &nbsp;sekonder
ba&#351;a&#287;r&#305;s&#305; yapan n�rolojik hastal&#305;klar i�in
kitab&#305;n ilgili b�l�mlerine bak&#305;lmal&#305;d&#305;r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<b><span lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tablo 1A. </span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Uluslararas&#305;
Ba&#351;a&#287;r&#305;s&#305; Toplulu&#287;u (IHS) 2004 s&#305;n&#305;flama
sisteminde&nbsp; primer ba&#351;a&#287;r&#305;s&#305; bozukluklar&#305;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren</span></u><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Auras&#305;z migren</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Aural&#305; migren (nonmigren ba&#351;a&#287;r&#305;l&#305; ve
  ba&#351;a&#287;r&#305;s&#305;z aura, ailesel ve sporadik hemiplejik migren ve
  baziler tip migren gibi alt gruplar&#305; vard&#305;r)</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>S&#305;kl&#305;kla migren �nc�l� olan �ocukluk �a&#287;&#305; periyodik
  sendromlar&#305; (siklik kusmalar, abdominal migren, �ocukluk
  �a&#287;&#305;n&#305;n iyi huylu paroksizmal vertigosu gibi alt gruplar&#305;
  vard&#305;r) </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Retinal migren</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.5.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Migren komplikasyonlar&#305; (kronik migren, status migrenozus,
  &#305;srarl&#305; aura, migren�z infarkt, migrenin tetikledi&#287;i n�bet
  gibi alt gruplar&#305; vard&#305;r)</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.6.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Olas&#305; migren</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gerilim tipi ba&#351;a&#287;r&#305;s&#305; </span></u><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(perikranyal
  duyarl&#305;l&#305;&#287;&#305;n e&#351;lik etti&#287;i ve etmedi&#287;i
  tipler)</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Seyrek epizodik gerilim tipi ba&#351;a&#287;r&#305;s&#305;</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>S&#305;k epizodik gerilim tipi ba&#351;a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kronik gerilim tipi ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Olas&#305; gerilim tipi ba&#351;a&#287;r&#305;s&#305;</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>K�me ba&#351;a&#287;r&#305;s&#305; ve kronik
  paroksizmal hemikranya</span></u><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>K�me ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Paroksizmal hemikranya</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Konjunktival kanlanma ve ya&#351;armal&#305; k&#305;sa s�reli tek
  yanl&#305; nevraljiform ba&#351;a&#287;r&#305;s&#305; (SUNCT)</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Olas&#305; trigeminal otonomik ba&#351;a&#287;r&#305;s&#305; </span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Di&#287;er primer ba&#351;a&#287;r&#305;lar&#305;</span></u></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Primer saplan&#305;c&#305; ba&#351;a&#287;r&#305;s&#305;</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Primer �ks�r�k ba&#351;a&#287;r&#305;s&#305;</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Primer egzersiz ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Cinsel etkinli&#287;e e&#351;lik eden primer
  ba&#351;a&#287;r&#305;s&#305; (preorgazmik, orgazmik)</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.5.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Hipnik ba&#351;a&#287;r&#305;s&#305;</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.6.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Primer g�kg�r�lt�s� ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.7.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>S�re&#287;en yar&#305;m ba&#351;a&#287;r&#305;s&#305; (Hemikranya
  kontinua)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.8.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Yeni g�nl�k &#305;srarl&#305; ba&#351;a&#287;r&#305;s&#305;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:12.0pt'><b><span lang=TR style='font-size:
14.0pt;font-family:Tahoma;mso-ansi-language:TR'>BA&#350;A&#286;RILI HASTAYA
TANISAL YAKLA&#350;IM</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ba&#351;a&#287;r&#305;s&#305; bulunan bir hasta de&#287;erlendirilirken, <i>ilk
yap&#305;lmas&#305; gereken bir sekonder ba&#351;a&#287;r&#305;s&#305;
bozuklu&#287;unun d&#305;&#351;lanmas&#305;d&#305;r</i>. Bu karar �yk�ye, genel
t&#305;bbi ve n�rolojik muayenelere dayand&#305;r&#305;l&#305;r. E&#287;er
ku&#351;kulu �zellikler mevcutsa, tan&#305; i�in baz&#305; testlerin
yap&#305;lmas&#305; gerekli olabilir. <i>Sekonder ba&#351;a&#287;r&#305;s&#305;
bozukluklar&#305; d&#305;&#351;land&#305;&#287;&#305;nda, yap&#305;lmas&#305;
gereken primer ba&#351;a&#287;r&#305;s&#305; bozuklu&#287;unun do&#287;ru
tan&#305;s&#305;n&#305;n konmas&#305;</i>d&#305;r. Ayn&#305; hastada birden
fazla ba&#351;a&#287;r&#305;s&#305; varsa, her biri ayr&#305; ayr&#305;
tan&#305; al&#305;r. �lkemizde yap&#305;lan prevalans
�al&#305;&#351;malar&#305;nda migren i�in rastlanma s&#305;kl&#305;&#287;&#305;
%16.4 iken gerilim tipi ba&#351;a&#287;r&#305;s&#305;n&#305;n
s&#305;kl&#305;&#287;&#305; %31.7 olarak belirlenmi&#351;tir. Bu denli s&#305;k
g�r�len hastal&#305;klara rastlant&#305;sal olarak ba&#351;ka
hastal&#305;klar&#305;n da e&#351;lik etme olas&#305;l&#305;&#287;&#305;
do&#287;al olarak y�ksektir. Bu nedenle, ba&#351;a&#287;r&#305;s&#305;
tan&#305;mlayan bir hastada daha �nceden tan&#305; konmu&#351; bir primer
ba&#351;a&#287;r&#305;s&#305; olsa bile, yeni tan&#305;mlad&#305;&#287;&#305;
ba&#351;a&#287;r&#305;s&#305; hakk&#305;nda, bu ba&#351;a&#287;r&#305;s&#305;
�zelliklerinin �nceki a&#287;r&#305;lar&#305;yla uyumlu olup
olmad&#305;&#287;&#305;n&#305; anlamaya y�nelik olarak tekrar bilgi almak ve
hastay&#305; muayene etmek gerekir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 1B.</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Uluslararas&#305; Ba&#351;a&#287;r&#305;s&#305; Toplulu&#287;u (IHS) 2004
s&#305;n&#305;flama sisteminde sekonder ba&#351;a&#287;r&#305;s&#305;
bozukluklar&#305;&nbsp; </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>5.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kafa travmas&#305; ile ili&#351;kili ba&#351;a&#287;r&#305;s&#305;</span></u><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-align:justify;text-indent:
  -18.0pt'><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.1&nbsp;&nbsp;&nbsp;&nbsp;
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Travma sonras&#305; akut
  ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-align:justify;text-indent:
  -18.0pt'><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.2&nbsp;&nbsp;&nbsp;&nbsp;
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Travma sonras&#305; kronik
  ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-align:justify;text-indent:
  -18.0pt'><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.3&nbsp;&nbsp;&nbsp;&nbsp;
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kam�&#305; darbesi tipi &nbsp;yaralanmaya
  ba&#287;lanan akut ba&#351;a&#287;r&#305;s&#305; (whiplash: ani ivmelenme/
  yava&#351;lama travmas&#305;)</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-align:justify;text-indent:
  -18.0pt'><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.4&nbsp;&nbsp;&nbsp;
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kam�&#305; darbesi tipi&nbsp;
  yaralanmaya ba&#287;lanan kronik ba&#351;a&#287;r&#305;s&#305;</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-align:justify;text-indent:
  -18.0pt'><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.5&nbsp;&nbsp;&nbsp;
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Travmatik intrakranyal hematoma
  ba&#287;l&#305; ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  8.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  5.6.&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Di&#287;er
  ba&#351; ve/veya boyun travmas&#305;na ba&#287;lanan ba&#351;a&#287;r&#305;s&#305;</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  8.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  5.7.&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kranyotomi
  sonras&#305; ba&#351;a&#287;r&#305;s&#305;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kranyal ya da servikal damarsal hastal&#305;klara ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305;</span></u></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&#304;skemik inme ya da ge�ici iskemik ata&#287;a ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Travmatik olmayan kafa i�i kanamaya ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Y&#305;rt&#305;lmam&#305;&#351; damarsal malformasyona ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Arterite ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.5.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Karotis ya da vertebral arter a&#287;r&#305;s&#305; (diseksiyon ve
  giri&#351;im sonras&#305;)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.6.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Beyin ven trombozuna ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.7.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Di&#287;er kafa i�i damarsal bozuklu&#287;a ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; (CADASIL, MELAS vb)</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Damar-d&#305;&#351;&#305; intrakranyal hastal&#305;klarla ili&#351;kili
  ba&#351;a&#287;r&#305;s&#305;</span></u><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Beyin omurilik s&#305;v&#305;s&#305; (BOS) bas&#305;n� y�ksekli&#287;ine
  ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>D�&#351;�k beyin omurilik s&#305;v&#305;s&#305; bas&#305;nc&#305;na
  ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&#304;nfeksiyon olmayan inflamatuvar hastal&#305;&#287;a ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&#304;ntrakranyal neoplazmalara ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; </span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.5.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&#304;ntratekal injeksiyonlara ba&#287;l&#305;
  ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.6.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Epileptik n�betlere ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.7.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Chiari malformasyon tip 1e ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>7.8.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Ge�ici ba&#351;a&#287;r&#305;s&#305; ve BOS lenfositozlu n�rolojik
  defisit sendromu (HaNDL)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>8.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Madde kullan&#305;m&#305; veya yoksunlu&#287;u ile ili&#351;kili
  ba&#351;a&#287;r&#305;s&#305;</span></u><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>8.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Akut madde kullan&#305;m&#305; ile ili&#351;kili
  ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>8.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&#304;la� a&#351;&#305;r&#305; kullan&#305;m&#305;
  ba&#351;a&#287;r&#305;s&#305; (&#304;AB)</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>8.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kronik ila� kullan&#305;m&#305;na ba&#287;lanan bir ters olay olarak
  ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>8.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Madde kesilmesine ba&#287;lanan ba&#351;a&#287;r&#305;s&#305;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>9.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><u><span lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&#304;nfeksiyona ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span></u></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>9.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kafa i�i infeksiyona ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>9.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sistemik infeksiyona ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>9.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>HIV/AIDS�e ba&#287;lanan ba&#351;a&#287;r&#305;s&#305;</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>9.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&#304;nfeksiyon sonras&#305; kronik ba&#351;a&#287;r&#305;s&#305;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>10.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp; </span><u><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>Homeostaz
  bozuklu&#287;una ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span></u></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>10.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Hipoksi ve /veya hiperkapniye ba&#287;lanan ba&#351;a&#287;r&#305;s&#305;
  </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>10.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Dializ ba&#351;a&#287;r&#305;s&#305;</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>10.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Arteriyel hipertansiyona ba&#287;lanan ba&#351;a&#287;r&#305;s&#305;</span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>10.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Hipotiroidizme ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>10.5.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A�l&#305;&#287;a ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>10.6.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kardiak ba&#351;a&#287;r&#305;s&#305; ve di&#287;er</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>11.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp; </span><u><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kafatas&#305;,
  boyun, g�zler, kulaklar, burun, sin�sler, di&#351;ler, a&#287;&#305;z veya
  di&#287;er y�z ve kafa yap&#305;lar&#305;na ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; veya y�z a&#287;r&#305;s&#305;</span></u><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>11.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kafa kemi&#287;i bozuklu&#287;una ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; </span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>11.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Boyun hastal&#305;klar&#305;na ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; </span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>11.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>G�z bozuklu&#287;una ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>11.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kulak bozuklu&#287;una ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>11.5.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Rinosin�zite ba&#287;lanan ba&#351;a&#287;r&#305;s&#305;</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>11.6.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Di&#351;ler, �ene veya ili&#351;kili yap&#305;lar&#305;n bozuklu&#287;una
  ba&#287;lanan ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>11.7.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;Temporomandib�ler eklem hastal&#305;&#287;&#305;na ba&#287;lanan
  ba&#351;a&#287;r&#305;s&#305; veya y�z a&#287;r&#305;s&#305; ve di&#287;er</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;mso-yfti-lastrow:yes'>
  <td width=619 valign=top style='width:464.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>12.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp; </span><u><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>Psikiyatrik
  hastal&#305;klara ba&#287;lanan ba&#351;a&#287;r&#305;s&#305; (12.1
  Somatizasyon bozuklu&#287;u ve 12.2 Psikotik bozuklu&#287;a ba&#287;l&#305;)</span></u><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp; </span><u><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma;mso-ansi-language:TR'>B�L�M
  C: Kranyal nevraljiler ve y�z a&#287;r&#305;s&#305;n&#305;n santral nedenleri</span></u><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.1.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Trigeminal nevralji</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.2.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Glossofaringeal nevralji </span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.3.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Nervus intermedius nevraljisi</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.4.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Superior laringeal nevralji</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.5.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Nazosilier nevralji </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.6.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Supraorbital nevralji</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.7.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Di&#287;er terminal dal nevraljileri</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.8.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Oksipital nevralji </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.9.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Boyun-dil sendromu </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.10.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>D&#305;&#351;tan bas&#305; ba&#351;a&#287;r&#305;s&#305;</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.11.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>So&#287;uk uyar&#305;s&#305; ba&#351;a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.12.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kranyal sinirlerin veya �st servikal k�klerin yap&#305;sal lezyonlar
  taraf&#305;ndan kompresyonu, irritasyonu veya distorsiyonu </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.13.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Optik n�rit</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.14.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Ok�ler diyabetik n�ropati </span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.15.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Herpes zostere ba&#287;lanan ba&#351; veya y�z a&#287;r&#305;s&#305; </span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.16.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Tolosa-Hunt sendromu </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.17.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Oftalmoplejik migren</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:39.6pt;text-indent:-21.6pt'><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>13.18.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Y�z a&#287;r&#305;s&#305;n&#305;n santral nedenleri</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;l&#305; Hastada �yk�
Al&#305;nmas&#305;</span></b></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ba&#351;a&#287;r&#305;l&#305; hastalar&#305;n ele al&#305;nmas&#305;nda ve
tan&#305;s&#305;n&#305;n konulmas&#305;nda en �nemli olan <i>ba&#351;a&#287;r&#305;s&#305;
�yk�s�n�n tam olarak al&#305;nmas&#305;</i>d&#305;r.
Ba&#351;a&#287;r&#305;s&#305; hastalar&#305;n&#305;n �o&#287;unda t&#305;bbi ve
n�rolojik muayeneler normal bulunur. Bu nedenle, do&#287;ru tan&#305; i�in
elimizdeki en yararl&#305; gere� ayr&#305;nt&#305;l&#305; �yk�d�r.
Ba&#351;a&#287;r&#305;s&#305; �yk�s� hastan&#305;n
ba&#351;a&#287;r&#305;lar&#305;n&#305;n ayr&#305;nt&#305;l&#305; bir tablosunu
�izmeli, ayr&#305;ca varsa tan&#305;y&#305; veya tedaviyi etkileyebilecek di&#287;er
t&#305;bbi durumlar hakk&#305;nda da bilgi sa&#287;lamal&#305;d&#305;r</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ba&#351;a&#287;r&#305;s&#305; �yk�s�nde a&#351;a&#287;&#305;daki
�e&#351;itli parametreler mutlaka sorulmal&#305;d&#305;r:</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;s&#305;n&#305;n
     tipi ve karakteri</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;lang&#305;c&#305;</span></li>
 <li class=MsoNormal style='page-break-after:avoid;mso-list:l2 level1 lfo1;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>S&#305;kl&#305;&#287;&#305;</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Yeri</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#350;iddeti </span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Aura ve prodromal
     belirtilerin olup olmamas&#305;</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>E&#351;lik eden belirtiler
     olup olmamas&#305; (bulant&#305;, kusma , foto-,fono-,osmofobi gibi)</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Presipite eden
     fakt�rler olup olmamas&#305;</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Uyku d�zeni</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Emosyonel
     fakt�rler</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Aile �yk�s�</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Medikal, cerrahi
     veya do&#287;um �yk�s�</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Alerji,
     ta&#351;&#305;t tutmas&#305; vb �zge�mi&#351; �yk�s�</span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�nceki
     medikasyonlar ve tedaviler</span></li>
</ul>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&#304;lk de&#287;erlendirme s&#305;ras&#305;nda sekonder
ba&#351;a&#287;r&#305;s&#305; bozuklu&#287;u
olas&#305;l&#305;&#287;&#305;n&#305; d�&#351;�nd�recek a&#351;a&#287;&#305;daki
<b>�</b><i>ba&#351;a&#287;r&#305;s&#305; alarm belirtileri</i><b>� </b>g�zden
ge�irmelidir: (<b>Tablo 2</b>)</span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;lk veya
     hayat&#305;n&#305;n en &#351;iddetli ba&#351;a&#287;r&#305;s&#305;</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Akut
     ba&#351;lang&#305;� </span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>S&#305;kl&#305;&#287;&#305;
     veya &#351;iddeti giderek artan ba&#351;a&#287;r&#305;s&#305; </span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Yeni ba&#351;layan
     ba&#351;a&#287;r&#305;s&#305;:</span></li>
 <ul style='margin-top:0cm' type=circle>
  <li class=MsoNormal style='mso-list:l0 level2 lfo2;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanserli&nbsp;
      hastada</span></li>
  <li class=MsoNormal style='mso-list:l0 level2 lfo2;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>50 ya&#351;
      �zerinde</span></li>
  <li class=MsoNormal style='mso-list:l0 level2 lfo2;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kafa
      travmas&#305;&#305;n ard&#305;ndan</span></li>
 </ul>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Egzersizle
     birlikte ortaya �&#305;kan ba&#351;a&#287;r&#305;s&#305; (�ks�r�k, efor,
     cinsel aktivite ile belirmesi )</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Belirli bir
     &#351;ekle uymayan ba&#351;a&#287;r&#305;s&#305;</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedaviye
     yan&#305;t vermeyen ba&#351;a&#287;r&#305;s&#305;</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sabah olan veya
     uykudan uyand&#305;ran ba&#351;a&#287;r&#305;s&#305;</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hi� yer
     de&#287;i&#351;tirmeyen ba&#351;a&#287;r&#305;s&#305;</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Al&#305;&#351;&#305;lmad&#305;k,
     uzun s�ren veya sebat eden aura</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Eski
     ba&#351;a&#287;r&#305;s&#305;&#305;n �zelliklerinde a�&#305;klanamayan
     de&#287;i&#351;iklik</span></li>
 <li class=MsoNormal style='mso-list:l0 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>N�rolojik
     ba&#351;ka yak&#305;nmalar&#305;n veya bulgular&#305;n e&#351;lik
     etti&#287;i ba&#351;a&#287;r&#305;s&#305; (ate&#351;, ense sertli&#287;i,
     papil�dem, g�rme kayb&#305;, n�bet, lateralizasyon bulgular&#305;,
     &#351;a&#351;k&#305;nl&#305;k, uyku hali gibi)</span></li>
</ul>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<b><span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 2:
Ba&#351;a&#287;r&#305;s&#305;n&#305;n de&#287;erlendirilmesinde baz&#305; alarm
belirtileri ve bulgular&#305; ile inceleme &#351;emalar&#305;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=671
 style='width:503.05pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=185 valign=top style='width:138.5pt;border:inset 1.0pt;padding:
  0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>BA&#350;A&#286;RISI</span></p>
  </td>
  <td width=236 valign=top style='width:176.85pt;border:inset 1.0pt;border-left:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>AYIRICI TANI</span></p>
  </td>
  <td width=250 valign=top style='width:187.7pt;border:inset 1.0pt;border-left:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>OLASI
  &#304;NCELEME</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=185 valign=top style='width:138.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>50 ya&#351;&#305;ndan sonra ortaya �&#305;kan
  ba&#351;a&#287;r&#305;s&#305;</span></p>
  </td>
  <td width=236 valign=top style='width:176.85pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Temporal arterit, yer kaplayan lezyon (YKL)</span></p>
  </td>
  <td width=250 valign=top style='width:187.7pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Sedimentasyon, n�rolojik g�r�nt�leme</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=185 valign=top style='width:138.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ani ba&#351;layan ba&#351;a&#287;r&#305;s&#305;</span></p>
  </td>
  <td width=236 valign=top style='width:176.85pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Subaraknoid kanama, hipofiz apopleksisi, AVM ya da
  YKL�nin i�ine kanama</span></p>
  </td>
  <td width=250 valign=top style='width:187.7pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rolojik g�r�nt�leme y�ntemleri,</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Lomber ponksiyon</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=185 valign=top style='width:138.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;s&#305;n&#305;n giderek artan
  �zellik g�stermesi</span></p>
  </td>
  <td width=236 valign=top style='width:176.85pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>YKL, subdural hematom, ila�lar&#305;n
  a&#351;&#305;r&#305; kullan&#305;m&#305;</span></p>
  </td>
  <td width=250 valign=top style='width:187.7pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rolojik g�r�nt�leme y�ntemleri,</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;la�lar&#305;n g�zden ge�irilmesi</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=185 valign=top style='width:138.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Sistemik hastal&#305;kla birlikte
  ba&#351;a&#287;r&#305;s&#305; (ate&#351;, ense sertli&#287;i, d�k�nt�ler)</span></p>
  </td>
  <td width=236 valign=top style='width:176.85pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Menenjit, ensefalit, sistemik infeksiyon, kollajen
  vask�ler hastal&#305;k</span></p>
  </td>
  <td width=250 valign=top style='width:187.7pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rolojik g�r�nt�leme y�ntemleri,</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Lomber ponksiyon</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=185 valign=top style='width:138.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kanser ya da HIV�li bir hastada yeni ba&#351;layan
  ba&#351;a&#287;r&#305;s&#305;</span></p>
  </td>
  <td width=236 valign=top style='width:176.85pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Menenjit (kronik ya da karsinomatozis), beyin abseleri
  (toksoplasma), metastazlar</span></p>
  </td>
  <td width=250 valign=top style='width:187.7pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rolojik g�r�nt�leme y�ntemleri</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Lomber ponksiyon</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=185 valign=top style='width:138.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Lateralizan n�rolojik semptomlar</span></p>
  </td>
  <td width=236 valign=top style='width:176.85pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>YKL, AVM, inme, kollajen vask�ler hastal&#305;k
  (antifosfolipid antikorlar&#305; i�eren)</span></p>
  </td>
  <td width=250 valign=top style='width:187.7pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rolojik g�r�nt�leme y�ntemleri</span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kollajen vask�ler hastal&#305;klar&#305;n
  ara&#351;t&#305;r&#305;lmas&#305;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;mso-yfti-lastrow:yes'>
  <td width=185 valign=top style='width:138.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Papil�dem</span></p>
  </td>
  <td width=236 valign=top style='width:176.85pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>YKL, idyopatik intrakranyal hipertansiyon, menenjit</span><span
  lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=250 valign=top style='width:187.7pt;border-top:none;border-left:
  none;border-bottom:inset 1.0pt;border-right:inset 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�rolojik g�r�nt�leme y�ntemleri</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Lomber ponksiyon</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;text-indent:14.2pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:12.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu t�r ku&#351;kuland&#305;r&#305;c&#305; durumlar
yoksa normal n�rolojik muayenesi olan bir hastada primer
ba&#351;a&#287;r&#305;s&#305; tan&#305;s&#305; i�in g��l� bir izlenim
olu&#351;tu&#287;undan g�r�nt�leme y�ntemleri gibi yard&#305;mc&#305; inceleme
y�ntemleri �o&#287;u kez gerekli de&#287;ildir, hatta baz&#305;
sak&#305;ncalar&#305; da olabilir. �rne&#287;in rastlant&#305;sal olarak
saptanan araknoid kist veya nonspesifik beyaz madde lezyonlar&#305; gibi
lezyonlar hastan&#305;n yakla&#351;&#305;m&#305;n&#305;, moralini ve hatta
tedaviyi k�t� y�nde etkileyebilir (&#350;ekil 1 a ve b).</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:12.0pt;margin-right:0cm;margin-bottom:
0cm;margin-left:35.25pt;margin-bottom:.0001pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="basagrisi1.jpg">&#350;ekil 1<span style='font-weight:normal'>.</span></a></span></u></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:
TR'> </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Her ikisi de auras&#305;z migrenli olan ve n�rolojik
ba&#351;ka bulgusu bulunmayan olgularda yap&#305;lan MRG ve BT incelemelerinin
s&#305;ras&#305;yla araknoid kist ve serebellar kalsifikasyon gibi
yak&#305;nmalar&#305; ile ili&#351;kisiz baz&#305; lezyonlar&#305; g�stermesi
bu hastalar&#305;n gereksiz &#351;ekilde endi&#351;elenmesine ve bir�ok ek
inceleme yap&#305;lmas&#305;na neden olmu&#351;tur. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:12.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Primer ba&#351;a&#287;r&#305;lar&#305; i�inde en
s&#305;k kar&#351;&#305;la&#351;&#305;lanlar migren ve gerilim tipi
ba&#351;a&#287;r&#305;lar&#305;d&#305;r. Bunlarla
kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda �ok daha seyrek
olmakla birlikte (2000 ki&#351;ide bir veya daha ender) �ok &#351;iddetli,
s&#305;k ba&#351;a&#287;r&#305;lar&#305;na neden olmalar&#305;, geleneksel
a&#287;r&#305; kesicilere yan&#305;t vermemeleri ve farkl&#305; tedaviler
gerektirmeleri nedeniyle <i>otonomik sefalaljiler (k�me
ba&#351;a&#287;r&#305;s&#305;, paroksizmal hemikranya</i> gibi) �nemli bir
primer ba&#351;a&#287;r&#305;s&#305; hastal&#305;&#287;&#305; grubunu
olu&#351;turmaktad&#305;r. �o&#287;u kez bu hastalar, do&#287;ru tan&#305;
almama nedeniyle y&#305;llarca &#351;iddetli a&#287;r&#305;lar �ekebilmektedir.
&#350;u an i�in d�nyada en s&#305;k ���nc� ba&#351;a&#287;r&#305;s&#305; tipi
ise iyatrojenik bir tablo olan <i>analjezik ila� a&#351;&#305;r&#305;
kullan&#305;m ba&#351;a&#287;r&#305;s&#305;</i>d&#305;r. Bu nedenle tedavi i�in
kullan&#305;lan analjeziklerin ayda 10 g�nden fazla al&#305;nmas&#305;n&#305;n
kendi ba&#351;&#305;na kronik bir ba&#351;a&#287;r&#305;s&#305; nedeni oldu&#287;u
konusunda hastalar mutlaka en ba&#351;tan uyar&#305;lmal&#305;d&#305;r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:12.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;l&#305; hastaya
yakla&#351;&#305;mda a&#351;a&#287;&#305;daki �zellikler
ayr&#305;nt&#305;l&#305; olarak ele al&#305;nmal&#305;d&#305;r: </span></p>

<p class=MsoNormal style='margin-top:12.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>1) Hastan&#305;n �zellikleri:</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> <i>Ba&#351;a&#287;r&#305;s&#305;n&#305;n
ba&#351;lang&#305;� ya&#351;&#305;</i> tan&#305; konulmas&#305;nda �nemli
ipu�lar&#305; verir. Primer ba&#351;a&#287;r&#305;lar&#305; genellikle �ocukluk
veya gen� eri&#351;kinlik ya&#351;lar&#305;nda ortaya �&#305;kar, oysa 50
ya&#351;&#305;ndan sonra ba&#351;layan ba&#351;a&#287;r&#305;lar&#305;
�ncelikle bir kitle lezyonu veya temporal arterit gibi ciddi bir sorunu akla
getirmelidir. Migrenlilerin sadece %2�sinde a&#287;r&#305;n&#305;n
ba&#351;lang&#305;c&#305; 50 ya&#351;&#305;n �zerindedir. K�me tipi
ba&#351;a&#287;r&#305;s&#305; 30�50 ya&#351; civar&#305;nda ba&#351;lar.
Gerilim tipi ba&#351;a&#287;r&#305;s&#305; ise genelde 20-40 ya&#351;lar&#305;nda
ortaya �&#305;kar. Hipnik ba&#351;a&#287;r&#305;s&#305; sendromu genellikle 60
ya&#351;&#305;ndan sonra ortaya �&#305;kar. Gen�lik y&#305;llar&#305;nda da
g�r�lebilen ama genelde 40 ya&#351;lar&#305;n �zerinde rastlanan �<i>analjezik
a&#351;&#305;r&#305; kullan&#305;m ba&#351;a&#287;r&#305;s&#305;</i>�, s&#305;k
kar&#351;&#305;la&#351;&#305;lan bir ba&#351;a&#287;r&#305;s&#305; nedeni
olarak hat&#305;rlanmal&#305;d&#305;r. Ya&#351;l&#305;larda
ba&#351;a&#287;r&#305;s&#305; daha seyrek g�r�l�r, ancak genellikle �nemli bir
sorun olu&#351;turur. Etyoloji ya&#351;a g�re farkl&#305;l&#305;k g�sterir,
ayr&#305;ca tan&#305; ve tedaviyi etkileyecek komorbid durumlar&#305;n bulunma
olas&#305;l&#305;&#287;&#305; ya&#351;l&#305;da daha fazlad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hastan&#305;n <i>cinsiyeti</i> de �nem ta&#351;&#305;yabilir. Migren i�in
kad&#305;nlarda erkeklere oranla 3 kat fazla bir s&#305;kl&#305;ktan s�z
edilebilirken, gerilim tipi ba&#351; a&#287;r&#305;lar&#305;nda b�yle bir
cinsiyet ay&#305;r&#305;m&#305; s�z konusu de&#287;ildir. K�me ba&#351;
a&#287;r&#305;lar&#305;nda ise erkek egemenli&#287;i �arp&#305;c&#305;d&#305;r.
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Gebelik</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>te a&#287;r&#305;n&#305;n kaybolmas&#305; migrenlilerde s&#305;kt&#305;r
veya tersine a&#287;r&#305;n&#305;n gebelikte ortaya �&#305;kmas&#305; (ven�z
tromboz gibi sekonder ba&#351;a&#287;r&#305;lar&#305; a�&#305;s&#305;ndan)
�nemlidir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>2) Ba&#351;a&#287;r&#305;s&#305;n&#305;n karakteri ve &#351;iddeti</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> hasta taraf&#305;ndan <i>zonklay&#305;c&#305;,
s&#305;k&#305;&#351;t&#305;r&#305;c&#305;, bas&#305;n� hissi, i&#287;ne batar
gibi, patlay&#305;c&#305;, &#351;im&#351;ek gibi, elektrik �arpar gibi</i>
&#351;eklinde farkl&#305; ifadelerle tan&#305;mlanabilir. Hasta
ba&#351;a&#287;r&#305;s&#305;n&#305; tan&#305;mlamakta zorlan&#305;rsa, �damar
atar gibi�, bir sarg&#305;yla s&#305;k&#305;lm&#305;&#351; gibi�, �b&#305;�ak
saplan&#305;r gibi� &#351;eklinde �rnekler verilip hangisine benzedi&#287;i sorulabilir.
A&#287;r&#305;n&#305;n &#351;iddeti de �ok �nemlidir. Migren
ba&#351;a&#287;r&#305;lar&#305;na k&#305;yasla gerilim tipi
ba&#351;a&#287;r&#305;lar&#305; �o&#287;unlukla hafif &#351;iddettedir. Migren
a&#287;r&#305;s&#305; pulsatil&nbsp;bir a&#287;r&#305;d&#305;r, hareketle
artar, &#351;iddetlidir ve genelde hastay&#305; g�nl�k hayat&#305;n&#305; devam
ettiremez hale getirir. Hasta karanl&#305;k ve hareketsiz bir yer ister,
&#305;&#351;&#305;k ve g�r�lt�den ka�&#305;n&#305;r. Zonklay&#305;c&#305; veya
bas&#305;n� hissi olu&#351;turan ba&#351;a&#287;r&#305;lar&#305; migren i�in
tipikken, s&#305;k&#305;&#351;t&#305;r&#305;c&#305;
ba&#351;a&#287;r&#305;s&#305;, en s&#305;k gerilim tipi
ba&#351;a&#287;r&#305;s&#305;nda ifade edilir. Hastalar gerilim tipi ba&#351;
a&#287;r&#305;lar&#305;n&#305; s&#305;kl&#305;kla bant gibi veya mengene gibi
olarak tan&#305;mlarlar. Kronik gerilim tipi ba&#351;a&#287;r&#305;s&#305;
kal&#305;c&#305; donuk ve doluluk hissi ile giden bir a&#287;r&#305;d&#305;r.
Migren ba&#351;a&#287;r&#305;s&#305;n&#305;n k���k ya&#351;larda
eri&#351;kinlerdekinden farkl&#305; karakter ta&#351;&#305;d&#305;&#287;&#305;
da unutulmamal&#305;d&#305;r. �ocukluk ya&#351;lar&#305;nda s&#305;kl&#305;kla
iki yanl&#305; ve frontal yerle&#351;imli ve yar&#305;m-bir saat gibi k&#305;sa
s�reler migren i�in tipiktir. K�me tipi ba&#351;a&#287;r&#305;s&#305; ise
derinden gelen can s&#305;k&#305;c&#305; ve rahats&#305;z edici bir
a&#287;r&#305;d&#305;r. Hasta yatamaz ve s�rekli gezinmek durumundad&#305;r.
Otonomik sefalaljilerin �nemli ve �ok ay&#305;rt ettirici bir �zelli&#287;i,
her zaman �ok &#351;iddetli olmalar&#305;d&#305;r. &#304;dyopatik
saplan&#305;c&#305; ba&#351;a&#287;r&#305;s&#305;nda de&#287;i&#351;en
b�lgelerde i&#287;ne veya b&#305;�ak batar gibi a&#287;r&#305;lar
tan&#305;mlan&#305;rken, trigeminal nevralji gibi nevraljik a&#287;r&#305;larda
&#351;im&#351;ekvari veya elektrik �arpar gibi a&#287;r&#305; ifadesi
kullan&#305;l&#305;r. Her t�r a&#287;r&#305; tipi ve &#351;iddeti sekonder
nedenlere ba&#287;l&#305; olarak da g�r�lebilir. Organik a&#287;r&#305;larda,
a&#287;r&#305;n&#305;n &#351;iddeti ve tabiat&#305; genelde de&#287;i&#351;ken
ve ilerleyicidir. Beyin t�m�r�n�n a&#287;r&#305;s&#305; genelde gerilim tipi
ba&#351;a&#287;r&#305;s&#305;n&#305; �a&#287;r&#305;&#351;t&#305;r&#305;r. Bir
anevrizman&#305;n veya arterio-ven�z malformasyonun kanamas&#305;
s&#305;kl&#305;kla s�rekli &#351;iddetli k�nt veya zonklay&#305;c&#305;
a&#287;r&#305; yarat&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>3) Ba&#351;a&#287;r&#305;s&#305;n&#305;n ba&#351;lang&#305;c&#305;</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> ile ilgili bilgiler de
tan&#305; i�in ipu�lar&#305; sa&#287;lar. Kafa travmas&#305; ard&#305;ndan
ortaya �&#305;kan ba&#351;a&#287;r&#305;s&#305; bir �post-konk�zyon�
ba&#351;a&#287;r&#305;s&#305; bozuklu&#287;unu veya kafa i�i bir patolojik
s�re� olas&#305;l&#305;&#287;&#305;n&#305; akla getirmelidir. Ancak kafa
travmas&#305; hem migreni hem de k�me ba&#351; a&#287;r&#305;lar&#305;n&#305;
tetikleyebilir. Do&#287;um �ncesi veya sonras&#305; d�nemde ortaya �&#305;kan
ba&#351;a&#287;r&#305;s&#305; bir kortikal ven veya dural sin�s trombozunu akla
getirmelidir. Ba&#351;a&#287;r&#305;s&#305;n&#305;n ortaya
�&#305;k&#305;&#351;&#305;n&#305;n ate&#351;le birlikte olmas&#305; infektif
bir nedeni d�&#351;�nd�r�r. Efor (�rne&#287;in a&#287;&#305;rl&#305;k
kald&#305;rma, spor sonras&#305;), subaraknoid kanamay&#305; veya �benin efor
ba&#351;a&#287;r&#305;s&#305;n&#305; ortaya �&#305;karabilir. <b>Ba&#351;a&#287;r&#305;s&#305;n&#305;n
zamansal gidi&#351;i</b> de �ok yol g�stericidir. �rne&#287;in migren
�zelliklerine sahip ba&#351;a&#287;r&#305;lar&#305; �eken bir hastada belirli
bir s�redir (�oklukla bir y&#305;l veya daha fazla) bu tip
ba&#351;a&#287;r&#305;lar&#305;n&#305;n tekrarl&#305;yor olmas&#305;,
a&#287;r&#305; aralar&#305;nda t�m�yle normale d�nme veya kronik
ba&#351;a&#287;r&#305;l&#305; durumlarda yine belirli bir s�redir devam ediyor
olmas&#305; (3 ay veya daha fazla) ve a&#287;r&#305; &#351;iddetinde ku&#351;ku
duyuracak bir progresyon veya ba&#351;ka n�rolojik belirtilerin olmamas&#305;
beklenir. Bununla birlikte epizodik migren ataklar&#305;na sahip
hastalar&#305;n, a&#351;&#305;r&#305; derecede s&#305;k a&#287;r&#305; kesici
kullan&#305;m&#305; (analjezik, antiromatizmal, ergotamin, triptan, narkotik
ila�lar gibi) ard&#305;ndan ataklar&#305;nda s&#305;kla&#351;ma ve
a&#287;r&#305; karakterinin de&#287;i&#351;mesi ve ba&#351;
a&#287;r&#305;lar&#305;n&#305;n s�rekli bir hal almas&#305; s&#305;k
kar&#351;&#305;la&#351;&#305;lan bir durum olup bu durum, �ila�
a&#351;&#305;r&#305; kullan&#305;m&#305; ba&#351;a&#287;r&#305;s&#305;� olarak
adland&#305;r&#305;lan sekonder bir ba&#351;a&#287;r&#305;s&#305;
hastal&#305;&#287;&#305;n&#305;n ifadesidir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>4) Ba&#351;a&#287;r&#305;s&#305;n&#305;n yerle&#351;imi</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> sadece y�zde ve hep
ayn&#305; yanda ise nevraljik a&#287;r&#305;lar&#305; veya sin�s
a&#287;r&#305;lar&#305;n&#305; d�&#351;�nd�rebilirken, g�z� ve ba&#351;&#305;n
di&#287;er b�l�mlerini (&#351;akak, al&#305;n gibi) i�ermesi durumu
de&#287;i&#351;tirir. Bu t�r a&#287;r&#305;lar e&#287;er hep tek yanl&#305; ve
ayn&#305; tarafta ise, �zellikle otonomik belirtilerin
varl&#305;&#287;&#305;nda, otonomik sefalaljileri akla daha �nce getirmelidir.
Migrenlilerin �o&#287;u a&#287;r&#305; taraf&#305;n&#305;n ataktan ata&#287;a
de&#287;i&#351;ebildi&#287;ini s�ylese de, %20�yi a&#351;an hastada
a&#287;r&#305;n&#305;n hep ayn&#305; yanda oldu&#287;u
unutulmamal&#305;d&#305;r. Migrenin aksine, k�me
ba&#351;a&#287;r&#305;s&#305;nda hastalar&#305;n sadece %10-15�i ataktan
ata&#287;a a&#287;r&#305;n&#305;n taraf de&#287;i&#351;tirdi&#287;ini s�yler.
Temporal arter b�lgesine lokalize bir a&#287;r&#305;, hastan&#305;n
ya&#351;&#305; ve a&#287;r&#305;n&#305;n ba&#351;lang&#305;� ya&#351;&#305;
ileri oldu&#287;unda, temporal arteriti �ncelikle d�&#351;�nd�rmelidir. Boyundan
ba&#351;layan veya boyna da yay&#305;lan a&#287;r&#305;lar servikal bir k�keni
akla getirebilirse de, migren ataklar&#305;na b�y�k s&#305;kl&#305;kla servikal
spazm&#305;n e&#351;lik etti&#287;i unutulmamal&#305;d&#305;r. Gerilim tipi
ba&#351;a&#287;r&#305;s&#305; ise tipik olarak iki yanl&#305;d&#305;r. &#304;ki
yanl&#305; veya bir yanda daha bask&#305;n olmakla birlikte di&#287;er yanda da
hissedilen ba&#351;a&#287;r&#305;lar&#305;, otonomik sefalaljiler ve nevraljik
a&#287;r&#305;lar i�in d&#305;&#351;lay&#305;c&#305; bir �zelliktir. Bu t�r
a&#287;r&#305;larda migren veya gerilim tipi ba&#351; a&#287;r&#305;lar&#305;
en s&#305;k olmakla birlikte �analjezik ila� a&#351;&#305;r&#305; kullan&#305;m
ba&#351;a&#287;r&#305;s&#305;�, �hipertansif ba&#351;a&#287;r&#305;s&#305;�,
�ilaca ba&#287;l&#305; ba&#351;a&#287;r&#305;s&#305;� gibi sekonder nedenler de
di&#287;er nedenleridir. Lokalize a&#287;r&#305;lar organik hastal&#305;klarla
da g�r�lebilir. Supratentoryal alanda a&#287;r&#305; olu&#351;turan
yap&#305;lar&#305;n ba&#351;l&#305;ca innervasyonu trigeminal sinirden
kaynaklan&#305;r. &#304;nfratentoryal a&#287;r&#305; olu&#351;turan
yap&#305;lar&#305;n innervasyonu ise �st servikal sinirlerden, glossofaringeus
ve vagus sinirlerinden kaynaklan&#305;r. Supratentoryal lezyonlar genellikle
frontal ba&#351; a&#287;r&#305;lar&#305;na yol a�arken, infratentoryal
lezyonlar s&#305;kl&#305;kla oksipital b�lgede a&#287;r&#305; olu&#351;turur.
Ancak, trigemino-servikal komplekse y�nelen n�ronlar&#305;n �rt�&#351;mesi
nedeni ile bu paternin d&#305;&#351;&#305;na �&#305;kan yay&#305;lmalar da s�z
konusu olabilir. Ba&#351;a&#287;r&#305;s&#305; net bir bi�imde g�z �evresine
s&#305;n&#305;rl&#305; ise, g�z hastal&#305;&#287;&#305; veya d�k�nt� �ncesi
oftalmik zoster akla gelmelidir. Trigeminal nevralji y�zde trigeminal sinirden
innerve olan herhangi bir b�lgede kendini g�sterebilir. Beyin t�m�r� bulunan
hastalar&#305;n yar&#305;s&#305;ndan biraz fazlas&#305;
ba&#351;a&#287;r&#305;s&#305;ndan yak&#305;n&#305;r; bunlar&#305;n da %80�inde
a&#287;r&#305; t�m�r�n bulundu&#287;u taraftad&#305;r. Serebrovask�ler
hastal&#305;klarla ili&#351;kili ba&#351; a&#287;r&#305;lar&#305; yayg&#305;n
veya lokalize olabilir. Lokalize oldu&#287;unda sadece yar&#305;s&#305; lezyon
taraf&#305;ndad&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>5) Ba&#351;a&#287;r&#305;s&#305;n&#305; tetikleyen nedenler:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Akut
ba&#351;a&#287;r&#305;s&#305;n&#305;n birlikte oldu&#287;u presipitan fakt�r
tan&#305;ya yard&#305;mc&#305; oldu&#287;u gibi ba&#351;a&#287;r&#305;s&#305;n&#305;n
�nlenmesinde ve koruyucu tedavisinde de �nemlidir. Migreni ortaya �&#305;karan
sebepler aras&#305;nda uykusuzluk, a&#351;&#305;r&#305; uyku, a�l&#305;k,
stres, stres sonras&#305; rahatlama, �zel baz&#305; yiyecekler (en s&#305;k
olarak �ikolata, peynirler, alkoll� i�ecekler, �zellikle k&#305;rm&#305;z&#305;
&#351;arap, turun�giller, monosodyum glutamat, nitrat ve aspartat i�eren
yiyecekler), yorgunluk, menstr�asyon, hava durumu, y�kseklik ve bas&#305;n�
de&#287;i&#351;iklikleri, fiziksel baz&#305; uyaranlar (parlak
&#305;&#351;&#305;k, y�ksek ses, parf�m, kimyasallar), baz&#305; ila�lar
(nitrogliserin, sildenafil, dipridamol gibi) yer almaktad&#305;r. Migrenlilerde
�ikolata yeme iste&#287;inin migren prodromunun bir par�as&#305; oldu&#287;u da
d�&#351;�n�lmektedir. Kokain kullan&#305;m&#305; ve kokain yoksunlu&#287;u da
migren benzeri ba&#351; a&#287;r&#305;lar&#305;n&#305; tetikleyebilir.
&nbsp;K�me tipi ba&#351;a&#287;r&#305;s&#305;nda alkol akut ata&#287;&#305;
ortaya �&#305;kar&#305;r. Egzersizler genelde organik ba&#351;
a&#287;r&#305;lar&#305;n&#305; tetikler ama egzersizle tetiklenen primer
ba&#351;a&#287;r&#305;lar&#305; da vard&#305;r. Akut fakat yinelemeyen
ba&#351;a&#287;r&#305;s&#305;nda tetikleyen neden �zellikle �nemlidir.
�rne&#287;in �ks�rmek, &#305;k&#305;nmak gibi kafa i�i bas&#305;nc&#305;
artt&#305;ran veya g��l� bir efor ya da cinsel ili&#351;ki gibi etkinlikleri
takiben geli&#351;en akut ba&#351;a&#287;r&#305;s&#305; akla ilk olarak
parenkimal veya subaraknoid kanamay&#305; getirmelidir. N�rolojik ve fizik
muayenenin normal olmas&#305; halinde, �zellikle de yineleyen bir durum s�z
konusuysa, idyopatik durumlar da akla gelmelidir, �rne&#287;in ��ks�r�k
ba&#351;a&#287;r&#305;s&#305;�, �orgazm ba&#351;a&#287;r&#305;s&#305;�, �efor
ba&#351;a&#287;r&#305;s&#305;�, �g�kg�r�lt�s� ba&#351;a&#287;r&#305;s&#305;�
gibi. Bu t�r seyrek rastlanan �zel t�r ba&#351; a&#287;r&#305;lar&#305;n&#305;n
�zelli&#287;i, ba&#351;ka durumlarda ortaya �&#305;kmamas&#305;, sadece tan&#305;mlanan
bu �zel durumlarda ortaya �&#305;kmas&#305; ve tekrarlay&#305;c&#305;
olmas&#305;d&#305;r. Di&#287;er yandan, stres, a�l&#305;k, uyku
de&#287;i&#351;ikli&#287;i (yetersiz uyku veya a&#351;&#305;r&#305; uyku ya da
�&#287;len uykusu gibi zaman&#305; kaym&#305;&#351; uyku) gibi tetikleyici
nedenlerin migren kadar gerilim tipi ba&#351;a&#287;r&#305;s&#305; i�in de s�z
konusu oldu&#287;unu unutmamak gerekir. Oysa koku (keskin parf�m kokusu),
parlak &#305;&#351;&#305;k, r�zg�r (lodos), sigara duman&#305;, mayal&#305;
i�kiler (k&#305;rm&#305;z&#305; &#351;arap) �zellikle migrene �zg�
tetikleyicilerdir. Kas k�kenli a&#287;r&#305;lar, duyarl&#305; b�lgenin
palpasyonu veya zorlanmas&#305; ile tetiklenebilir. Trigeminal nevralji, tetik
noktaya dokunmakla ortaya �&#305;kar&#305;labilir. Bu noktalar&#305;n yemek
yeme, konu&#351;ma, so&#287;u&#287;a maruz kalma, di&#351;leri f&#305;r�alama,
dokunma, t&#305;ra&#351; olma veya y�z y&#305;kama gibi hafif uyaranlarla
uyar&#305;lmas&#305; bir ata&#287;&#305; tetikleyebilir.
Ba&#351;a&#287;r&#305;s&#305;n&#305; att&#305;ran nedenlerden boyun
spazm&#305;n&#305;n migrene de s&#305;kl&#305;kla e&#351;lik etti&#287;i
unutulmamal&#305;d&#305;r. Ba&#351; ve beden hareketleri (merdiven �&#305;kma,
e&#287;ilip kalkma gibi) migren i�in �zellikle artt&#305;r&#305;c&#305; rol
oynarken, gerilim tipi ba&#351;a&#287;r&#305;s&#305;nda etkili olmas&#305; beklenmez.
G�r�lt�, her t�r ba&#351;a&#287;r&#305;s&#305;nda k�t� etki g�sterirken
a&#287;r&#305; s&#305;ras&#305;nda &#305;&#351;&#305;k ve koku, �zellikle
migren a&#287;r&#305;s&#305;nda �o&#287;u kez rahats&#305;z edicidir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ba&#351;a&#287;r&#305;s&#305;n&#305; <b>iyile&#351;tiren nedenler</b>
i�inde uyumak, karanl&#305;k ve sessiz ortam migren i�in �o&#287;u kez
iyile&#351;tirici bir role sahiptir. K�me ba&#351;a&#287;r&#305;s&#305;nda
y�ksek yo&#287;unluklu oksijen soluma (15 lt/dakika) saniyeler veya dakikalar
i�inde a&#287;r&#305;y&#305; ge�irebilir. Ba&#351;a so&#287;uk uygulamak yine
migren i�in iyile&#351;tirici bir uygulama olabilir. Gebelik ve menopoz
d�nemleri de migrenli kad&#305;nlarda rahatlama d�nemleri olarak
hat&#305;rlan&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>5) Ba&#351;a&#287;r&#305;s&#305;&#305;n s&#305;kl&#305;&#287;&#305; ve
s�resi</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> tan&#305;da �nemli ipu�lar&#305; verir ve tedavimizi y�nlendirir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Organik hastal&#305;klarda ortaya �&#305;kan ba&#351;a&#287;r&#305;s&#305;
genelde �zel bir patern g�stermez, s&#305;kl&#305;&#287;&#305; ve di&#287;er
�zellikleri progresiftir. Primer ba&#351;a&#287;r&#305;lar&#305;nda
a&#287;r&#305; s&#305;kl&#305;&#287;&#305; kritik �neme sahiptir. Migren
ataklar&#305; belli bir d�zende gelir, genelde ayda 2-8 kez olur. Bir g�n
i�inde birden fazla atak al&#305;&#351;&#305;lm&#305;&#351; de&#287;ildir.
E&#287;er ila� a&#351;&#305;r&#305; kullan&#305;m&#305; s�z konusu
de&#287;ilse, g�nl�k veya g�n a&#351;&#305;r&#305; migren ata&#287;&#305; (<i>kronik
migren</i>) olduk�a seyrek kar&#351;&#305;la&#351;&#305;lan bir durumdur.
Migren ata&#287;&#305;n&#305;n ila� kullan&#305;lmad&#305;&#287;&#305;nda 4
saat ile 3 g�n aras&#305; bir s�re devam etmesi beklenir. 72 saatten uzun
s�rmeleri halinde, �<i>migren statusu�</i> terimi kullan&#305;l&#305;r. Oysa
epizodik gerilim ba&#351; a&#287;r&#305;lar&#305;nda bir ritim s�z konusu
de&#287;ildir ve atak s�releri dakikalardan g�nler-haftalara dek olduk�a
de&#287;i&#351;kendir, bir g�n i�inde birka� kez de ortaya �&#305;kabilir.
Otonomik sefalaljiler s�re konusunda daha tutarl&#305; bir gruptur. Bunlar
i�inde en uzun s�reli ve en seyrek olan&#305; k�me
ba&#351;a&#287;r&#305;s&#305;d&#305;r. K�me ba&#351;a&#287;r&#305;s&#305;
�o&#287;unlukla 15 dakika ile 3 saat aras&#305; bir s�reye sahiptir, bununla
birlikte daha uzun s�rmesi de tan&#305;y&#305; d&#305;&#351;lamaz. &#304;lk ba&#351;lang&#305;�
g�nleri ve sonlan&#305;&#351; g�nleri d&#305;&#351;&#305;nda,
s&#305;kl&#305;&#287;&#305; iki g�nde birden g�nde 8�e dek de&#287;i&#351;ir.
Paroksizmal hemikranya ise k�me ba&#351;a&#287;r&#305;s&#305;na g�re daha
k&#305;sa s�reli (2-30 dakika) ve g�n i�inde �ok daha fazla say&#305;da gelmesi
ile (g�nde 10�dan fazla) k�me ba&#351;a&#287;r&#305;s&#305;ndan
ayr&#305;labilir. Otonomik sefalaljiler i�inde en k&#305;sa s�reli olan&#305;
ise SUNCT (konjunktival k&#305;zar&#305;kl&#305;k ve ya&#351;armal&#305; ani
ba&#351;lang&#305;�l&#305;, k&#305;sa s�reli tek yanl&#305; nevraljiform
ba&#351;a&#287;r&#305;s&#305; ataklar&#305;) olup s�resi 5 saniye ile 4 dakika
aras&#305; de&#287;i&#351;ir ve g�nde y�zlerce kez&nbsp; bile olabilir.
Nevraljik a&#287;r&#305;lar bundan da daha k&#305;sa s�relidir (saniyelik),
seyrek veya g�n i�inde �ok say&#305;da olabilir. Hemikranya kontinuada ise
a&#287;r&#305;n&#305;n hi� kesilmeden aylard&#305;r s�r�yor olmas&#305; ve
arada &#351;iddetlenmeler kurald&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>6) Ba&#351;a&#287;r&#305;s&#305;na e&#351;lik edenler</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> de tan&#305; i�in
ipu�lar&#305; vermektedir. Migrende gastrointestinal semptomlar olarak bulant&#305;
ve kusma g�r�l�r. Ayr&#305;ca �dizziness�, fotofobi, fonofobi, tinnitus ve
bulan&#305;k g�rme e&#351;lik edebilir, hafif g�z ya&#351;armas&#305;, g�z
kanlanmas&#305; olabilir. K�me tipi ba&#351;a&#287;r&#305;s&#305;nda ve
di&#287;er otonomik sefalaljilerde ise g�z ya&#351;armas&#305;, y�z
k&#305;zarmas&#305;, burun t&#305;kan&#305;kl&#305;&#287;&#305; veya
ak&#305;nt&#305;s&#305; gibi otonomik belirtiler ve parsiyel Horner Sendromu
tek yanl&#305; ve belirgin olarak g�r�l�r. &nbsp;Kronik gerilim tipi
ba&#351;a&#287;r&#305;s&#305;nda ise genellikle hastan&#305;n elinde somatik,
emosyonel ve fizik semptomlar&#305; g�steren uzun bir liste vard&#305;r.
Gerilim tipi ba&#351;a&#287;r&#305;s&#305;na hemen hi� bir &#351;ey e&#351;lik
etmez. <b>Aura</b> varl&#305;&#287;&#305;nda art&#305;k
ba&#351;a&#287;r&#305;s&#305;n&#305;n �zellikleri �nem ta&#351;&#305;maz, hatta
auray&#305; ba&#351;a&#287;r&#305;s&#305; izlemeyebilir (a&#287;r&#305;s&#305;z
aura). Aural&#305; migrenlilerin t&#305;kay&#305;c&#305; damar
hastal&#305;klar&#305; y�n�nden artm&#305;&#351; bir riske sahip olduklar&#305;
ve �zellikle sigara ve/veya �strojen kullan&#305;m&#305;n&#305;n bu riski genel
topluma g�re daha da artt&#305;rd&#305;&#287;&#305; bilinmeli ve hastalar
uyar&#305;lmal&#305;d&#305;r.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ayr&#305;ca, hemipleji ve baziler bulgular &#351;eklinde aura
varl&#305;&#287;&#305;nda ise triptanlar&#305;n kullan&#305;lmas&#305;n&#305;n
sak&#305;ncal&#305; oldu&#287;u unutulmamal&#305;d&#305;r. Sekonder
ba&#351;a&#287;r&#305;s&#305; bozukluklar&#305;na s&#305;kl&#305;kla �ift
g�rme, epileptik n�betler, tinnitus ve fokal n�rolojik bulgu gibi �zellikler
e&#351;lik eder. Organik ba&#351; a&#287;r&#305;lar&#305;nda, lezyonun
yerle&#351;imine g�re s&#305;kl&#305;kla n�rolojik bulgular mevcuttur. Kafa i�i
kitleleri hastalar&#305;n yar&#305;s&#305;nda bulant&#305; ile veya
bulant&#305;s&#305;z (projektil) kusma ile birlikte g�r�l�r. Temporal arterit
kafa derisinde s&#305;n&#305;rl&#305; bir hassasiyet, halsizlik, polimiyalji
romatika, subfebril ate&#351; veya ba&#351;ka bir sistemik belirti ile ya da
g�rme kayb&#305; veya inme ile ili&#351;kili olabilir. E&#287;er mevcutsa �ene
klodikasyosu temporal arterit i�in patognomoniktir. Ate&#351; ve ense
sertli&#287;i menenjite i&#351;aret eder. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>7) Emosyon ve &nbsp;sosyal fakt�rler:</span></i></b><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�yk� al&#305;n&#305;rken
hastaya aile, evlilik ve i&#351; ili&#351;kileri sorulmal&#305; ve stres
fakt�rleri varsa ortaya �&#305;kar&#305;lmal&#305;d&#305;r. Bu t�r
sorular&#305;n sorulmas&#305; i�in uygun ortam, zaman ve hastan&#305;n doktora
g�veni sa&#287;lanmal&#305;d&#305;r. Bu s&#305;rada tedaviyi y�nlendirecek
hastan&#305;n gebe kalma iste&#287;i olmas&#305;, kilosunu fazla bulmas&#305;
gibi baz&#305; bilgiler de elde edilir. Ayr&#305;ca ila� a&#351;&#305;r&#305;
kullan&#305;m ba&#351;a&#287;r&#305;s&#305; tedavisi gibi baz&#305; durumlarda
hastan&#305;n tedavisi s&#305;ras&#305;nda aile deste&#287;i almas&#305; �ok
�nemlidir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>8) �zge�mi&#351; ve uyku
paterni:</span></i></b><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hekim
hastan&#305;n ge�irmi&#351; oldu&#287;u t�m medikal ve cerrahi
hastal&#305;klar&#305; ve durumlar&#305; (do&#287;um, menapoz gibi) ve varsa
kafa travmas&#305;n&#305; bilmelidir. Herhangi yeni bir hastal&#305;k veya
tedavi ba&#351;a&#287;r&#305;s&#305;n&#305;n nedeni olabilir, ya da tedavi
stratejisinde �nem ta&#351;&#305;r. Hastaya �nceden lomber ponksiyon ya da
beyin cerrahisi giri&#351;imi yap&#305;ld&#305;ysa bilinmesi, intrakranyal
hipotansiyona ba&#287;l&#305; post�ral ba&#351; a&#287;r&#305;lar&#305;n&#305;
de&#287;erlendirmek i�in �nem ta&#351;&#305;r. Ba&#351;a&#287;r&#305;s&#305;na
spesifik alerjik etkenler veya yiyecekler sebep olabilir. Glokom, yeni
tan&#305;nan hipertansiyon dializ, hipotirodi, sin�zit gibi hastal&#305;klar ve
yeni ba&#351;lanm&#305;&#351; oral kontraseptif dahil t�m tedaviler
&nbsp;mutlaka bilinmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>K�me tipi ba&#351;a&#287;r&#305;s&#305; s&#305;k olarak, <i>hipnik
ba&#351;a&#287;r&#305;s&#305;</i> ise tipik olarak her gece ayn&#305; zamanda
uyand&#305;r&#305;r. Migrenlilerde ba&#351;a&#287;r&#305;s&#305; genellikle
uyan&#305;kken ba&#351;lar, migren a&#287;r&#305;s&#305; genelde uykuda d�zelme
e&#287;ilimindedir, ancak uzun ataklarda ertesi sabah da a&#287;r&#305; devam
edebilir. Kronik gerilim tipi ba&#351;a&#287;r&#305;s&#305; olan hasta s&#305;k
s&#305;k ve erken uyan&#305;r. Uyku bozuklu&#287;u ayn&#305; zamanda bir
depresyon belirtisidir. <i>Depresyon</i> uykuya dalmada g��l�k, uykuyu
s�rd�rmede g��l�k veya sabah erken uyanma ile gidebilir. Anksiyete ile
ili&#351;kili ba&#351;a&#287;r&#305;s&#305;nda hasta uykuya dalmakta zorluk
�eker. Hipertansiyon a&#287;r&#305;s&#305; uyan&#305;rken olur ve g�n
ilerledik�e azal&#305;r. Akut sin�zit a&#287;r&#305;s&#305; ise sabah ortaya
�&#305;kar ve g�n ilerledik�e artar. <i>Uyku apnesi</i> s&#305;k rastlanan bir
durumdur, �zellikle kilolu ki&#351;ilerde sabah ba&#351;
a&#287;r&#305;lar&#305;na yol a�abilir. Bu a�&#305;dan hastalar
sorgulanmal&#305;, ku&#351;kulu durumlarda da polisomnografik inceleme
yap&#305;lmal&#305;d&#305;r. Uyku paterni ayr&#305;ca profilatik tedavide ila�
se�iminde de �nem ta&#351;&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kronik ba&#351;a&#287;r&#305;l&#305; hastan&#305;n
�zge�mi&#351;indeki ba&#351;ar&#305;l&#305; ve ba&#351;ar&#305;s&#305;z
tedaviler ba&#351;a&#287;r&#305;s&#305;n&#305;n tan&#305;s&#305;n&#305;n ortaya
konulmas&#305;na ve uygun tedavi se�imine yard&#305;mc&#305; olur.
Hastan&#305;n daha �nce denedi&#287;i ve yan etki g�rmeyip fayda g�rd�&#287;�
tedavinin devam&#305; genelde do&#287;ru bir yakla&#351;&#305;md&#305;r.
Ayr&#305;ca ba&#351;a&#287;r&#305;s&#305; ile e&#351; zamanl&#305;
ba&#351;lanm&#305;&#351; herhangi bir ilac&#305;n
ba&#351;a&#287;r&#305;s&#305;n&#305; tetiklemi&#351; olma
olas&#305;l&#305;&#287;&#305; ak&#305;lda tutulmal&#305;d&#305;r. Nitratlar,
amantadin, sildenafil, dipridamol, simetidin, reserpin, indometazin, hormonal
tedaviler, baz&#305; antibiyotikler ba&#351;ta olmak �zere �e&#351;itli ila�lar
ba&#351;a&#287;r&#305;s&#305;n&#305; ba&#351;lat&#305;r. Kad&#305;nlarda oral
kontraseptif kullan&#305;m&#305; veya postmenapozal hormon tedavisi
a&#287;r&#305;n&#305;n &#351;iddetini, s&#305;kl&#305;&#287;&#305;n&#305;,
s�resini ve komplikasyonlar&#305;n&#305; artt&#305;rabilir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>9) Aile �yk�s�:</span></i></b><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> &nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Migren ailesel bir
hastal&#305;kt&#305;r ve ailede genelde migrenli ba&#351;ka hastalar vard&#305;r.
�zellikle aural&#305; migren olgular&#305;nda bu yatk&#305;nl&#305;k daha
belirgindir, genetik k�keni ortaya ilk konan ciddi bir aural&#305; migren formu
olan <b>ailesel hemiplejik migrende</b> ailede etkilenmi&#351; bir ba&#351;ka
bireyin varl&#305;&#287;&#305; tan&#305; i�in gereklidir. E&#287;er yoksa
ayn&#305; tablo sporadik hemiplejik migren olarak adland&#305;r&#305;l&#305;r.
K�me tipi ba&#351;a&#287;r&#305;s&#305;nda ise s&#305;kl&#305;kla aile �yk�s�
yoktur. Kronik gerilim tipi ba&#351;a&#287;r&#305;s&#305;nda ise ailede
depresyon �yk�s� bildirilmi&#351;tir. Ailesel
ba&#351;a&#287;r&#305;lar&#305;nda ortak �evresel fakt�rler de rol oynayabilir,
�rne&#287;in t�ten bir baca b�t�n ailede karbon monoksit
ba&#351;a&#287;r&#305;s&#305;na yol a�abilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;l&#305;
Hastan&#305;n Muayenesi</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;l&#305; hastan&#305;n
muayenesinde ayr&#305;nt&#305;l&#305; fizik muayene ve n�rolojik muayene yapmak
temeldir. A&#351;a&#287;&#305;daki noktalar �nemlidir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Vital&nbsp; Bulgular</span></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR;mso-char-type:symbol;mso-symbol-font-family:Tahoma'><span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61623;</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ate&#351;: Sistemik
infeksiyonu g�sterir. Ense sertli&#287;i varsa menenjit d�&#351;�n�l�r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR;mso-char-type:symbol;mso-symbol-font-family:Tahoma'><span
style='mso-char-type:symbol;mso-symbol-font-family:Tahoma'>&#61623;</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR;mso-char-type:symbol;
mso-symbol-font-family:Tahoma'><span style='mso-char-type:symbol;mso-symbol-font-family:
Tahoma'>&#61472;</span></span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Hipertansiyona ba&#287;l&#305;
ba&#351;a&#287;r&#305;s&#305;nda diastolik&nbsp; bas&#305;n� 110 mmHg ve
�st�d�r ve tedavi ile kontrol alt&#305;na al&#305;n&#305;nca
ba&#351;a&#287;r&#305;s&#305; da d�zelir. Ba&#351;a&#287;r&#305;s&#305;
hipertansiyon veya hipertansiyon nedeniyle kullan&#305;lan ila�lar&#305;n yan
etkisi olarak ortaya �&#305;kabilece&#287;i gibi migren gibi
ba&#351;a&#287;r&#305;l&#305; durumlar&#305;n atak s&#305;ras&#305;nda
s&#305;kl&#305;kla kan bas&#305;nc&#305;nda ge�ici y�kselmeye yol
a�abilece&#287;i de ak&#305;lda tutulmal&#305;d&#305;r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><u><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;&nbsp; Muayenesi:</span></u></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Palpasyon ve osk�ltasyon. Temporal arterlerde belirginle&#351;me,
bo&#287;umlanma, geni&#351;leme ve hassasiyet bulunmas&#305; klinik uyumluysa
temporal arteriti d�&#351;�nd�rmelidir, ancak akut migren ata&#287;&#305;na da
e&#351;lik edebilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>G�z&nbsp; Muayenesi:</span></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>K�me tipi ba&#351;a&#287;r&#305;s&#305; i�in
karakteristik �zellikler: konjunktival k&#305;zarma, tek tarafl&#305; ptoz,
k&#305;smi Horner Sendromu gibi bulgulard&#305;r. Tonometri
ba&#351;a&#287;r&#305;l&#305; olguda glokomu d&#305;&#351;lamak i�in
gereklidir. &#304;ntrakranyal bas&#305;n� art&#305;&#351;&#305;nda g�z dibinde
papil�dem saptan&#305;r. <i>Ba&#351;a&#287;r&#305;s&#305; olan bir
hastan&#305;n g�z dibi bak&#305;lmadan muayenesi yap&#305;lm&#305;&#351; kabul
edilmemelidir.</i></span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Kulak- Burun-Bo&#287;az&nbsp;
Muayenesi:</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>KBB infeksiyon ve hastal&#305;klar&#305;n&#305;
d&#305;&#351;lar.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Y�z&nbsp; Muayenesi:</span></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tetik nokta varl&#305;&#287;&#305; trigeminal
nevralji i�in karakteristiktir, SUNCT gibi baz&#305; otonom sefalaljilerde de
g�r�lebilir</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Boyun&nbsp; Muayenesi:</span></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hareket k&#305;s&#305;tl&#305;l&#305;&#287;&#305;,
spazm ve gerginlik de&#287;erlendirilmelidir. Temporomandib�ler eklemler
hassasiyet, hareket k&#305;s&#305;tl&#305;l&#305;&#287;&#305;, asimetri ve
�t&#305;k&#305;rdama� a�&#305;s&#305;ndan incelenmelidir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yard&#305;mc&#305;
Tan&#305; Y�ntemleri</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Radyolojik testler</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Direkt grafiler, BT
(bilgisayarl&#305; tomografi),&nbsp; MRG (Manyetik rezonans g�r�nt�leme) </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Akut sin�zit varl&#305;&#287;&#305;nda sin�s
grafileri anlaml&#305;d&#305;r. Art&#305;k �ok seyrek kullan&#305;lan
di&#287;er direkt filmler, frakt�rleri, ayr&#305;k s�t�rleri, pineal gland
itilmesini, d�vme bak&#305;r g�r�n�m� ile kafa i�i bas&#305;n� art&#305;&#351;&#305;n&#305;
g�sterir; intrakranyal kalsifikasyonlar, sella b�y�kl�&#287;� ve
erozyonlar&#305; konusunda bilgi verir. Ayr&#305;ca litik lezyonlar ile
hiperosteozis ve metastazlar&#305; g�sterebilir. Baziler invajinasyon konusunda
yard&#305;mc&#305; olur. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>BT ve MRG daha �nce belirtilmi&#351; olan sekonder
ba&#351;a&#287;r&#305;s&#305; ku&#351;kusu olan durumlarda istenir, primer
ba&#351; a&#287;r&#305;lar&#305;nda gerekli de&#287;ildir. BT akut
ba&#351;a&#287;r&#305;s&#305;nda en kolay, h&#305;zl&#305; ve en �ok
kullan&#305;lan y�ntemdir. Ayr&#305;ca, BT kronik ba&#351;a&#287;r&#305;s&#305;nda,
beyin t�m�rleri, kronik subdural hematom ve hidrosefaliyi
d&#305;&#351;lamak&nbsp; konusunda da yard&#305;mc&#305; olur, hastada varsa
beyin �demini g�sterir. &#304;nme &#351;�phesi, �yk� ve&nbsp; muayene
K&#304;BAS d�&#351;�nd�r�yorsa, lomber ponksiyon yap&#305;lmadan �nce kitle
etkisinin d&#305;&#351;lanmas&#305; amac&#305;yla, kafa travmalar&#305; ve
a�&#305;k, kapal&#305; k&#305;r&#305;klar varsa ve Glasgow koma skorlamas&#305;
9 dan a&#351;a&#287;&#305; olan kafa travmalar&#305; ve komalarda BT
yap&#305;lmas&#305; uygundur. MRG g�n�m�zde bir�ok a�&#305;dan BT incelemesinin
�n�ne ge�mi&#351;tir. MRG ba&#351;l&#305;ca demiyelinizan plaklar (multipl
skleroz), arka �ukur t�m�rleri ve inmeleri iyi g�sterir ve BT� ye g�re �nemli
�st�nl�k ta&#351;&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
7.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Lomber ponksiyon</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> (LP) kafa i�i&nbsp;
infeksiyon ve SAK tan&#305;lar&#305;n&#305; koymak amac&#305;yla klinik
&#351;�phe varsa ense sertli&#287;i ve ate&#351; mevcudiyetinde
yap&#305;lmal&#305;d&#305;r. Post-LP ba&#351;a&#287;r&#305;s&#305; riski
vard&#305;r. Yeni tan&#305;mlanan bir tablo olan HANDLE (headache and neurological
deficits with cerebrospinal fluid lymphocytosis) sendromunda da ge�ici
n�rolojik defisitleri olan hastalarda LP lenfositozu g�stermek amac&#305;yla
yap&#305;l&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er tan&#305; testleri</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> (Rutin biyokimya
ara&#351;t&#305;rmalar&#305;, kan say&#305;m&#305;, sedimentasyon, EKG, tiroid
fonksiyon testleri gibi) ba&#351;a&#287;r&#305;s&#305;n&#305;n sekonder
nedenlerini ve hastan&#305;n genel durumunu ara&#351;t&#305;rmak i�in
yap&#305;lmal&#305;d&#305;r. <b><i>EEG</i></b> ise
ba&#351;a&#287;r&#305;s&#305;nda �ok s&#305;k kullan&#305;lmaz. E&#287;er
ba&#351;a&#287;r&#305;s&#305; epileptik ataklarla birlikte ise uygulan&#305;r.
Kronik ba&#351;a&#287;r&#305;s&#305;nda yararl&#305; de&#287;ildir. Pozitron
emisyon tomografi (PET), fonksiyonel MRG gibi �al&#305;&#351;malar ise migrenin
patofizyolojisini a�&#305;klama y�n�nden ara&#351;t&#305;rmalarda
kullan&#305;lan y�ntemlerdir.Transkranyal magnetik stim�lasyon ve di&#287;er
elektrofizyolojik y�ntemler de ara&#351;t&#305;rma ama�l&#305; uygulanmaktad&#305;r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;s&#305;n&#305;n
&#351;iddetinin ortaya konmas&#305;nda daha net bir yakla&#351;&#305;m&#305;n
kullan&#305;lmas&#305;n&#305; yararl&#305;d&#305;r ve ki&#351;inin kendi
kendine doldurdu&#287;u Migren K&#305;s&#305;tl&#305;l&#305;&#287;&#305;
De&#287;erlendirme (MIDAS) Sorgulama Formu T�rk�e�ye adapte edilmi&#351;tir. Bu
formla ki&#351;inin g�nl�k ya&#351;am&#305;nda kaybetti&#287;i g�n
say&#305;s&#305; (i&#351;e/okula gitmedi&#287;i g�nler ve y�ksek oranda
k&#305;s&#305;tlanman&#305;n ya&#351;and&#305;&#287;&#305; g�nler)
�l��lmektedir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Ba&#351;a&#287;r&#305;l&#305; bir hastan&#305;n takibinde <i>ba&#351;a&#287;r&#305;s&#305;
g�nl�&#287;�</i> kullan&#305;lmas&#305; �ok �nemlidir, bu g�nl�kten tedavi
s�recinin objektif olarak izlenmesinin d&#305;&#351;&#305;nda tan&#305; i�in de
�nemli ipu�lar&#305; ve tetikleyici fakt�rlerin saptanmas&#305;
sa&#287;lanabilir (&#350;ekil 2). Hastaya bir ba&#351;a&#287;r&#305;s&#305;
g�nl�&#287;� verilerek atak say&#305;s&#305;, kullan&#305;lan ila� ve a&#287;r&#305;n&#305;n
tedaviye cevap verip vermedi&#287;inin yaz&#305;lmas&#305; istenir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:35.4pt;line-height:150%'><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;color:blue;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:35.4pt;line-height:150%'><b><u><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;color:blue;
mso-ansi-language:TR'><a href="basagrisi2.jpg">&#350;ekil 2<span
style='font-weight:normal'>.</span></a></span></u></b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;color:blue;
mso-ansi-language:TR'> </span><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>�rnek bir
ba&#351;a&#287;r&#305;s&#305; g�nl�&#287;�</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:12.0pt;text-align:justify'><b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>SIK
RASTLANAN PR&#304;MER BA&#350; A&#286;RILARI</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>M&#304;GREN</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Migren, t�m
ba&#351;a&#287;r&#305;s&#305; hastal&#305;klar&#305; i�inde doktora en fazla
ba&#351;vuru nedeni olan durumdur. Migren tan&#305;s&#305; i�in �zel bir
laboratuvar testi veya radyolojik inceleme yoktur. &#304;nsanl&#305;k tarihi
kadar eski bir hastal&#305;k olan migren toplum i�in olduk�a �nemli bir
sa&#287;l&#305;k sorunudur, D�nya Sa&#287;l&#305;k �rg�t� taraf&#305;ndan en
�ok k&#305;s&#305;tl&#305;l&#305;k yapan hastal&#305;klar aras&#305;nda ele
al&#305;nm&#305;&#351;t&#305;r. Kad&#305;nlar&#305;n yakla&#351;&#305;k %
20'sinin, erkeklerin ise % 8'inin migrenli oldu&#287;u bilinmektedir. Atak
s&#305;ras&#305;ndaki olumsuz etkileri d&#305;&#351;&#305;nda da okul ve
i&#351; performans&#305;nda d�&#351;me ve sosyal problemler gibi kronik
etkileri vard&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Karakteristik �zellikleri
tekrarlay&#305;c&#305; olmas&#305;, ata&#287;&#305;n ila�s&#305;z olarak 4
saatten fazla s�rmesi (ve 3 g�nden az), tek yanl&#305; olu&#351;u (%80
hastada), zonklay&#305;c&#305; olmas&#305;, atak s&#305;ras&#305;nda
s&#305;kl&#305;kla &#305;&#351;&#305;ktan ve sesten rahats&#305;zl&#305;k,
merdiven �&#305;kma gibi fiziksel eylemlerle a&#287;r&#305;da art&#305;&#351;,
a&#287;r&#305;ya s&#305;kl&#305;kla bulant&#305; veya kusman&#305;n e&#351;lik
etmesi, a&#287;r&#305;n&#305;n orta &#351;iddette veya &#351;iddetli
olmas&#305;d&#305;r. Migren �o&#287;u kez �ncesinde bir n�rolojik defisit
olmaks&#305;z&#305;n ortaya �&#305;karken (<b>auras&#305;z migren</b>),
migrenli hastalar&#305;n %10�15 kadar&#305;nda a&#287;r&#305;lar&#305;n hemen
�ncesinde 5�60 dakika aras&#305; s�ren, ge�ici n�rolojik belirtiler g�r�lebilir
(<b>aural&#305; migren</b>). En s&#305;k g�rsel (hemianopsi, beyaz
&#305;&#351;&#305;klar g�rme, k&#305;r&#305;k �izgiler g�rme gibi) veya
dilde-y�zde-kolda uyu&#351;ma, g��s�zl�k, konu&#351;mada bozulma gibi
bulgular&#305;n birka�&#305; veya vertigo gibi di&#287;er arka sistem bulgular&#305;,
hatta uyan&#305;kl&#305;k kusuru &#351;eklinde <b>aura</b> olabilir. Hemen
ard&#305;ndan veya 1 saat i�inde a&#287;r&#305; ortaya �&#305;kabilir ya da
auray&#305; nadiren ba&#351;a&#287;r&#305;s&#305; izlemeyebilir. Migren
ataklar&#305; �oklukla epizodik ataklar &#351;eklinde gelirken, en az 3
ayd&#305;r her g�n veya g�na&#351;&#305;r&#305; olacak &#351;ekilde
kronikle&#351;mi&#351; olarak da g�r�lebilir. Bu durumun en b�y�k nedeni
a&#287;r&#305; kesici ila� a&#351;&#305;r&#305; kullan&#305;m&#305;d&#305;r.
B�yle bir durumda a&#287;r&#305; kesicilere en az 2 ay gibi bir s�re ara
verilmeden a&#287;r&#305;lar&#305;n kontrol� m�mk�n de&#287;ildir ve a&#287;r&#305;
kesiciler a&#351;&#305;r&#305; kullan&#305;ld&#305;&#287;&#305; s�rede
yap&#305;lan profilaktik tedavi �abalar&#305; da �o&#287;u kez
ba&#351;ar&#305;s&#305;zl&#305;kla sonu�lan&#305;r. <b>Tablo 3</b>�te IHS
s&#305;n&#305;flamas&#305;ndaki ilgili b�l�mler �zetlenmi&#351;tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<b><span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-font-kerning:18.0pt;mso-ansi-language:TR;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<h1><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 3. </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Uluslararas&#305;
Ba&#351;a&#287;r&#305;s&#305; Derne&#287;i: Migren Kriterleri (2004)</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></h1>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=644
 style='width:483.0pt;margin-left:-3.6pt;border-collapse:collapse;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=644 valign=top style='width:483.0pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.1
  Auras&#305;z Migren</span></b><b><i><span lang=TR style='font-size:8.0pt;
  font-family:Tahoma;mso-ansi-language:TR'> </span></i></b><span lang=TR
  style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Daha �nce
  kullan&#305;lm&#305;&#351; olan terimler: Genel (<i>Common</i>) migren, hemikranya
  simpleks</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;color:black;mso-ansi-language:
  TR'>Tan&#305;m:</span></b><span lang=TR style='font-size:8.0pt;font-family:
  Tahoma;color:black;mso-ansi-language:TR'> 4 � 72 saat s�ren ataklarla kendini
  g�steren tekrarlayan ba&#351;a&#287;r&#305;s&#305;.
  Ba&#351;a&#287;r&#305;s&#305;n&#305;n tipik �zellikleri</span><span lang=TR
  style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>;
  unilateraldir, zonklay&#305;c&#305; tarzdad&#305;r, orta &#351;iddette ya da
  &#351;iddetlidir, rutin fiziksel aktiviteyle k�t�le&#351;me izlenir ve mide
  bulant&#305;s&#305; ve/veya fotofobi ve fonofobi e&#351;lik eder.</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;sal
  kriterler:</span></b><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>A.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>B - D kriterlerine uyan en az 5 atak</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>B.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>4 - 72 saat aras&#305; s�ren ba&#351;a&#287;r&#305;s&#305; ataklar&#305;
  (tedavi edilmeyen ya da tedavisi ba&#351;ar&#305;s&#305;z olan)</span><span
  lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>C.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Ba&#351;a&#287;r&#305;s&#305; a&#351;a&#287;&#305;daki �zelliklerin en az
  ikisini ta&#351;&#305;mal&#305;d&#305;r:</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>i.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>unilateral lokalizasyon</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>ii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>zonklay&#305;c&#305; karakter</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>iii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>orta &#351;iddette ya da &#351;iddetli a&#287;r&#305;</span><span
  lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>iv.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>rutin fiziksel aktiviteyle k�t�le&#351;me ya da rutin fiziksel
  aktiviteden (�rn, y�r�me ya da merdiven �&#305;kma) ka�&#305;nmaya neden olma</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>D.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;Ba&#351;a&#287;r&#305;s&#305; s&#305;ras&#305;nda
  a&#351;a&#287;&#305;dakilerden en az biri g�r�l�r:</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>i.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>mide bulant&#305;s&#305; ve/veya kusma</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>ii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>fotofobi ve fonofobi</span><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:TR'>E.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Ba&#351;ka bir hastal&#305;kla ili&#351;kili de&#287;ildir.</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=644 valign=top style='width:483.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.2
  Aural&#305; Migren</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;m</span></b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>:
  Genelde 5 - 20 dakikada yava&#351; yava&#351; geli&#351;en ve 60 dakikadan az
  s�ren geri d�n�&#351;�ml�, fokal n�rolojik semptom ataklar&#305;yla kendini
  g�steren tekrarlayan durum. S&#305;kl&#305;kla aura semptomlar&#305;n&#305;
  takiben auras&#305;z migrende g�r�lene benzer ba&#351;a&#287;r&#305;s&#305;
  izler. Daha az s&#305;kl&#305;kla, ba&#351;a&#287;r&#305;s&#305;nda migren
  �zellikleri g�r�lmez veya ba&#351;a&#287;r&#305;s&#305; hi� <span
  style='color:black'>yoktur.</span></span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=644 valign=top style='width:483.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><i><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.2.1
  Migren Ba&#351;a&#287;r&#305;l&#305; Tipik Aura</span></i></b><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>A.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>B - D kriterlerine uyan en az 2 atak</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>B.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#351;a&#287;&#305;dakilerden en az birini ta&#351;&#305;yan aura
  g�r�l�r, ancak <u>motor g��s�zl�k g�r�lmez</u>: <b>(not: bu durumda
  hemiplejik migren s�zkonusudur)</b></span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>i.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>pozitif belirtiler (titre&#351;en &#305;&#351;&#305;klar, spotlar,
  �izgiler) veya negatif belirtiler i�eren (�rn, g�rme kayb&#305;) tam d�zelen
  g�rsel semptomlar</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>ii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>pozitif belirtiler (�rn, kar&#305;ncalanma) ve/veya negatif belirtiler
  i�eren (�rn, uyu&#351;ma) tam d�zelen duyusal semptomlar</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>iii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>tam d�zelen disfazik konu&#351;ma bozuklu&#287;u</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>C.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#351;a&#287;&#305;dakilerden en az ikisi:</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>i.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>homonim g�rsel semptomlar ve/veya unilateral duysal semptomlar</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>ii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>5 dakika ya da daha uzun s�rede yava&#351; yava&#351; geli&#351;en en az
  bir aura semptomu ve/veya 5 dakikadan uzun s�rede g�r�len birbirini izleyen
  farkl&#305; aura semptomlar&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:54.0pt;text-align:justify;text-indent:-54.0pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>iii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>her bir semptom 5 dakikadan uzun ve 60 dakikadan k&#305;sa s�rer</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>D.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Aura s&#305;ras&#305;nda veya takip eden 60 dakika i�erisinde 1.1'de
  anlat&#305;lan <i>Auras&#305;z migren</i> kriterlerinden B - D'ye uyan
  ba&#351;a&#287;r&#305;s&#305; ba&#351;lar</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:TR'>E.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Ba&#351;ka bir hastal&#305;kla ili&#351;kili de&#287;ildir.</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=644 valign=top style='width:483.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'><span lang=TR style='font-size:
  8.0pt;font-family:Tahoma;mso-fareast-font-family:"Times New Roman";
  mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><i><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.2.2
  Non-migren ba&#351; a&#287;r&#305;l&#305; tipik aura</span></i></b><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;m:</span></b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>
  G�rsel ve/veya duysal ve/veya konu&#351;ma semptomlar&#305;ndan olu&#351;an
  tipik aura. Yava&#351; geli&#351;mesi, bir saatten fazla s�rmemesi, hem
  negatif hem de pozitif �zellikler bar&#305;nd&#305;rmas&#305; ve tam geri
  d�nme olan ama b�l�m 1.1'de anlat&#305;lan <i>Auras&#305;z migren</i>
  kriterlerine uymayan farkl&#305; ba&#351;a&#287;r&#305;s&#305;n&#305;n
  e&#351;lik etti&#287;i auran&#305;n belirleyici �zellikleridir.</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;sal
  kriterler:</span></b><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>A.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>B - D kriterlerine uyan en az iki atak</span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>B.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Aura a&#351;a&#287;&#305;dakilerden en az birini ta&#351;&#305;r, fakat
  motor g��s�zl�k yoktur:</span><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:53.6pt;text-align:justify;text-indent:-53.6pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>i.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>pozitif (�rn, titre&#351;en &#305;&#351;&#305;k, spotlar veya �izgiler)
  ve/veya negatif (�rn, g�rme kayb&#305;) belirtilerin de i�inde oldu&#287;u
  tam d�zelen g�rsel semptomlar</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:53.6pt;text-align:justify;text-indent:-53.6pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>ii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>pozitif (�rn, kar&#305;ncalanma) ve/veya negatif (�rn, uyu&#351;ma)
  belirtilerin de oldu&#287;u tam d�zelen duyumsal semptomlar</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:53.6pt;text-align:justify;text-indent:-53.6pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>iii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>tam d�zelen disfazik konu&#351;ma bozuklu&#287;u</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>C.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#351;a&#287;&#305;dakilerden en az ikisi:</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:53.6pt;text-align:justify;text-indent:-53.6pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>i.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>homonim g�rsel semptomlar ve/veya unilateral duysal semptomlar</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:53.6pt;text-align:justify;text-indent:-53.6pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>ii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>5 dakika veya daha uzun s�rede yava&#351; yava&#351; geli&#351;en en az
  bir aura semptomu ve/veya 5 dakikadan daha uzun s�rede birbirini izleyen
  farkl&#305; aura semptomlar&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:53.6pt;text-align:justify;text-indent:-53.6pt;text-autospace:
  none'><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>iii.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>her bir semptom 5 dakikadan uzun ve 60 dakikadan k&#305;sa s�rer</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;text-autospace:
  none'><span lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:
  TR'>D.</span><span lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Aura s&#305;ras&#305;nda veya takip eden 60 dakika i�inde, b�l�m 1.1'de
  anlat&#305;lan <i>Auras&#305;z migren</i> B-D kriterlerine uymayan
  ba&#351;a&#287;r&#305;s&#305; ba&#351;lar</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt'><span
  lang=TR style='font-size:8.0pt;font-family:Arial;mso-ansi-language:TR'>E.</span><span
  lang=TR style='font-size:7.0pt;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span><span lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Ba&#351;ka bir hastal&#305;kla ili&#351;kili de&#287;ildir.</span><span
  lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td width=644 valign=top style='width:483.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><i><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.1
  Kronik migren</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;m:</span></b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'> <u>A&#351;&#305;r&#305;
  analjezik ila� al&#305;nmad&#305;&#287;&#305; takdirde</u> 3 aydan daha fazla
  s�re boyunca ayda 15 veya daha �ok g�n migren ba&#351;a&#287;r&#305;s&#305;
  g�r�l�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;sal
  kriterler:</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>A. </span></b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>3
  aydan fazla bir s�re boyunca ayda 15 ya da daha fazla g�n, b�l�m 1.1'de
  anlat&#305;lan <i>Auras&#305;z migren</i> kriterlerinden C ve D'ye uyan
  Ba&#351;a&#287;r&#305;s&#305;</span><span lang=TR style='mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;text-align:justify;text-autospace:none'><b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>B </span></b><span
  lang=TR style='font-size:8.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;ka
  bir hastal&#305;kla ili&#351;kili de&#287;ildir.</span><span lang=TR
  style='mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migrenden s�z edildi&#287;i zaman �o&#287;unlukla
ba&#351;a&#287;r&#305;s&#305; sadece �&#351;iddetli a&#287;r&#305; boyutu� ile
de&#287;erlendirilmektedir. H�lbuki a&#287;r&#305;, migrenin sadece bir d�nemi
olup, <i>migreni serebral disfonksiyona ba&#287;l&#305; olarak &#351;ekillenen
ve farkl&#305; d�nemler i�inde ortaya �&#305;kan bir semptomlar kompleksi
olarak ele almak daha uygundur</i>. Migren�in bu d�nemlerini, a&#287;r&#305;
�ncesinde ortaya �&#305;kan ve ki&#351;inin duyu durumunda veya bili&#351;sel
i&#351;levlerinde de&#287;i&#351;ikliklerle &#351;ekillenen, kimi zaman da
otonom ve sistemik belirtilerinin e&#351;lik etti&#287;i <b>prodrom</b> d�nemi,
varsa aura d�nemi, ard&#305;ndan a&#287;r&#305;n&#305;n ba&#351;lamas&#305;,
a&#287;r&#305; ve a&#287;r&#305;n&#305;n sonlanmas&#305; ile &#351;ekillenen
�a&#287;r&#305;� d�nemi ve son olarak da <b>postdrom</b> d�nemi olarak
s&#305;ralayabiliriz. (<b>Tablo 4</b>) Hastadan iyi bir �yk�
al&#305;nd&#305;&#287;&#305;nda migrenlilerin yakla&#351;&#305;k
%50-60�&#305;nda prodrom belirtilerinin bir ya da daha fazlas&#305;yla
kar&#351;&#305;la&#351;&#305;ld&#305;&#287;&#305; g�r�lecektir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 4 :</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Migren prodrom
d�neminde kar&#351;&#305;la&#351;&#305;labilecek ba&#351;l&#305;ca semptomlar</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=521 valign=top style='width:390.5pt;border:inset 1.0pt;padding:
  0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
  avoid'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>N�ro-psikolojik semptomlar</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:84.5pt'>
  <td width=521 valign=top style='width:390.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt;height:84.5pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#351;&#305;r&#305;
  duyarl&#305;l&#305;k-tepkisellik, depresif duygu durumu</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�fori,
  nadiren hiperaktive</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Durgunluk/donukluk,
  konsantrasyon ve dikkatte azalma, d�&#351;�ncede yava&#351;lama</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kelime
  bulma g��l�&#287;�, konu&#351;urken tak&#305;lma</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Artm&#305;&#351;
  &#305;&#351;&#305;k-ses-koku duyarl&#305;l&#305;&#287;&#305;</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Esneme,
  uyuma iste&#287;i</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=521 valign=top style='width:390.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sistemik/otonom
  semptomlar</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes;height:70.25pt'>
  <td width=521 valign=top style='width:390.5pt;border:inset 1.0pt;border-top:
  none;padding:0cm 3.5pt 0cm 3.5pt;height:70.25pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ense
  sertli&#287;i</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Halsizlik</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A�l&#305;k,
  tatl&#305; yeme iste&#287;i, i&#351;tah art&#305;&#351;&#305; veya
  i&#351;tahs&#305;zl&#305;k</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#351;&#305;r&#305;
  su i�me, v�cutta su tutulmas&#305;, s&#305;k idrara �&#305;kma</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kar&#305;nda
  &#351;i&#351;lik hissi, kab&#305;zl&#305;k veya ishal hali</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migren Patofizyolojisi</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Son y&#305;llarda ba&#351;a&#287;r&#305;s&#305;,
�zellikle de migren geneti&#287;i konusunda �nemli geli&#351;meler
olmu&#351;tur. Bug�n i�in migren, genetik fakt�rlerin �evresel fakt�rlerle
etkile&#351;im g�sterdi&#287;i kompleks �ok genli (poligenik) bir hastal&#305;k
olarak kabul edilmektedir. Aural&#305; migrende genetik fakt�rlerin auras&#305;z
migrene g�re daha fazla rol� oldu&#287;u konusunda �e&#351;itli bulgular
vard&#305;r. Sorumlu lok�sler ve yatk&#305;nl&#305;k genlerinin tam olarak
hangileri oldu&#287;u ve say&#305;s&#305; hen�z bilinmemektedir. Migrenin
ailesel �zellik g�sterdi&#287;i uzun zamand&#305;r bilinmekte ve deneyimli klinisyenler
taraf&#305;ndan tan&#305;ya yard&#305;m amac&#305;yla bile
kullan&#305;lmaktayd&#305;. Buna kar&#351;&#305;n yo&#287;un
ara&#351;t&#305;rmalara ra&#287;men &#351;u an i�in sadece migrenlilerin �ok
k���k bir oran&#305;n&#305; olu&#351;turan ve karakteristik bir klinik tablo
olan ailesel <i>hemiplejik migren</i>in (familyal hemiplejik migren (FHM))
genleri bulunabilmi&#351;, ancak �ok daha s&#305;k g�r�len auras&#305;z migren
formlar&#305;n&#305;n genlerine hen�z ula&#351;&#305;lamam&#305;&#351;t&#305;r.
Otozomal dominant tip genetik ge�i&#351; g�steren tek genli (monogenik) bu aural&#305;
migren formunun kalsiyum kanal&#305; (CACNA1a), Na-K-ATPaz pompas&#305;
(ATP1A2) ve sodyum kanal&#305; (SCN1A) ile ili&#351;kili baz&#305; genlerdeki
mutasyonlardan kaynaklad&#305;&#287;&#305; kesin olarak
kan&#305;tlanm&#305;&#351;t&#305;r. Bu veriler de migrenin bir kanalopati, yani
iyon kanal hastal&#305;&#287;&#305; oldu&#287;u g�r�&#351;�n� desteklemektedir.
Bu mutasyonlar&#305; ta&#351;&#305;yan baz&#305; aile bireylerinde auras&#305;z
migren ya da tamamen normal fenotip bulunabilmesi olay&#305;n di&#287;er ilgin�
bir boyutudur.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�te yandan bu genlerin ilk bulunan ikisi
ara&#351;t&#305;r&#305;lm&#305;&#351; ve s&#305;k rastlanan di&#287;er migren
fenotipleri i�in bir ka� olgu d&#305;&#351;&#305;nda anlaml&#305; bir
yatk&#305;nl&#305;k b�lgesi olu&#351;turmad&#305;klar&#305; g�r�lm�&#351;t�r.
Yap&#305;lan ba&#287;lant&#305; analizi �al&#305;&#351;malar&#305;nda �ok
farkl&#305; kromozomlar �zerinde birbirinden ba&#287;&#305;ms&#305;z
ba&#287;lant&#305; b�lgeleri g�sterilmi&#351;tir. Baz&#305;
�al&#305;&#351;malarda elde edilen sonu�lar di&#287;erleri taraf&#305;ndan,
metodolojik nedenlerle ve daha da �nemlisi etnik farkl&#305;l&#305;klar
nedeniyle do&#287;rulanamam&#305;&#351;t&#305;r. Aday olarak kabul edilebilen
genlerde �ok say&#305;da yap&#305;lm&#305;&#351; olan polimorfizmlerle
ili&#351;kilendirme �al&#305;&#351;malar&#305; mevcuttur, ancak bunlar&#305;n
da �nemi net de&#287;ildir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migren geneti&#287;i ara&#351;t&#305;rmalar&#305;n&#305;n gelecekte
s&#305;k rastlanan ve a&#287;&#305;r formlar&#305;n genlerini
ayd&#305;nlatmas&#305;, spesifik tan&#305; ve tedavi a�&#305;s&#305;ndan �nem
ta&#351;&#305;maktad&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;s&#305;n&#305;n patofizyolojisi</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
genellikle santral serotoninerjik ve adrenerjik a&#287;r&#305; mod�le eden
sistemleri i�ine alan n�rovask�ler teoriye g�re a�&#305;klanmaya
�al&#305;&#351;&#305;l&#305;r. N�rojenik inflamasyonun migren
a&#287;r&#305;s&#305;ndan sorumlu oldu&#287;u ve trigeminovask�ler sistemin
aktive oldu&#287;u d�&#351;�n�lmektedir. Yakla&#351;&#305;k 20 y&#305;l �nce
ba&#351;a&#287;r&#305;s&#305;n&#305;n patofizyolojik a�&#305;klamas&#305;
olarak vask�ler ba&#351;a&#287;r&#305;s&#305;n&#305;n damarlar&#305;n dilatasyonu,
gerilim ba&#351;a&#287;r&#305;s&#305;n&#305;n (tension headache) ise boyun ve
ba&#351; kaslar&#305;n&#305;n kontraksiyonu ile ortaya
�&#305;kt&#305;&#287;&#305; d�&#351;�n�l�yordu. Wolf�un ilk
�al&#305;&#351;malar&#305; a&#287;r&#305;ya duyarl&#305; intrakranyal
yap&#305;lar&#305; g�stermi&#351;tir.&nbsp; Bu yap&#305;lar ven�z sinusler,
dural, meningeal, di&#287;er arter ve venler, Willis polligonu yapan b�y�k
arterlerin proksimalleri, 5, 7, 9 ve 10 kranyal sinirler ve �st servikal
sinirlerin a&#287;r&#305;ya duyarl&#305; lifleri, kafa taban&#305;ndaki dura
materin damarlara kom&#351;u par�alar&#305;, paranazal sinus mukozalar&#305;,
di&#351;ler, kaslar, deri ve deri alt&#305; dokusudur. Beyin y�zeyinin
a&#287;r&#305;ya duyarl&#305; olmad&#305;&#287;&#305;, cerrahlar&#305;n
yapt&#305;&#287;&#305; ara&#351;t&#305;rmalar sonucunda bildirilmi&#351;tir.
&#304;ntrakranyal arterlerin dilatasyonu ya da BOS (beyin omurilik
s&#305;v&#305;s&#305;) yollar&#305;n&#305;n t&#305;kanmas&#305; nedeniyle artan
kafa i�i bas&#305;nc&#305; ya da a&#287;r&#305;ya duyarl&#305;
yap&#305;lar&#305;n inflamasyonunun, beynin gerilmesi ile a&#287;r&#305;y&#305;
yaratt&#305;&#287;&#305; d�&#351;�n�lmektedir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="basagrisi3.jpg">&#350;ekil 3.</a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Ba&#351;a&#287;r&#305;s&#305; patofizyolojisinde �nem ta&#351;&#305;yan
yap&#305;lar &#351;ekilde g�sterilmi&#351;tir. Korteks, talamus (Tal), hipotalamus
(Ht), limbik sistem ve periakuaduktal gri madde (PAG) ba&#351;ta olmak �zere
beyinsap&#305; yap&#305;lar&#305; aras&#305;nda yo&#287;un
ba&#287;lant&#305;lar bulunmaktad&#305;r ve bu yap&#305;lar trigeminoservikal
kompleks ile ba&#287;lant&#305;l&#305;d&#305;r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Migren olu&#351;umunda kortikal aktivite
varl&#305;&#287;&#305; bug�n kabul g�ren bir g�r�&#351;t�r. Migrene
ba&#287;l&#305; kan ak&#305;m&#305; de&#287;i&#351;iklikleri ve fonksiyonel MRG
sinyali kortikal yay&#305;lan depresyon olarak bilinen Leao taraf&#305;ndan
tan&#305;mlanm&#305;&#351; tabloyla benzer zamansal ve yerle&#351;imsel
�zellikler g�stermektedir. Kortikal yay&#305;lan depresyonun auran&#305;n
alt&#305;nda yatan temel mekanizma oldu&#287;u
kan&#305;tlanm&#305;&#351;t&#305;r, ancak hala tam a�&#305;kl&#305;&#287;a
kavu&#351;mam&#305;&#351; sorular vard&#305;r. Migrenli olgularda normallerle
k&#305;yasland&#305;&#287;&#305;nda transkranyal magnetik stim�lasyonla fosfen
olu&#351;ma e&#351;i&#287;inin d�&#351;�k veya de&#287;i&#351;ken olmas&#305;
altta yatan bilinmeyen yatk&#305;nl&#305;k fakt�rlerine i&#351;aret etmektedir.
Migren patofizyolojisinde beyinsap&#305; mekanizmalar&#305;n&#305;n da
katk&#305;s&#305; oldu&#287;u kesindir. &nbsp;Bulant&#305;, otonom semptomlar
gibi e&#351;lik�iler bu yap&#305;lardaki de&#287;i&#351;ik sinyallerden
kaynaklanmaktad&#305;r. Dorsolateral pons ve mezensefalon PET
�al&#305;&#351;malar&#305;nda aktivite g�r�len yap&#305;lard&#305;r ve
periakuaduktal gri madde (PAG) de �nem ta&#351;&#305;maktad&#305;r.
Hipotalamusun oreksin sisteminin migren ve k�me
ba&#351;a&#287;r&#305;s&#305;ndaki potansiyel rol� �zerinde de
durulmaktad&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Trigeminal yolak ya da trigeminovask�ler sistem burada
tutulan ana yap&#305;d&#305;r. Kalsitonin geni ile ili&#351;kili peptid (CGRP)
denen serebral otoreg�lasyonda �nemli rol� olan n�ropeptidin migren
ata&#287;&#305; s&#305;ras&#305;nda artt&#305;&#287;&#305; ve bu sistemin aktivasyonunda
rol oynad&#305;&#287;&#305;n&#305;n g�sterilmesi son y&#305;llardaki �nemli
geli&#351;melerdendir ve yeni tedavi stratejilerine y�n vermi&#351;tir.
Trigeminal nosiseptif n�ronlar&#305;n d&#305;&#351;&#305;nda astrositlerin
etkisiz elemanlar olmay&#305;p dalgalar yoluyla migren mekanizmalar&#305;nda
katk&#305;s&#305; oldu&#287;u da baz&#305; �al&#305;&#351;malarda
savunulmu&#351;tur. Trigeminal duysal n�ronlar&#305; etkileyen mekanik
bas&#305;n�, iyonik de&#287;i&#351;imlerin (artm&#305;&#351; K,
artm&#305;&#351; osmolarite, azalm&#305;&#351; pH gibi) yan&#305; s&#305;ra
substans P, bradikinin, endotelin ve CGRP gibi peptidler ve glutamat, serotonin,
histamin, ATP, adenozin gibi n�rotransmitterler oldu&#287;una
inan&#305;lmaktad&#305;r. Nitrikoksid de vask�ler h�crelerden konstriksiyon
s&#305;ras&#305;nda sal&#305;nan ve �nemli rol oynayan maddelerden biridir.
&#304;nen ve �&#305;kan a&#287;r&#305; kontrol sistemleri, beyinsap&#305; kan
damarlar&#305;n&#305; inerve eden �&#305;kan serotronerjik sistemi (midbrain
raphe) i�erir ve talamusa, hipotalamus ve kortekse do&#287;ru
yay&#305;l&#305;r. Bu sistem hem uyku hem de n�roendokrin kontrol� sa&#287;lar.
&#304;nen a&#287;r&#305;y&#305; mod�le eden serotonerjik sistem,
beyinsap&#305;n&#305;n PAG k&#305;s&#305;m&#305;ndan ba&#351;lar,
medullan&#305;n rafe magnusuna ula&#351;&#305;r ve spinal kordun dorsal boynuzunda
sonlan&#305;r. PAG�n&#305;n stim�lasyonu insanda potent aneljeziyi ortaya
�&#305;kar&#305;r. Noradrenerjik a&#287;r&#305; kontrol sistemi ponsun lokus
seruleusundan kaynaklan&#305;r. &#304;nen n�ronlar spinal kordda sonlan&#305;r.
�&#305;kan noradrenerjik sistem, lokus seruleustan ba&#351;lar, mikrosirk�lasyonu
innerve eder ve serebral kortekse yay&#305;l&#305;r. Merkezi sinir sistemi
periferik a&#287;r&#305; resept�rlerinden gelen a&#287;r&#305;y&#305; module
eden sistemler yoluyla gelen uyar&#305;lar&#305; kontrol eder. Serotoninerjik
sistemde 5-HT (5-Hidroksi triptamin) adrenerjik sistemde oldu&#287;u gibi,
enkafalin n�ronlar&#305;yla etkile&#351;ir. Norepinefrin, GABA i�eren eden
intern�ronlar kullan&#305;l&#305;r. Primer duysal n�ronlardan uyar&#305;lar
yaln&#305;zca MSS�ne de&#287;il perifere de gider. Periferik trigeminal
n�ronlar da sensitizasyon fenomeni g�sterirler, aljezik bir uyarana maruz
kal&#305;nca ayn&#305; veya farkl&#305; uyaran i�in cevap e&#351;i&#287;i
d�&#351;mektedir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Menstr�el
Migren</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kesin tan&#305;mlamalar de&#287;i&#351;mekle birlikte
menstr�el migren tan&#305;m&#305; premenstr�el d�nemde olu&#351;an migren
ataklar&#305;n&#305; tan&#305;mlamaktad&#305;r. Klinik g�zlemler, migren
ba&#351;a&#287;r&#305;lar&#305;n&#305;n menstr�el d�nem �ncesinde daha s&#305;k
ve daha &#351;iddetli oldu&#287;unu ortaya �&#305;karm&#305;&#351;t&#305;r. Bu
ba&#351;a&#287;r&#305;lar&#305; di&#287;er migren
ba&#351;a&#287;r&#305;lar&#305;n&#305;n cevap verdi&#287;i tedavilere diren�li
kalabilir, uzayabilir ve �ok daha &#351;iddetli olabilir. Menstr�asyon&nbsp;
s&#305;ras&#305;nda migren ataklar&#305; s&#305;k g�r�lmesine kar&#351;&#305;n,
e&#287;er ataklar&#305;n %90�&#305; menstr�asyon s&#305;ras&#305;nda oluyorsa
bu menstr�el migren ad&#305;n&#305; al&#305;r.
Ba&#351;a&#287;r&#305;s&#305;n&#305;n menstr�el migren olarak
tan&#305;mlanabilmesi i�in ataklar&#305;n %90�&#305;n&#305;n adetten �nceki 2
g�n ve adetin son g�n� aras&#305;nda olmas&#305; gerekmektedir. Migren riski
�detin ilk 3 g�n� daha fazlad&#305;r. Bu tablonun alt&#305;nda �strojenin
yatt&#305;&#287;&#305; d�&#351;�n�lmekle birlikte net olarak
kan&#305;tlanm&#305;&#351; bir mekanizma yoktur. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Depresyon ve
Migren</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Migren prodromu, kriz d�nemi ve ikisi aras&#305;ndaki
d�nemlerde psikiyatrik semptomlar&#305;n s&#305;k g�r�ld�&#287;�
bildirilmi&#351;tir. Liveing 1873 y&#305;l&#305;nda depresyon ve
yorgunlu&#287;u migrenin tipik �zellikleri olarak
tan&#305;mlam&#305;&#351;t&#305;r. Daha sonralar&#305; ise migren
hastalar&#305; aras&#305;nda bir apati duyusu, enerji eksikli&#287;i ve
yorgunluk ile karakterize olan hafif zihinsel ve fiziksel depresyonun s&#305;k
olu&#351;u bildirmi&#351;tir. Wolf migrenli hastalarda, karakteristik �zellik
olarak, a&#351;&#305;r&#305; fiziksel yorgunluk ve apatinin bulundu&#287;unu
kaydetmi&#351;tir.&nbsp;1988 y&#305;l&#305;nda ise Blau, afektif bozukluklar&#305;
karakterize eden semptomlara benzer migren prodromunu, iritabilite, depresyon
ya da co&#351;ku, motor aktivitede bozukluklar, i&#351;tah ve uyku
de&#287;i&#351;ikliklerini i�eren semptomlardan s�z etmi&#351;tir. Bu klinik
g�zlemlerin tutarl&#305;l&#305;&#287;&#305;na kar&#351;&#305;l&#305;k migren
ile depresyon aras&#305;ndaki ili&#351;kiyi sistematik olarak ele alan kontroll�
�al&#305;&#351;malar&#305;n say&#305;s&#305; �ok azd&#305;r. Migren ile
depresyon aras&#305;ndaki ili&#351;ki g�zden ge�irildi&#287;inde dikkate
de&#287;er bir benzerlik oldu&#287;u g�r�lmektedir. Her iki bozukluk da
kad&#305;n ve gen� eri&#351;kinlerde daha s&#305;kt&#305;r, &#305;rk ve sosyal
s&#305;n&#305;f a�&#305;s&#305;ndan benzer bir da&#287;&#305;l&#305;m g�sterir.
Farkl&#305; incelemelerde, her iki bozukluk i�in de benzer prevalans
g�r�lmektedir. Her iki durumda ba&#351;lang&#305;� ortalama
ya&#351;&#305;n&#305;n 24-29 olmas&#305; da �nemlidir. Bu bulgular&#305;n ve
yap&#305;lan az say&#305;daki �al&#305;&#351;malar&#305;n
&#305;&#351;&#305;&#287;&#305;nda migren ve depresyon etyolojik olarak
ili&#351;kili bulunmu&#351;tur. Bu nedenle ya ortak gizli patolojik
mekanizmalar&#305; payla&#351;maktad&#305;rlar ya da bozukluklardan birisinin
di&#287;erine yol a�mas&#305; veya onun geli&#351;mesine neden olmas&#305;
&#351;eklinde bir sebep sonu� ili&#351;kisi s�z konusudur. Ancak &#351;unu da
bilmemiz gerekir: migren ile di&#287;er durumlar aras&#305;nda hep ili&#351;ki
aranm&#305;&#351;t&#305;r. �rne&#287;in 1920�lerde ge�erli olan ili&#351;ki
epilepsi ile oland&#305;r. Bug�n hala migren ve epilepsi aras&#305;nda
ili&#351;ki kurulmaktad&#305;r ve genetik �al&#305;&#351;malar bu
ba&#287;lant&#305;y&#305; kan&#305;tlam&#305;&#351;t&#305;r. �zellikle �ocukluk
�a&#287;&#305;nda g�r�len abdominal migren ile abdominal epilepsi aras&#305;nda
bir ili&#351;kinin bulundu&#287;undan ve ay&#305;r&#305;c&#305; tan&#305;da
akl&#305;m&#305;za bu olas&#305;l&#305;&#287;&#305;n da gelmesinden s�z
edilmektedir. 1930 ve 40 y&#305;llar&#305; aras&#305;nda ise migren ve alerji
aras&#305;nda ili&#351;ki aranm&#305;&#351;t&#305;r. Bug�n migrenin ?ya da
alerji ile kesin bir ilgisi oldu&#287;u kan&#305;tlanamam&#305;&#351;t&#305;r.
Bunun d&#305;&#351;&#305;nda da kronik a&#287;r&#305;,
ba&#351;a&#287;r&#305;s&#305; ve depresyon aras&#305;ndaki ili&#351;ki,
psikiyatrik ve psikososyal a�&#305;dan&nbsp; ayr&#305;ca g�zden ge�irilmesi
gereken bir konudur.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migren Tedavisi</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migren tedavi edilmelidir ��nk� migren ata&#287;&#305; s&#305;ras&#305;nda
hasta i&#351;ini yapamaz duruma gelerek �retim ve kapasite kayb&#305;na
u&#287;rar. Ayr&#305;ca hastan&#305;n hayat kalitesi a&#287;r&#305; nedeniyle
d�&#351;er. Migren tan&#305;s&#305; koyulduktan sonra hastaya migrenin
hayat&#305; tehdit eden bir beyin hastal&#305;&#287;&#305;
olmad&#305;&#287;&#305; ve tedavisinin belli bir d�zene g�re ve hekimle
i&#351;birli&#287;i i�inde yap&#305;lmas&#305; gerekti&#287;i
a�&#305;klanmal&#305;d&#305;r. Patofizyolojisi tam bilinmeyen migrenin tedavisi
bu nedenle semptomatiktir. Son y&#305;llarda yap&#305;lan epidemiyolojik
�al&#305;&#351;malar �zellikle aural&#305; migrenin 45 ya&#351; alt&#305;
kad&#305;nlarda artm&#305;&#351; bir iskemi riski (3.8-6.2 kat)
yaratt&#305;&#287;&#305;n&#305; g�stermi&#351;tir. Bu durum sigara ve
di&#287;er risk fakt�rleri bulundu&#287;unda artmaktad&#305;r ve bu nedenle
hastalar bilgilendirilmelidir. Migrenli olgularda sessiz infarktlar&#305;n ve
sessiz ak akmadde lezyonlar&#305;n&#305;n da artm&#305;&#351; oldu&#287;u
g�sterilmi&#351;tir (<b>&#350;ekil 4</b>).</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.25pt'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'><a
href="basagrisi4.jpg">&#350;ekil 4.</a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-ansi-language:TR'> </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Migrenli
olgularda normallere g�re daha s&#305;k rastland&#305;&#287;&#305;
bildirilmi&#351; olan ve tam olarak �nemi bilinmeyen beyaz madde
lezyonlar&#305; bazen ciddi boyutlara ula&#351;abilmektedir. Aural&#305;
migreni olan bu olguda &nbsp;hatal&#305; olarak multipl skleroz
tan&#305;s&#305; ile ara&#351;t&#305;rmalar yap&#305;lm&#305;&#351;t&#305;.<span
style='color:blue'> &nbsp;</span></span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Migrenin &#304;la�la Tedavisi</span></i></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migrende ila� tedavisi ataklardan korunmaya y�nelik �<i>profilaktik</i>�
veya �nleyici/koruyucu tedavi ve ata&#287;&#305;n a&#287;r&#305;, bulant&#305;,
kusma gibi yak&#305;nmalar&#305;n&#305;n giderilmesine y�nelik �<i>atak
(akut/a&#287;r&#305;) tedavisi</i>� olarak iki &#351;ekilde yap&#305;l&#305;r.
Profilaktik tedavi belirli bir s�re boyunca d�zenli ila� kullanarak
a&#287;r&#305; s&#305;kl&#305;&#287;&#305;n&#305; ve &#351;iddetini
azalt&#305;lmaya y�neliktir. Profilaktik tedavi herkese ayn&#305; &#351;ablonun
uygulanmad&#305;&#287;&#305;, her hastaya �zel olarak karar verilmesi gereken
bir tedavi &#351;eklidir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Atak tedavisinde olgular&#305;n bir k&#305;sm&#305;nda aspirin,
asetaminofen, naproksen, etodolak veya ibuprofen gibi a&#287;&#305;z yolu ile
al&#305;nan basit ve nonsteroidal analjezikler veya kafein ile kombine
edilmi&#351; analjezikler etkilidir. Ancak kombine ila�lardan ka�&#305;nmak
tercih edilmelidir. Karanl&#305;k ve sakin bir odada, buz paketi koyarak
dinlenmek a&#287;r&#305;n&#305;n giderilmesini kolayla&#351;t&#305;r&#305;r.
E&#287;er uyunabilirse genellikle hasta a&#287;r&#305;dan kurtulmu&#351; olarak
uyan&#305;r. S&#305;k atakl&#305; olgularda (ayda 5den fazla) analjezik
kullan&#305;m s&#305;n&#305;rlar&#305; belirlenmeli ve hasta ila�
a&#351;&#305;r&#305; kullan&#305;m ba&#351;a&#287;r&#305;s&#305; konusunda
uyar&#305;lmal&#305;d&#305;r. Hastal&#305;&#287;&#305; tetikleyen fakt�rlerden
ka�&#305;nma, �&#287;�n atlamama, uyku saatlerinin d�zenli olmas&#305;n&#305;n
sa&#287;lamas&#305; gibi baz&#305; basit tedbirlerle a&#287;r&#305;n&#305;n
s&#305;kl&#305;&#287;&#305; azalt&#305;labilir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Atak Tedavisi </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>(<b>Tablo 3 a ve b</b>)</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migren i�in �zel olan atak tedavisinde ergot preparatlar&#305; ve triptan
grubu (sumatriptan, eletriptan, rizatriptan, frovatriptan gibi) gibi migrene
�zel tedaviler �nemli bir yer tutmaktad&#305;r. Ergo t�revi ila�lar&#305;n uzun
s�reli kullan&#305;mda daha da belirginle&#351;en genel damar
daralt&#305;c&#305; riskleri, �ok daha ucuz olmalar&#305;na kar&#351;&#305;n,
bu tip yan etkileri ta&#351;&#305;mayan se�ici serotoninerjik ila�lar olan
triptanlar&#305;n g�n�m�zde migren spesifik ila�lar olarak ergo t�revlerine
tercih edilmelerine neden olmu&#351;tur. Triptanlar 5HT1B ve1D resept�r
agonistidir. Bulant&#305;s&#305; �ok belirgin olan hastalarda kas i�i ve
damardan enjeksiyonlar d&#305;&#351;&#305;nda hastan&#305;n kendine
uygulayabilece&#287;i deri alt&#305; enjeksiyon &#351;eklinde ve nazal sprey
&#351;eklinde de triptan grubu ila�lar �retilmi&#351;tir. Bu ila�lar
hastan&#305;n her atakta doktor ba&#351;vurusu yapmaktan kurtulmas&#305;
a�&#305;s&#305;ndan �ok �nem ta&#351;&#305;maktad&#305;r. Atak tedavisinde
opiodlerin ve kortikosteroidlerin yeri yoktur. Anti-emetikler ise yararl&#305;
kabul edilmektedir, NSA&#304;den 20 dakika �nce al&#305;nmalar&#305; hem
bulant&#305;y&#305; giderir, hem de mideden emilimi artt&#305;r&#305;r,
ayr&#305;ca hafif a&#287;r&#305; giderici etkileri de oldu&#287;u ileri
s�r�lmektedir. Metoklopamid (10-20 mg oral veya &#304;V, &#304;M) ve domperidon
(20-30 mg) kullan&#305;labilir, diskinezi riski a�&#305;s&#305;ndan dikkatli
olunmal&#305;d&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Atak tedavisinde ila�lar&#305;n ba&#351;a&#287;r&#305;s&#305;
ba&#351;lang&#305;c&#305;nda m�mk�n oldu&#287;unca erken al&#305;nmas&#305;
�nerilmektedir. Migren tedavisinin hastan&#305;n ya&#351;am kalitesini
y�kseltmeye y�nelik oldu&#287;u unutulmamal&#305; ve tedavi her hastan&#305;n
durumuna ve �zel gereksinimlerine g�re y�nlendirilmelidir. Her hastada uygun
bir standart yakla&#351;&#305;m olmad&#305;&#287;&#305;
unutulmamal&#305;d&#305;r. �rne&#287;in uyuyarak ata&#287;&#305;n&#305; ge�irebilen
ve ila� almay&#305; sevmeyen ya da yan etki g�ren bir hastaya di&#287;erlerine
iyi gelen bir analjezi&#287;i almas&#305; i�in &#305;srar etmek uygun
de&#287;ildir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 3a. </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migren atak tedavisinde g�n�m�zde s&#305;k kullan&#305;lan baz&#305;
nonspesifik ila�lar</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=89 valign=top style='width:67.05pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;la� </span></b></p>
  </td>
  <td width=70 valign=top style='width:52.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�nerilen Doz</span></b></p>
  </td>
  <td width=61 valign=top style='width:45.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Etkinlik D�zeyi</span></b></p>
  </td>
  <td width=124 valign=top style='width:93.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Olas&#305; veya S&#305;k Yan Etki</span></b><span
  lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Olumlu Komorbid Durum</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Olumsuz Komorbid Durum veya Kontrendikasyon</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=89 valign=top style='width:67.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Asetil salisilik asit</span></p>
  </td>
  <td width=70 valign=top style='width:52.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1000 mg</span></p>
  </td>
  <td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>++</span></p>
  </td>
  <td width=124 valign=top style='width:93.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gastrointestinal sistem yan etkileri, kanama
  e&#287;ilimi</span><span lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Koroner arter hastal&#305;&#287;&#305;, ge�ici iskemik
  atak</span><span lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>B�brek hastal&#305;&#287;&#305;, karaci&#287;er
  hastal&#305;&#287;&#305;, peptik �lser, gastrit, kanamal&#305; durumlar</span><span
  lang=FI style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=89 valign=top style='width:67.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Parasetamol (<u>+</u>Kafein)</span></p>
  </td>
  <td width=70 valign=top style='width:52.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>500-1000 mg</span></p>
  </td>
  <td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>?+</span></p>
  </td>
  <td width=124 valign=top style='width:93.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nadir (karaci&#287;er, kan ve deri)</span><span
  lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gebelik</span></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Karaci&#287;er hastal&#305;&#287;&#305;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=89 valign=top style='width:67.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Naproksen </span></p>
  </td>
  <td width=70 valign=top style='width:52.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>550-1100 mg</span></p>
  </td>
  <td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>++</span></p>
  </td>
  <td width=124 valign=top style='width:93.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gastrointestinal sistem yan etkileri</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Artrit ve di&#287;er a&#287;r&#305;l&#305; durumlar</span></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�lser, gastrit</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=89 valign=top style='width:67.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Metamizol oral ve &#304;.V.</span></p>
  </td>
  <td width=70 valign=top style='width:52.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1000mg </span></p>
  </td>
  <td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
  <td width=124 valign=top style='width:93.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hipotansiyon Agran�lositoz,</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>-</span></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Porfiri, kan diskrazileri, glikoz 6 P dehidrogenaz
  eksikli&#287;i</span><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=89 valign=top style='width:67.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Diklofenak Potasyum</span></p>
  </td>
  <td width=70 valign=top style='width:52.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>50-100 mg</span></p>
  </td>
  <td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>++</span></p>
  </td>
  <td width=124 valign=top style='width:93.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gastrointestinal sistem yan etkileri</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Artrit ve di&#287;er a&#287;r&#305;l&#305; durumlar</span></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�lser, gastrit, �rtiker, kolit, karaci&#287;er ve
  b�brek yetmezli&#287;i</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=89 valign=top style='width:67.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Flurbiprofen</span></p>
  </td>
  <td width=70 valign=top style='width:52.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>100-300 mg</span></p>
  </td>
  <td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>++</span></p>
  </td>
  <td width=124 valign=top style='width:93.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gastrointestinal sistem yan etkileri</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Romatizmal hastal&#305;klar, dismenore</span></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Renal ve hepatik fonk bozuklu&#287;u, s&#305;v&#305;
  retansiyonu, �dem</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;mso-yfti-lastrow:yes'>
  <td width=89 valign=top style='width:67.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;buprofen</span></p>
  </td>
  <td width=70 valign=top style='width:52.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>200-8000</span></p>
  </td>
  <td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>++</span></p>
  </td>
  <td width=124 valign=top style='width:93.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gastrointestinal sistem yan etkileri</span></p>
  </td>
  <td width=124 valign=top style='width:93.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Romatizmal hastal&#305;klar, dismenore</span></p>
  </td>
  <td width=150 valign=top style='width:112.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Renal ve hepatik fonk bozuklu&#287;u, s&#305;v&#305;
  retansiyonu, �dem</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-indent:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<b><span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 3b. </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Migren atak tedavisinde g�n�m�zde s&#305;k kullan&#305;lan baz&#305;
spesifik ila�lar</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=90 valign=top style='width:67.15pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;la� </span></p>
  </td>
  <td width=70 valign=top style='width:52.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�nerilen Doz</span></p>
  </td>
  <td width=60 valign=top style='width:44.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Etkinlik D�zeyi</span></p>
  </td>
  <td width=125 valign=top style='width:93.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Olas&#305; veya S&#305;k Yan Etki</span><span lang=FI
  style='mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
  <td width=125 valign=top style='width:93.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Olumlu Komorbid Durum</span></p>
  </td>
  <td width=150 valign=top style='width:112.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Olumsuz Komorbid Durum veya Kontrendikasyon</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=90 valign=top style='width:67.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Eletriptan (Oral)</span></p>
  </td>
  <td width=70 valign=top style='width:52.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>40 mg</span></p>
  </td>
  <td width=60 valign=top style='width:44.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+++</span></p>
  </td>
  <td width=125 rowspan=7 valign=top style='width:93.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Ate&#351; basmas&#305;, k&#305;rg&#305;nl&#305;k,&nbsp;
  halsizlik, asteni, sersemlik hali, ba&#351; s�nmesi, bulant&#305;, g�&#287;�ste
  bas&#305;n�, s&#305;k&#305;nt&#305; hissi ve a&#287;r&#305;</span></p>
  </td>
  <td width=125 rowspan=7 valign=top style='width:93.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Yok </span></p>
  </td>
  <td width=150 rowspan=7 valign=top style='width:112.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Baziler tip migren, hemiplejik migren, peptik �lser,
  periferik arter hastal&#305;&#287;&#305;, Prinzmetal anjinas&#305;, kontrol
  edilemeyen hipertansiyon</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=90 valign=top style='width:67.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Naratriptan (Oral)</span></p>
  </td>
  <td width=70 valign=top style='width:52.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>2.5 mg</span></p>
  </td>
  <td width=60 valign=top style='width:44.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=90 valign=top style='width:67.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Sumatriptan (Oral)</span></p>
  </td>
  <td width=70 valign=top style='width:52.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>50-100 mg</span></p>
  </td>
  <td width=60 valign=top style='width:44.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+++</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=90 valign=top style='width:67.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Zolmitriptan (Oral, nazal)</span></p>
  </td>
  <td width=70 valign=top style='width:52.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>2.5 mg</span></p>
  </td>
  <td width=60 valign=top style='width:44.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+++</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=90 valign=top style='width:67.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Rizatriptan</span></p>
  </td>
  <td width=70 valign=top style='width:52.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>10 mg</span></p>
  </td>
  <td width=60 valign=top style='width:44.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+++</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=90 valign=top style='width:67.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Frovatriptan*</span></p>
  </td>
  <td width=70 valign=top style='width:52.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>2.5 mg</span></p>
  </td>
  <td width=60 valign=top style='width:44.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>++</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;mso-yfti-lastrow:yes'>
  <td width=90 valign=top style='width:67.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Sumatriptan (Subk�tan)</span></p>
  </td>
  <td width=70 valign=top style='width:52.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>6 mg</span></p>
  </td>
  <td width=60 valign=top style='width:44.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>++++</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-indent:35.4pt'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>*Frovatriptan daha uzun
etkilidir ve perimenstr�el migrende koruyucu tedavide kullan&#305;labilmektedir.
</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Epidemiyolojik �al&#305;&#351;malar �zellikle gen� kad&#305;nlarda migrenin
inme i�in ba&#287;&#305;ms&#305;z bir risk fakt�r� oldu&#287;unu
g�stermektedir. Migrenli hastalara mutlaka sigara i�memeleri
�&#287;�tlenmelidir. <i>�zellikle hemiplejik migren, baziler migren ve
uzam&#305;&#351; aural&#305; migren hastalar&#305;nda vazokonstrikt�r ila�lar
kullan&#305;lmamal&#305; veya s&#305;n&#305;rl&#305; tutulmal&#305;d&#305;r.</i>
Kontroll� �al&#305;&#351;malar&#305;n g�venli ve etkin olduklar&#305;n&#305;
g�stermesine ra&#287;men, aural&#305; migrende beta blokerlerin
kullan&#305;m&#305; tart&#305;&#351;mal&#305;d&#305;r. Ca kanal blokerleri,
valproat, topiramat, gabapentin ve lamotrijin aural&#305; migrenlilerde
di&#287;er se�enekler aras&#305;nda say&#305;labilir. <i>Aural&#305; migren
olarak adland&#305;r&#305;lan ataklarda, a&#287;r&#305; ba&#351;lamadan �nce
aura d�neminde verilen triptan grubu ila�lar&#305;n etkisiz
kalaca&#287;&#305;n&#305; bilmek �nemlidir</i>. Bir di&#287;er bilgi de
migrenlilerde allodini durumu geli&#351;ti&#287;inde art&#305;k triptana
cevab&#305;n kaybolmas&#305;d&#305;r. <i>Allodini</i> hastan&#305;n genellikle
ba&#351;&#305;nda bazen de taraflar&#305;nda normalde a&#287;r&#305;l&#305;
olmayan bir uyaran&#305;n (eliyle dokunma gibi) rahats&#305;z edici olarak
alg&#305;lanmas&#305; ve kal&#305;c&#305; bir ke�ele&#351;me hissetmesi olarak
tan&#305;mlanabilir. Trigeminal yollar&#305;n santral
duyarl&#305;la&#351;mas&#305; sonucunda olu&#351;ur. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Profilaktik Tedavi</span></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Atak tedavisine yeterli cevap vermeyen ve/veya atak tedavilerinin yan
etkilerinin tolere edilemez d�zeyde oldu&#287;u, ayda 3 den fazla say&#305;da
migren ata&#287;&#305; ge�iren hastalarda profilaktik tedavi indikedir.
Ayr&#305;ca 48 saatten uzun s�ren migren ataklar&#305;, hasta taraf&#305;ndan
subjektif olarak dayan&#305;lmaz &#351;iddette bulunan migren a&#287;r&#305;lar&#305;
ve komplike migren ataklar&#305; (hemiplejik migren, baziler migren,
uzam&#305;&#351; aural&#305; migren, migrenle ili&#351;kili infarkt gibi nadir
durumlar) y�ksek oranda profilaksi gerektirir. Migrene ba&#287;l&#305;
kay&#305;plar&#305;n (i&#351;g�c�, sosyal ya&#351;am) yani disabilitenin
d�zeltilmesi ve ya&#351;am kalitesinin y�kseltilmesi de tek ba&#351;&#305;na profilaksi
indikasyonu kabul edilmelidir.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Koruyucu tedavide kullan&#305;lan ila�lar migren atak
s&#305;kl&#305;&#287;&#305;n&#305; ve &#351;iddetini azalt&#305;rlar ve migren
s&#305;kl&#305;&#287;&#305;n&#305;n y�zde ellinin �st�nde azalmas&#305;
tedavinin etkinli&#287;ini g�sterir. Profilaktik ila�lar d�&#351;�k dozlarda
ba&#351;lanarak yava&#351; yava&#351; artt&#305;r&#305;l&#305;r ve
etkinli&#287;i de&#287;erlendirebilmek i�in iki �� ay beklemek gerekir.
Profilakside kullan&#305;lan ila�lar �e&#351;itli gruplardand&#305;r,
�rne&#287;in hipertansiyon kontrol� ama�l&#305; ila�lar (</span><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>beta-</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Blokerler:</span><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>propranolol,
metoprolol, n�bivolol veya verapamil gibi), epilepsi ila�lar&#305; (valproik
asid, topiramat, gabapentin gibi) depresyon ila�lar&#305; (amitriptilin,
venlafaksin, serotonin geri al&#305;m inhibit�rleri gibi), flunarizin ve
pizotifen say&#305;labilir. Profilaksi alt&#305;ndaki bir hastan&#305;n
kulland&#305;&#287;&#305; ilac&#305;n olas&#305; yan etkileri konusunda �nceden
bilgi sahibi olmas&#305; ve hekim kontrol�nde kalmas&#305; �nemlidir. Bu
ila�lar&#305;n b�y�k k&#305;sm&#305; migren indikasyonu olmayan ila�lar
oldu&#287;undan hastaya yan etkileri konusunda ayr&#305;nt&#305;l&#305; bilgi
verilmeli ve bilgilendirilmi&#351; olur imzalat&#305;lmal&#305;d&#305;r.
&#304;la� se�erken hastan&#305;n durumuna ve di&#287;er
hastal&#305;klar&#305;na g�re olumlu (</span><span lang=TR style='font-family:
Wingdings;mso-ansi-language:TR'>J</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> ) veya olumsuz durumlar (</span><span lang=TR
style='font-family:Wingdings;mso-ansi-language:TR'>L</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>) dikkatle ele
al&#305;nmal&#305;d&#305;r (<b>Tablo 4</b>).</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<h2 style='page-break-after:auto;text-autospace:none'><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Migren
profilaksisinde ila� g�nde 1 veya en fazla 2 dozda al&#305;nmal&#305;d&#305;r
ve bir ba&#351;a&#287;r&#305;s&#305; g�nl�&#287;�n�n kullan&#305;m&#305;
sa&#287;lanmal&#305;d&#305;r. Hasta bir sorunla
kar&#351;&#305;la&#351;t&#305;&#287;&#305;nda doktora ula&#351;abilmeli ve
3-6-9 aylarda kontrolleri yap&#305;lmal&#305;d&#305;r.&nbsp; Profilaksiye
yan&#305;ts&#305;z olguda g�nl�&#287;� dikkatle ele al&#305;nmal&#305;,
hastan&#305;n beklenti d�zeyi ve atak tedavisi, dozu, ilac&#305; gerekti&#287;i
gibi kullan&#305;p kullanmad&#305;&#287;&#305;, yan etkiler g�zden
ge�irilmelidir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></h2>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hastan&#305;n iyi uyku d�zeni, beslenme ve spor gibi, ya&#351;am hijyenine
dikkat etmesi, tetikleyicilerden uzak durmas&#305; �&#287;�tlenmelidir.
Profilaksinin&nbsp; endike oldu&#287;u olgularda en s&#305;k yap&#305;lan
hatalar aras&#305;nda tedavide gecikme, d�&#351;�k doz ve k&#305;sa s�re
kullan&#305;m ve ila� se�erken komorbiditeye dikkat edilmemesi
say&#305;labilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<b>Tablo&nbsp; 4.</b> Migren profilaksisinde ila� se�iminde
kormorbitenin rol�</span><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Komorbid durum</span></b></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Etki</span></b></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Profilaksi se�imi</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren + hipertansiyon</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>J</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>beta bloker, kalsiyum kanal blokeri</span><span
  lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren + anjina</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>J</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kalsiyum kanal blokeri</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren + stres</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>J</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>beta bloker</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren + depresyon</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>J</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>trisiklik antidepresan, SSRI </span><span lang=DA
  style='mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>beta bloker</span><span lang=DA style='mso-ansi-language:
  DA'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren + insomni</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>J</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>trisiklik antidepresan</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren + epilepsi</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>J</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>valproat, topiramat </span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>trisiklik antidepresan</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren + obezite</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>J</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>valproat, flunarizin, amitriptilin, </span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>topiramat</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren + ast&#305;m</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>beta bloker</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren +Raynaud fenomeni</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>beta bloker</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren +ya&#351;l&#305; hasta</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>trisiklikler, kalsiyum kanal blokeri</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren +zay&#305;f beden</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Topiramat, beta bloker</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren +dikkat gerektiren i&#351;</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>trisiklikler, topiramat</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren +karaci&#287;er hastal&#305;&#287;&#305;</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Valproat</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren +glokom</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Topiramat</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;mso-yfti-lastrow:yes'>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Migren +b�brek ta&#351;&#305;</span></p>
  </td>
  <td width=55 valign=top style='width:40.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Wingdings;mso-ansi-language:TR'>L</span></p>
  </td>
  <td width=355 valign=top style='width:266.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Topiramat</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Migren statusu</span></i><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> 72 saatten uzun s�ren ataklar
veya 4 saatten k&#305;sa s�ren a&#287;r&#305;s&#305;z d�nemlerin
d&#305;&#351;&#305;nda devam eden ataklar veya standart atak tedavisine
cevaps&#305;z uzam&#305;&#351; migren &#351;eklinde tan&#305;mlanabilir.
Hastan&#305;n h&#305;zla kortikosteroidler (deksametazon 16 mg &#304;V gibi),
antiemetik (&#304;V), antiepileptik (&#304;V), magnezyum (1 gr &#304;V),
ketodolak veya gere&#287;inde opioidler gibi se�eneklerle tedavisi
sa&#287;lanmal&#305;d&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:35.4pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Migren tedavisinde
ba&#351;ar&#305;s&#305;zl&#305;&#287;&#305;n nedenleri:</span></i></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;
     eksik veya yanl&#305;&#351;t&#305;r </span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;
     konmam&#305;&#351; ba&#351;ka bir hastal&#305;&#287;a ba&#287;l&#305;
     sekonder ba&#351;a&#287;r&#305;s&#305; bozuklu&#287;u mevcuttur</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yanl&#305;&#351;
     tan&#305; konmu&#351; bir primer ba&#351;a&#287;r&#305;s&#305;
     bozuklu&#287;u mevcuttur</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;ki
     veya daha fazla farkl&#305; ba&#351;a&#287;r&#305;s&#305; bozuklu&#287;u
     mevcuttur</span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�nemli
     tetikleyici fakt�rler g�zden ka�&#305;r&#305;lm&#305;&#351;t&#305;r </span></li>
</ul>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hormonal
tetikler</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Psikososyal
fakt�rler (Depresyon ve madde ba&#287;&#305;ml&#305;l&#305;&#287;&#305;)</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;
a&#287;r&#305;lar&#305;n&#305; tetikleyen di&#287;er ila�lar </span></p>

<p class=MsoNormal style='margin-left:54.0pt;text-indent:16.8pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ya&#351;am
&#351;eklinin ba&#351;a&#287;r&#305;s&#305;n&#305; tetiklemesi (stres,
uykusuzluk, alkol kullan&#305;m&#305; vb.)</span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l3 level1 lfo4;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;la�
     a&#351;&#305;r&#305; kullan&#305;m&#305; vard&#305;r</span></li>
 <li class=MsoNormal style='mso-list:l3 level1 lfo4;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kafein
     a&#351;&#305;r&#305; kullan&#305;m&#305; vard&#305;r</span></li>
 <li class=MsoNormal style='mso-list:l3 level1 lfo4;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedavi
     dozlar&#305; ve yakla&#351;&#305;m yetersizdir</span></li>
</ul>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Etkisiz ila�</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#351;&#305;r&#305;
ba&#351;lang&#305;� dozu</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yetersiz devam
dozu</span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yetersiz
tedavi s�resi</span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l5 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hastan&#305;n
     ger�ek�i olmayan y�ksek beklenti d�zeyi</span></li>
 <li class=MsoNormal style='mso-list:l5 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedaviyi
     zorla&#351;t&#305;ran di&#287;er hastal&#305;klar&#305;n
     varl&#305;&#287;&#305;</span></li>
 <li class=MsoNormal style='mso-list:l5 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Atak
     tedavisinde kusma oldu&#287;u halde oral yolla uygulama </span></li>
 <li class=MsoNormal style='mso-list:l5 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bulant&#305;
     ve gastrik staz olan olgularda �nce anti-emetik verilmemesi</span></li>
 <li class=MsoNormal style='mso-list:l5 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;
     verimi �ok d�&#351;t�&#287;� halde basit analjeziklerle yetinilmeye
     �al&#305;&#351;&#305;lmas&#305;</span></li>
 <li class=MsoNormal style='mso-list:l5 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kombine
     analjeziklerin ve Ergo preparatlar&#305;n&#305;n yo&#287;un
     kullan&#305;m&#305;</span></li>
</ul>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoBodyTextIndent2 style='text-indent:0cm'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>GER&#304;L&#304;M
T&#304;P&#304; BA&#350;A&#286;RILARI</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:2.0pt;
margin-left:0cm;text-autospace:none'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Primer ba&#351;a&#287;r&#305;lar&#305; i�inde en s&#305;k
kar&#351;&#305;la&#351;&#305;lan tip gerilim tipi
ba&#351;a&#287;r&#305;lar&#305;d&#305;r (GTB). T�rkiye�de y&#305;ll&#305;k
prevalans&#305; yakla&#351;&#305;k %32 dir. GTB�ler migrenden daha s&#305;k
g�r�lmekle birlikte g�rece daha hafif ba&#351;a&#287;r&#305;lar&#305;na neden
olduklar&#305;ndan hekime ba&#351;vuruda daha geri plandad&#305;r.
S&#305;kl&#305;kla 20 ya&#351; civar&#305;nda ba&#351;lar, her ya&#351;ta
g�r�lebilir. Kad&#305;nlarda biraz daha s&#305;k g�r�lmekle birlikte aradaki
fark migrende oldu&#287;u kadar �arp&#305;c&#305; de&#287;ildir.
S&#305;kl&#305;kla iki yanl&#305; bir ba&#351;a&#287;r&#305;s&#305;na neden
olmas&#305;, zonklay&#305;c&#305; olmamas&#305;, hareketle artmamas&#305;, atak
s&#305;ras&#305;nda bulant&#305;n&#305;n olmay&#305;&#351;&#305; ve
&#305;&#351;&#305;ktan rahats&#305;zl&#305;k duymama karakteristik
�zelli&#287;idir. Ataklar &#351;eklinde gelebildi&#287;i gibi, 3 aydan daha
uzun s�redir g�nl�k veya g�n a&#351;&#305;r&#305;
ba&#351;a&#287;r&#305;s&#305;n&#305;n oldu&#287;u kronikle&#351;mi&#351; halde
de g�r�lmesi seyrek de&#287;ildir. Bu kronik form doktora daha s&#305;k
ba&#351;vuru nedenidir. GTB�nin lokalizasyonu de&#287;i&#351;kendir ve
semptomlar&#305; ayn&#305; hastada bile tek tip de&#287;ildir. Bu nedenle bir
���p sepeti� tan&#305;s&#305; gibi ele alan yazarlar vard&#305;r. Baz&#305;
ara&#351;t&#305;rmac&#305;lar ise migren ile ayn&#305; spektrumun di&#287;er
ucu oldu&#287;u g�r�&#351;�ndedir. GTB�li olgular&#305;n %10 kadar&#305;nda
ba&#351;a&#287;r&#305;s&#305; zonklay&#305;c&#305; gibi hissedilebilir ve
ba&#351;ka olgularda tek yanl&#305; a&#287;r&#305; olabilir. Kaslarda gerginlik
%80 olguda palpasyonla saptan&#305;r ve hastalar s&#305;kl&#305;kla dikkat
eksikli&#287;inden yak&#305;n&#305;rlar. Depresif ruh durumu, anksiyete
bozuklu&#287;u, somatoform bozukluklar ve di&#287;er yak&#305;nmalar e&#351;lik
edebilir. Baz&#305; hastalarda fibromiyalji ve miyofasyal a&#287;r&#305;
sendromu birlikteli&#287;i vard&#305;r.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:2.0pt;
margin-left:0cm;text-autospace:none'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:2.0pt;
margin-left:0cm;text-autospace:none'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Gerilim tipi ba&#351;a&#287;r&#305;lar&#305; IHS
s&#305;n&#305;flamas&#305;nda <b>Tablo 1A2�</b>de g�r�ld�&#287;� gibi seyrek,
s&#305;k ve kronik olarak grupland&#305;r&#305;lm&#305;&#351;t&#305;r ve bu
hasta i�in sorun olma boyutu ve tedaviyi y�nlendirmek a�&#305;s&#305;ndan
anlaml&#305;d&#305;r. <b><i>Seyrek epizodlu gerilim tipi
ba&#351;a&#287;r&#305;s&#305; </i></b>yakla&#351;&#305;k olarak ayda 1 g�nden
daha seyrek (y&#305;lda 12 g�nden az) g�r�l�r. 30 dakikal&#305;k
olabildi&#287;i gibi g�nlerce de s�rebilen seyrek ba&#351;a&#287;r&#305;s&#305;
epizodlar&#305;d&#305;r. A&#287;r&#305;, tipik olarak bilateral,
bask&#305;l&#305; veya s&#305;k&#305;&#351;t&#305;r&#305;c&#305; karakterde ve
hafif - orta &#351;iddettedir ve rutin fiziksel aktivite ile k�t�le&#351;mez.
Mide bulant&#305;s&#305;na rastlanmaz; fotofobi ya da fonofobi g�r�lebilir. <b><i>S&#305;k
epizodlu gerilim tipi ba&#351;a&#287;r&#305;s&#305;</i> ise</b> en az 3 ay
boyunca ayda bir g�n veya daha �ok, fakat 15 g�nden daha az g�r�len ve
(y&#305;lda 12 g�n veya daha fazla ve 180 g�nden az) bir durumdur, di&#287;er
�zellikleri ayn&#305;d&#305;r. <b><i>Kronik gerilim tipi
ba&#351;a&#287;r&#305;s&#305;</i></b> ise g�nl�k olarak veya �ok s&#305;k
g�r�len epizodik gerilim tipi ba&#351;a&#287;r&#305;s&#305;ndan geli&#351;en
bir <span style='color:black'>durumdur. Ortalama �� ay boyunca 15 g�n veya daha
fazla g�n g�r�len ba&#351;a&#287;r&#305;s&#305; (y&#305;lda 180 veya daha fazla
g�n) di&#287;er �zellikler a�&#305;s&#305;ndan benzerdir. </span>Ba&#351;ka bir
<span style='color:black'>hastal&#305;kla</span> ili&#351;kili
olmad&#305;&#287;&#305;n&#305;n g�sterilmesi �nem ta&#351;&#305;r. Yurdumuzda
olduk�a s&#305;k rastlanan (%5�in �st�nde) ve polikliniklere s&#305;k
ba&#351;vuran grubu olu&#351;turmaktad&#305;r. Ya&#351;am kalitesi �zerine
olumsuz etkisi olan bir durumdur. &#304;la� a&#351;&#305;r&#305; kullan&#305;m&#305;na
yol a�abilir ve baz&#305; olgularda kronik migrenden ayr&#305;m&#305; sorun
yaratabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:2.0pt;
margin-left:0cm;text-autospace:none'><span lang=TR style='mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Patofizyoloji</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>GTB�lerin patofizyolojisi net de&#287;ildir. Muhtemelen anormal kas
kas&#305;lmas&#305;n&#305;n de&#287;il, anormal n�ron
duyarl&#305;l&#305;&#287;&#305; ve a&#287;r&#305;n&#305;n
kolayla&#351;mas&#305;n&#305;n bir klinik yans&#305;mas&#305;d&#305;r. Nitrik
oksitin (NO) gerilim tipi ba&#351;a&#287;r&#305;s&#305;nda lokal bir arac&#305;
madde oldu&#287;u savunulmaktad&#305;r. Ge�mi&#351;te kas k�kenli bir
ba&#351;a&#287;r&#305;s&#305; oldu&#287;u iddia edilmi&#351;se de kan&#305;t
yoktur ve artm&#305;&#351; EMG aktivitesi olmamas&#305;, botulinum toksin
uygulamalar&#305;n&#305;n ba&#351;ar&#305;s&#305;z olmas&#305; buna ters
d�&#351;mektedir. Trigeminal siniri motor n�ronlara ba&#287;layan intern�ronlarda
anormal bir mod�lasyon bulundu&#287;u d�&#351;�n�lmektedir. Bu anormallik bazal
ganglionlardan, limbik sistemden veya dorsal raphe nukleusundaki serotonerjik
n�ronlardan kaynaklanabilir. Bir g�r�&#351;e g�re kronik gerilim tipinde
supraspinal fasilitasyon sonucu trigeminal kaudal nukleus n�ronlar&#305;
a&#351;&#305;r&#305; duyarl&#305; hale gelmektedir. E&#287;er migrende damarsal
nosisept�r�n a&#351;&#305;r&#305; duyarl&#305;l&#305;&#287;&#305; s�z konusu
ise, kronik GTB�da da perikranyal kaslarda myofasiyal nosisept�r�n
a&#351;&#305;r&#305; duyarl&#305;l&#305;&#287;&#305; ile giden bir bozukluk s�z
konusu olabilir. Sekonder segmental santral duyarl&#305;la&#351;ma,
uyar&#305;lar&#305;n supraspinal mod�lasyon bozuklu&#287;u ve miyofasyal
dokudan do&#287;an uzam&#305;&#351; a&#287;r&#305;l&#305; uyar&#305;lar&#305;n
kronik forma d�n�&#351;�nde �nemli oldu&#287;u d�&#351;�n�lmektedir. Akut atak
fiziksel veya psikolojik stresle, ya da fizyolojik olmayan �al&#305;&#351;ma
ko&#351;ullar&#305; sonucu ortaya �&#305;kabilir. Zorlanan kaslardan gelen
nosisepsiyon art&#305;&#351;&#305; a&#287;r&#305; mod�lasyonu bozulmu&#351; bir
ki&#351;ide ata&#287;&#305; tetikleyebilir. Emosyonel mekanizmalar da endojen
antinosiseptif sistemi bask&#305;layabilir. Nosiseptif n�ronlar&#305;n uzun
vadeli potansiyasyonu ve antinosiseptif sistemin aktivitesinin azalmas&#305;
kronik GTB�na yol a�abilir. Trigeminal kaudal nukleus n�ronlar&#305;n&#305;n
duyarl&#305;la&#351;mas&#305; normalde a&#287;r&#305;ya yol a�mayacak
uyaranlar&#305;n a&#287;r&#305;l&#305; olmas&#305; ve tetik noktalar&#305;
olu&#351;turarak migren ve GTB belirtilerinin �ak&#305;&#351;mas&#305;na ve
trigeminal vask�ler sistemin de aktivasyonuna yol a�abilir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tedavisi migrene benzer prensipler i�ermektedir ve daha az se�eneklidir.
Atak s&#305;ras&#305;nda genelde parasetamol gibi basit analjezikler veya
NSA&#304; ila�lar yeterlidir, herhangi birinin di&#287;erlerine �st�nl�&#287;�
g�sterilmemi&#351;tir. Tedavide hasta temelli bir yakla&#351;&#305;m uygundur.
Kronik GTBA�da antidepresan ila�lar kullan&#305;l&#305;r. Profilaksisinde
antidepresanlar&#305;n antinosiseptik etkisi antidepresan etkiden
kaynaklanmamaktad&#305;r. Profilakside amitriptilin en etkili
ila�lardand&#305;r. Sersemlik hissi, a&#287;&#305;z kurulu&#287;u,
ta&#351;ikardi, kalpte ileti blo&#287;u, n�bet, g�rme bozuklu&#287;u, idrar
retansiyonu gibi yan etkileri vard&#305;r ve ileri ya&#351;ta, obez hastalarda
ve MAO inhibit�r� kullanma �yk�s� olanlarda kullan&#305;lmamal&#305;d&#305;r.
SSRI grubunun da (Paroksetin 20 mg, Fluoksetin 20 mg, Citalopram 10-20 mg,
Sertralin&nbsp; 50-100 mg, Fluvoksamin50-100 mg ve di&#287;erleri)
etkinli&#287;i vard&#305;r. Bulant&#305;, uyuklama, terleme, a&#287;&#305;z kurulu&#287;u,
impotans, ekstrapiramidal bozukluklar, ve n�bet gibi yan etkiler olduk�a
seyrektir. MAO inhibit�r� kullanan, karaci&#287;er yetmezli&#287;i ve renal
yetmezlik olan hastada verilmemelidir. Baz&#305; olgular Tizanidin 2-8 mg/g�n
kullan&#305;m&#305;ndan yarar g�rebilir. Gerilim ba&#351; a&#287;r&#305;lar&#305;nda
ila� tedavisi ile birlikte gev&#351;eme teknikleri, stresle m�cadele
y�ntemleri, �e&#351;itli egzersizler ve masaj gibi uygulamalar&#305;n
yap&#305;ld&#305;&#287;&#305; ila� d&#305;&#351;&#305; tedaviler de
ba&#351;ar&#305;l&#305; sonu�lar vermektedir. Baz&#305; merkezlerde oksipital
sinir blokaj&#305; &#351;eklinde teknikler ila� tedavisine yan&#305;ts&#305;z
kronik olgularda denenmektedir.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>K�ME (DEMET, CLUSTER)
BA&#350;A&#286;RISI</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Trigeminal otonomik sefalaljiler</span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> trigeminal sinir
da&#287;&#305;l&#305;m&#305;na uyan b�lgede ba&#351;a&#287;r&#305;s&#305; ile
birlikte kranyal otonomik aktivasyon ile karakterize bir dizi ba&#351;
a&#287;r&#305;s&#305; sendromundan olu&#351;ur. En s&#305;k g�r�leni k�me ba&#351;a&#287;r&#305;s&#305;d&#305;r.
K�me ba&#351;a&#287;r&#305;s&#305;, gerilim ve migren
ba&#351;a&#287;r&#305;s&#305;ndan sonra en s&#305;k g�r�len primer ba&#351;
a&#287;r&#305;lar&#305;ndand&#305;r. Her ya&#351;ta rastlanmakla birlikte daha
yayg&#305;n olarak 20-40 ya&#351; aras&#305; ortaya �&#305;kmaktad&#305;r.
�ocuklarda ve ya&#351;l&#305;larda �ok seyrek g�r�l�r, erkeklerde ve sigara
daha i�enlerde s&#305;kt&#305;r. A&#287;r&#305;n&#305;n tipik �zellikleri tek
tarafl&#305;, �ok &#351;iddetli ve k&#305;sa s�reli olmas&#305;d&#305;r. K�me
ba&#351;a&#287;r&#305;s&#305; olarak adland&#305;r&#305;lmas&#305;n&#305;n en
belirgin nedeni periyodik &#351;ekilde olu&#351;mas&#305;d&#305;r. Bu
ba&#351;a&#287;r&#305;s&#305; primer olabilece&#287;i gibi, nadir de olsa, sekonder
bir nedenle de ortaya �&#305;kabilir. Deneysel �al&#305;&#351;malar ve insanda
fonksiyonel g�r�nt�leme incelemeleri ile olu&#351;an bilgi birikimi, bu
ba&#351;a&#287;r&#305;s&#305; tipinde fizyolojik trigeminal parasempatik
refleksin aktive olarak sekonder kranyal sempatik disfonksiyona neden
oldu&#287;unu d�&#351;�nd�rmektedir ve hipotalamusun nosiseptif ve otonom
yollara mod�lat�r rol� �zerinde durulmaktad&#305;r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Orbital, supraorbital, temporal tek tarafl&#305;,
15-180 dakika s�ren ve g�n a&#351;&#305;r&#305; bir kez ile g�nde 8 defaya
kadar ortaya �&#305;kan &#351;iddetli ataklard&#305;r. <span style='color:black'>Bilinmeyen
nedenlerle erkeklerde kad&#305;nlara g�re 3-4 kez daha s&#305;kt&#305;r. </span>�o&#287;u
hasta atak s&#305;ras&#305;nda huzursuz ya da ajitedir. Ataklara
a&#351;a&#287;&#305;dakilerden biri ya da daha fazlas&#305; t�m� ayn&#305;
tarafta olarak e&#351;lik edebilir:</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�&nbsp;&nbsp;&nbsp; Parsiyel Horner Sendromu (miyoz, pitoz)<br>
�&nbsp;&nbsp;&nbsp; Burun t&#305;kan&#305;kl&#305;&#287;&#305; veya
ak&#305;nt&#305;s&#305;<br>
�&nbsp;&nbsp;&nbsp; G�z ya&#351;armas&#305; (nazolakrimal kanal&#305;n
blokaj&#305;na ba&#287;l&#305; olarak)<br>
�&nbsp;&nbsp;&nbsp; Konjuktival kanlanma<br>
�&nbsp;&nbsp;&nbsp; Al&#305;n ve y�zde terlemede art&#305;&#351; (nadir)<br>
�&nbsp;&nbsp;&nbsp; Ate&#351; basmas&#305; (nadir)<br>
�&nbsp;&nbsp;&nbsp; Y�z� ve g�z kapa&#287;&#305;n&#305; i�eren �dem (�ok
seyrek)<br>
�&nbsp;&nbsp;&nbsp; Supraorbital �cold spot� (termografi ile
saptanm&#305;&#351;)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Sistemik belirtiler<br>
�&nbsp;&nbsp;&nbsp; Bradikardi<br>
�&nbsp;&nbsp;&nbsp; Hipertansiyon<br>
�&nbsp;&nbsp;&nbsp; Gastrik salg&#305; �retiminde art&#305;&#351;</span><span
lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;color:black;mso-ansi-language:TR'>Ataklar, al&#305;&#351;&#305;ld&#305;k
bi�imde aylar ya da y&#305;llar s�ren d�zelme d�nemleri ile
ayr&#305;lm&#305;&#351; olan, haftalarca ya da aylarca s�ren diziler (k�me
d�nemleri) bi�iminde ortaya �&#305;kar. Ancak hastalar&#305;n
yakla&#351;&#305;k % 10-15�inde d�zelme olmaks&#305;z&#305;n kronik belirtiler
olur ve bu durum kronik k�me olarak adland&#305;r&#305;l&#305;r. Bir k�me
d�nemi s&#305;ras&#305;nda ve kronik tipte, ataklar d�zenli olarak ortaya
�&#305;kar ve alkol, histamin ya da nitrogliserin ile uyar&#305;labilir.
A&#287;r&#305; her bir k�me d�nemi s&#305;ras&#305;nda hemen hemen
de&#287;i&#351;meksizin ayn&#305; yerde ortaya �&#305;kar. En k�t� ataklar
s&#305;ras&#305;nda a&#287;r&#305; yo&#287;unlu&#287;u &#351;iddetlidir.
Hastalar genellikle uzanamazlar ve tipik olarak dola&#351;mak zorunda
kal&#305;rlar. Akut ataklar posterior hipotalamik gri maddenin aktivasyonunu
i�erir. K�me ba&#351;a&#287;r&#305;s&#305;, olgular&#305;n
yakla&#351;&#305;k&nbsp; % 5 inde kal&#305;tsal olabilir. Baz&#305; hastalarda
sadece bir tek k�me d�nemi de olabilmektedir. Trigeminal nevralji ile birlikte
olan k�me ba&#351;a&#287;r&#305;s&#305; (<i>k�me-tik sendromu</i>) da
tan&#305;mlanm&#305;&#351;t&#305;r</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Klinik olarak, �ok hasta g�rmeyen hekimler s&#305;kl&#305;kla k�me
ba&#351;a&#287;r&#305;s&#305; ile migreni
kar&#305;&#351;t&#305;rmaktad&#305;rlar. K�me ba&#351;a&#287;r&#305;s&#305;
tipik olarak 6-12 hafta s�ren senelik ataklar halinde orta ya&#351;l&#305;
erkeklerde ortaya �&#305;kar. Bu �k�me� d�nemlerinde, sabah erkenden (�alar
saat ba&#351;a&#287;r&#305;s&#305;) ya da uyuduktan sonra bir saat i�inde
a&#287;r&#305;yla uyan&#305;rlar. Alkol ald&#305;ktan sonra 20-30 dakika i�inde
kriz d�nemi ba&#351;lar ve hastalar doktor taraf&#305;ndan s�z� edilmeden �nce
bile alkolden ka�&#305;nmalar&#305; gerekti&#287;ini bilirler. Periyodik
olmas&#305; ana �zelli&#287;idir, epizodlar&#305; en �ok ilkbahar ve sonbaharda
g�r�l�r. 2-3 ay s�rer ve remisyon devri 1-2 y&#305;l (s&#305;n&#305;rlar&#305;
2 ay-20 y&#305;ld&#305;r) devam eder. Atakta aura yoktur ve a&#287;r&#305;
10-15 dakikada en y�ksek seviyeye ula&#351;&#305;r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tedavi </span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Akut atakta 5-8 litre/dakika oksijen inhalasyonu %70 oran&#305;nda
ba&#351;ar&#305;l&#305; olmaktad&#305;r. Medikal tedavi olarak intramusk�ler
dihidroergotamin, triptanlar ve akut atakta kortikosteroidler
kullan&#305;labilir.&nbsp; K�me ba&#351;a&#287;r&#305;s&#305;n&#305;n tipik
�zelli&#287;i analjezik ila�lara ve migrenin tipik profilaksisine �o&#287;u kez
yan&#305;ts&#305;zl&#305;klar&#305;d&#305;r. Verapamil, lityum ve steroidlerle
profilaksiye yan&#305;t verirler.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Patofizyoloji</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>K�menin
ba&#351;a&#287;r&#305;s&#305; da trigeminal sinirin nosiseptif oftalmik
dallar&#305; yoluyla ta&#351;&#305;n&#305;r. P maddesi ve CGRP trigeminal
ganglion veya lifleri aktive oldu&#287;unda sal&#305;nd&#305;&#287;&#305;
bilinen n�ropeptidlerdir. CGRP insanda bilinen en g��l� vazodilatat�rlerdendir
ve sal&#305;n&#305;m&#305; sonucunda n�rojenik bir inflamasyon tetiklenir ve
dural kan damarlar&#305; geni&#351;ler. K�me ba&#351;a&#287;r&#305;s&#305;nda
da trigeminovask�ler sistemin aktive oldu&#287;u hastalar&#305;n k�me
ata&#287;&#305; s&#305;ras&#305;nda eksternal j�g�ler venlerinde CGRP
d�zeylerinin artt&#305;&#287;&#305;n&#305;n g�sterilmesi ile
kesinle&#351;mi&#351;tir. Otonom bulgular ise kranyal parasempatik liflerin
aktivasyonuna sekonderdir. Bu lifler superior salivator nukleusdan
kaynaklan&#305;r ve trigeminal nukleus kaudalis ile fonksiyonel bir
beyinsap&#305; ba&#287;lant&#305;lar&#305; vard&#305;r. Bu lifler 7.sinir ile
seyreder ve pterigopalatin ganglionda sinaps yaparlar. Post-ganglionik lifler
beyin damarlar&#305;na ve nazal mukozaya vazomotor ve sekretomotor innervasyon
sa&#287;larlar. K�me ba&#351;a&#287;r&#305;l&#305; ki&#351;ilerde bu yolda
aktivasyon oldu&#287;u VIP kan d�zeylerinin atak s&#305;ras&#305;nda belirgin
&#351;ekilde artt&#305;&#287;&#305;n&#305;n g�sterilmesi ile desteklenmi&#351;tir.
Horner sendromu geli&#351;mesi postganglioniktir ve karotid sempatik pleksusunun
tutulumu ile ba&#287;lant&#305;l&#305;d&#305;r. Karotis kavern�z par�as&#305;,
bu d�zeyde parasempatik, sempatik ve trigeminal lifler biraraya
geldi&#287;inden en uygun lokalizasyon gibi g�r�nmektedir. G�r�nt�leme
�al&#305;&#351;malar&#305; da kavern�z sin�sde arteryel geni&#351;leme ve ven�z
d�n�&#351;te obstr�ks�yon g�stermi&#351;tir. Sendromun periodisitesi ise hen�z
a�&#305;kl&#305;&#287;a kavu&#351;mu&#351; de&#287;ildir. Oreksinler gibi
baz&#305; genlerde mutasyon varl&#305;&#287;&#305; spek�le edilmektedir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:12.0pt;text-align:justify'><i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Trigeminal Otonomik
Sefalaljiler</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> i�in ortak �zellikler a&#287;r&#305;n&#305;n �ok &#351;iddetli olu&#351;u,
her zaman tek yanl&#305; olu&#351;u, her zaman otonomik belirtilerin ata&#287;a
e&#351;lik edi&#351;i (g�zde ya&#351;arma, k&#305;zarma, &#351;i&#351;me,
burunda o yanda t&#305;kanma veya ak&#305;nt&#305;, al&#305;nda veya y�zde
terleme gibi), herg�n veya g�n a&#351;&#305;r&#305; olu&#351;u ve �nceki
say&#305;lan ba&#351;a&#287;r&#305;l&#305; durumlara g�re k&#305;sa s�reli
olu&#351;u, g�n i�inde tekrarlayabilmeleridir (<b>Tablo 5</b>). A&#287;r&#305;
yerle&#351;imi ve karakteri t�m otonomik sefalaljilerde benzer olabilmekle
birlikte, a&#287;r&#305; s�releri ve tekrarlama say&#305;lar&#305; en
ay&#305;rt edici �zellikleridir. <i>K�me (Cluster)
Ba&#351;a&#287;r&#305;s&#305;</i>, yukarda anlat&#305;ld&#305;&#287;&#305; gibi
en uzun s�reli olan&#305; olup ataklar 15 dakika ile 3 saat aras&#305;
s�rebilir ve g�n a&#351;&#305;r&#305; bir kere ile g�nde 8 kere aras&#305;nda
de&#287;i&#351;en s&#305;kl&#305;kta gelebilir. <i>Paroksismal hemikranya</i>
ve <i>SUNCT </i>(<i>short-lasting, unilateral, neuralgiform headache attacks
with conjunctival injection and tearing</i>) hastal&#305;&#287;&#305; ise �ok
daha nadir durumlar olup k�me ba&#351;a&#287;r&#305;s&#305;ndan daha k&#305;sa
s�reli olu&#351;lar&#305;yla ayr&#305;l&#305;rlar. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Paroksismal Hemikranya</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Sjaastad ve Dale taraf&#305;ndan 1974�de tan&#305;mlanm&#305;&#351; olan
paroksismal hemikranya (PH), �ok seyrek g�r�len bir primer
ba&#351;a&#287;r&#305;s&#305;d&#305;r. Kad&#305;nlarda daha s&#305;k g�r�l�r ve
25-40 ya&#351; aras&#305;ndaki ki&#351;ilerde rastlanmaktad&#305;r.
A&#287;r&#305; kesinlikle hep ayn&#305; tarafta &#351;iddetli olarak ortaya
�&#305;kar, k&#305;sa s�ren ve remisyonsuz ba&#351;
a&#287;r&#305;lar&#305;d&#305;r. S&#305;kl&#305;kla kroniktir, ancak epizodik
formu da tan&#305;mlanm&#305;&#351;t&#305;r. Ki&#351;i hemen bir yere oturma ya
da yatma ihtiyac&#305; duyar. A&#287;r&#305;n&#305;n yap&#305;s&#305;
zonklay&#305;c&#305;, damar atar gibi, oyucu, delici olarak
tan&#305;mlanabilir. Ataklar&#305;n ortalama g�nl�k s&#305;kl&#305;&#287;&#305;
5-20 aras&#305;ndad&#305;r ve her seferinde a&#287;r&#305; s�resi 2-45dakika
aras&#305;ndad&#305;r. &#304;li&#351;kili otonom de&#287;i&#351;iklikler k�me
ba&#351;a&#287;r&#305;s&#305;ndakine �ok benzer ancak <i>tipik �zellik
indometazinle 3 g�n i�inde tam kontrol edilebilmesidir</i>. &#304;li&#351;kili
otonom belirtilerin hemen hemen tamam&#305; kranyal parasempatik aktivasyonla
ili&#351;kilidir. Tek istisnas&#305; muhtemelen k&#305;smi bir sempatik
defisite ba&#287;l&#305; olan Horner sendromudur. PH ay&#305;r&#305;c&#305;
tan&#305;s&#305;nda dikkat edilmesi gereken sekonder nedenlerin MRG ile
ara&#351;t&#305;r&#305;lmas&#305; d&#305;&#351;&#305;nda bir konu da trigeminal
nevralji ile birlikte g�r�lebilece&#287;i ve bir PH-tik sendromunun
tan&#305;mlanm&#305;&#351; oldu&#287;unun ak&#305;lda tutulmas&#305;d&#305;r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tedavisi, g�nde �� kez 25 mg indometazindir. E&#287;er cevap
al&#305;namazsa yava&#351;�a 225 mg�a �&#305;kar&#305;lmas&#305;n&#305;
�nerilmektedir. &#304;ndometazine cevaps&#305;zl&#305;k ancak 150 mg oral (100
mg IM) veya �zeri dozlarda de&#287;erlendirilebilir. T�m hastalarda olas&#305;
gastrointestinal yan etkilerine kar&#351;&#305; �nlem
al&#305;nmal&#305;d&#305;r (H2 resept�r antagonistleri, antasitler,
misoprostol). Epizodik formda indometazin genellikle tahmin edilen atak
s�resinden daha uzun bir s�re verilir ve azalt&#305;larak kesilir. Remisyon
d�nemleri olsa da, kronik formda �ok uzun s�reli tedavi gerekir.
&#304;ndometazinin etki mekanizmas&#305; bilinmemektedir ve nitrik oksid
�retimini azalt&#305;c&#305; etkisi ve CGRP ve VIP �zerinden etkili oldu&#287;u
san&#305;lmaktad&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>SUNCT Sendromu</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> (Tek tarafl&#305; g�z ya&#351;armas&#305; ve
k&#305;zarmas&#305;n&#305;n e&#351;lik etti&#287;i k&#305;sa s�reli
nevraljiform a&#287;r&#305;lar)</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Sjaastad�&#305;n 1978�de tan&#305;mlad&#305;&#287;&#305; bu tablo primer
ba&#351; a&#287;r&#305;lar&#305;n&#305;n en seyrek g�r�nenlerindendir.
Di&#287;er a&#287;r&#305;lardan farkl&#305; olarak ileri ya&#351;larda ortaya
�&#305;kar, ortalama g�r�lme ya&#351;&#305; 50�dir. Erkeklerde daha s&#305;k
g�r�l�r. A&#287;r&#305;n&#305;n yap&#305;s&#305; &#351;iddetli,
yak&#305;c&#305;, oyucu, elektrik �arpm&#305;&#351; gibidir. A&#287;r&#305; 5
ila 240 saniye s�ren paroksizmler halinde gelir,<sup> </sup>bir saatte 5-6 atak
(g�nde 3-200 atak) s&#305;kt&#305;r. Status formu da bildirilmi&#351;tir.
Ba&#351;a&#287;r&#305;s&#305;yla birlikte burun
t&#305;kan&#305;kl&#305;&#287;&#305;, burun ak&#305;nt&#305;s&#305;, g�z �demi
gibi belirtilere de rastlan&#305;r. Ataklar genelde g�nd�z olur, baz&#305;
olgularda ataklar trigeminal veya boyun gibi b�lgelerde bas&#305;n�,
�i&#287;neme veya hareketle tetiklenebilir. Tedavide denenen ila�lar&#305;n
�o&#287;u ba&#351;ar&#305;s&#305;zd&#305;r. En �ok antiepileptik ila�lardan
(Lamotrigin 200-400mg,&nbsp; topiramat 50-300mg, gabapentinle kombinasyonlar)
yararlanabilir. Sekonder SUNCT sendromu g�steren bir�ok olgu sunumu vard&#305;r
ve daima arka �ukur lezyonlar&#305; ile ili&#351;kilidir, Bu durum hastalara
MRG incelemesi yap&#305;lmas&#305;n&#305;n gereklili&#287;ini ortaya
koymaktad&#305;r.<b> </b>Fonksiyonel MRG ile bir hastada ipsilateral
hipotalamik aktivasyon bildirilmi&#351;tir. Diren�li olgularda&nbsp;
kortikostreoidler, azotioprin ve �e&#351;itli invazif prosed�rler
�nerilmi&#351;tir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 5. </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>K&#305;sa s�reli baz&#305; ba&#351;a&#287;r&#305;lar&#305;nda
ay&#305;r&#305;c&#305; tan&#305;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=541
 style='width:405.75pt;mso-cellspacing:0cm;border:solid white 1.0pt;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;height:25.7pt'>
  <td width=97 valign=top style='width:72.75pt;border:solid windowtext 1.0pt;
  border-right:none;padding:0cm 0cm 0cm 0cm;height:25.7pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�zellik</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 0cm 0cm 0cm;height:25.7pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>K�me</span></b></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 0cm 0cm 0cm;height:25.7pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>KPH</span></b></p>
  </td>
  <td width=72 valign=top style='width:54.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 0cm 0cm 0cm;height:25.7pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>EPH</span></b></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 0cm 0cm 0cm;height:25.7pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>SUNCT</span></b></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0cm 0cm 0cm 0cm;height:25.7pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Saplan&#305;c&#305;</span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>ba&#351;a&#287;r&#305;s&#305;</span></b></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 0cm 0cm 0cm;height:25.7pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Trigeminal nevralji</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:19.6pt'>
  <td width=97 valign=top style='width:72.75pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:19.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Cinsiyet (E:K)</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:19.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>4:1</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:19.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1:3</span></p>
  </td>
  <td width=72 valign=top style='width:54.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:19.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1:1</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:19.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>2.3:1</span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:19.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>K&gt;E</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:19.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>K&gt;E</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:28.4pt'>
  <td width=97 valign=top style='width:72.75pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Atak S�resi</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>15-180 dakika</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>2-45 dak</span></p>
  </td>
  <td width=72 valign=top style='width:54.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1-30 dak</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>5-250saniye</span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&lt;1s</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&lt;1s</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:28.4pt'>
  <td width=97 valign=top style='width:72.75pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Atak s&#305;kl&#305;&#287;&#305;</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1-8/g�n</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1-40/g</span></p>
  </td>
  <td width=72 valign=top style='width:54.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>3-30/g</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>1/g�n-30/saat</span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>de&#287;i&#351;ken</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>de&#287;i&#351;ken</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:28.4pt'>
  <td width=97 valign=top style='width:72.75pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Otonom bulgular</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
  <td width=72 valign=top style='width:54.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>-</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:28.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>-</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:21.6pt'>
  <td width=97 valign=top style='width:72.75pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tedavi </span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>�zg�n</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=72 valign=top style='width:54.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>zor</span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;padding:0cm 0cm 0cm 0cm;
  height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>CBZ</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes;height:21.6pt'>
  <td width=97 valign=top style='width:72.75pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;ndometazin etkisi</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+/-</span></p>
  </td>
  <td width=48 valign=top style='width:36.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
  <td width=72 valign=top style='width:54.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>-</span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>+</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 0cm 0cm 0cm;height:21.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>-</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>KPH: kronik paroksizmal hemikranya EPH: epizodik
paroksizmal hemikranya</span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>SUNCT:Tek tarafl&#305; g�z ya&#351;armas&#305; ve
k&#305;zarmas&#305;n&#305;n e&#351;lik etti&#287;i k&#305;sa s�reli
nevraljiform a&#287;r&#305;lar</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&#304;LA� A&#350;IRI KULLANIM BA&#350;A&#286;RISI</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<h3 style='page-break-after:auto;text-autospace:none'><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
normal'>A&#351;&#305;r&#305; ila� kullanmaya ba&#287;l&#305;
ba&#351;a&#287;r&#305;s&#305; (&#304;AKB), ergotamin, triptan, basit
analjezikler, opioidler, kombine analjeziklerin ayda 10-15 g�nden fazla
al&#305;nmas&#305;na ba&#287;l&#305; olarak geli&#351;en sekonder nitelikte
ba&#351;a&#287;r&#305;s&#305;d&#305;r (</span><span lang=TR style='font-size:
12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 1</span><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
normal'>). Tipik bir klinik tablosu yoktur, genelde altta migren gibi primer
bir ba&#351;a&#287;r&#305;s&#305; vard&#305;r. T�m ba&#351;a lokalize, k�nt,
s&#305;k&#305;&#351;t&#305;r&#305;c&#305; veya zonklay&#305;c&#305; olabilir.
Genelde hafif, e&#351;lik�i semptomu olmayan devaml&#305; bir
a&#287;r&#305;d&#305;r, zaman zaman &#351;iddetlenebilir. IHS taraf&#305;ndan
belirlenen kriterler; �ncesinde primer bir ba&#351;a&#287;r&#305;s&#305;
olmas&#305;, g�nl�k veya �ok s&#305;k a&#287;r&#305; (&gt; 15 g�n/ay);
analjezik ila�lar&#305;n uygunsuz kullan&#305;m&#305; (ila� kullan&#305;m&#305;
&gt; 10 G�n ayda ve &gt; 3 ay&#305; a&#351;an zamandan beri)&nbsp; ve
ila�lar&#305;n b&#305;rak&#305;lmas&#305; ile d�zelme &#351;eklinde �zetlenebilir.
Kad&#305;nlarda erkeklerden 3-4 kat fazla rastlanmaktad&#305;r, ortalama 40
ya&#351;lar&#305;nda tan&#305; konulur. Baz&#305; hastalarda primer
ba&#351;a&#287;r&#305;s&#305;n&#305;n devam s�resi 20 y&#305;l, k�t�
kullan&#305;m&#305;n s�resi 10 y&#305;l gibi s�releri a&#351;abilmektedir
Migren ve GTB�dan sonra 3. en s&#305;k tip ba&#351;a&#287;r&#305;s&#305;d&#305;r
ve kronik g�nl�k ba&#351;a&#287;r&#305;s&#305; olgular&#305;n&#305;n 1/3 � bu
tan&#305;y&#305; almaktad&#305;r. Ergenlik �a&#287;&#305;nda ve hatta
�ocuklarda artan oranlar bildirilmesi endi&#351;e vericidir Genel pop�lasyonda
% 1-2 s&#305;kl&#305;kta hatta daha s&#305;k oldu&#287;u bildirilmektedir.
&#304;lgin� bir durum, devaml&#305; NSA&#304; kullanmak durumunda olan
artritlilerde seyrek geli&#351;mesi ve sadece migreni olan artritlilerde ortay
�&#305;kmas&#305;d&#305;r. Bu durum genetik yatk&#305;nl&#305;k ile
a�&#305;klanabilir. &#304;la�-ba&#287;&#305;ml&#305;l&#305;&#287;&#305;
(psikolojik ve fiziksel) ile benzer mekanizmalar i�erdi&#287;i, santral
sensitizasyonun ve reseptor reg�lasyonunun (serotonin vs siklooksijenaz
sistemleri) rol� oldu&#287;u ileri s�r�lmektedir. Kronik suma- ve zolmitriptan
tedavisi ile hayvan modellerinde korteks ve beyin sap&#305; serotonin
respet�rlerinde anlaml&#305; azalma g�sterilmi&#351;tir. Arka k�k
n�ronlar&#305;nda artm&#305;&#351; uyar&#305;labilirli&#287;in yan&#305;
s&#305;ra n�roplastik kal&#305;c&#305; de&#287;i&#351;iklikler oldu&#287;u
ileri s�r�lm�&#351;t�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></h3>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Yurdumuzda &#304;AKB�ya en s&#305;k yol a�an ila� grubu ergo
bile&#351;ikleridir. Triptanlar&#305;n daha k&#305;sa s�rede &#304;AKB�ya yol
a�abildi&#287;i ama tedavisinin de daha kolay oldu&#287;u bilinmektedir. Basit
analjeziklerle ortaya �&#305;km&#305;&#351; �ok say&#305;da &#304;AKB olgusu da
vard&#305;r. Tedavide esas olan ila�lar&#305;n tamamen kesilmesi, bu d�nemdeki
geri �ekilme semptomlar&#305;n&#305;n tedavisi ve ileriye y�nelik n�ks� �nlemek
i�in ve ba&#351;a&#287;r&#305;s&#305; s&#305;kl&#305;&#287;&#305;n&#305;
kontrol i�in profilaksi dahil �nlemlerin al&#305;nmas&#305;d&#305;r. &#304;AKB
da n�kslerin s&#305;k oldu&#287;u bilinmektedir. Kombine ila�lar ve opioidlerle
n�ks daha s&#305;kt&#305;r.&nbsp; </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<h2 style='page-break-after:auto;text-autospace:none'><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hastaya
yeterli &#351;ekilde a�&#305;klamak ve motivasyonu sa&#287;lamak tedavide
esast&#305;r, ayaktan veya yatarak ila� kesme konusunda hasta ve hekim birlikte
karar verebilir. Genelde ayaktan kesim tercih edilmektedir. Rutin
a&#287;r&#305; tedavisinin b&#305;rak&#305;lmas&#305;n&#305; k�pr� tedavisi
(genelde amitriptilin ve anti-emetik; kortizon veya di&#287;er) ve yoksunluk
semptomlar&#305;n&#305;n giderilmesi (2-10 g�n) izler. Hastalar �zellikle ilk bir
hafta i�erisinde kar&#351;&#305;la&#351;acaklar&#305; yoksunluk belirtileri
(sinirlilik, huzursuzluk, ba&#351;a&#287;r&#305;s&#305;nda &#351;iddetlenme,
bulant&#305;, kusma, uykusuzluk, diyare ve tremor gibi) a�&#305;s&#305;ndan
uyar&#305;lmal&#305; ve destek olunmal&#305;d&#305;r. E&#351;lik eden
davran&#305;&#351; modifikasyon tedavileri, ayl&#305;k dozlar&#305;n
s&#305;n&#305;rlanmas&#305; ve hastaya uygun profilaksi ba&#351;lanmas&#305;
�nemlidir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></h2>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>ENDER G�R�LEN&nbsp;D&#304;&#286;ER PR&#304;MER BA&#350; A&#286;RILARI</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hemikranya kontinua:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Sjaastad ve Spierings taraf&#305;nda 1984�de
tan&#305;mlanm&#305;&#351;t&#305;r. Unilateral, otonom bulgu ve migren�z
bulgular&#305;n eklendi&#287;i, &#351;iddetlenmelerle giden devaml&#305; bir
ba&#351;a&#287;r&#305;s&#305;d&#305;r. Otonom bulgular di&#287;er
trigeminotonomik sefaljilere g�re geride planda oldu&#287;undan bu grupta ele
al&#305;nmam&#305;&#351;t&#305;r. Saplan&#305;c&#305; komponenti de
vard&#305;r. Asl&#305;nda �ok nadir olmad&#305;&#287;&#305; ve kronik g�nl�k a&#287;r&#305;lar&#305;n
i�inde tan&#305;nmad&#305;&#287;&#305; d�&#351;�n�lmektedir.
Ay&#305;r&#305;c&#305; tan&#305;s&#305;nda di&#287;er trigeminotonomik
sefaljiler d&#305;&#351;&#305;nda transforme migren, kronik gerilim tipi
ba&#351;a&#287;r&#305;s&#305; ve <i>yeni g�nl�k s�re&#287;en
ba&#351;a&#287;r&#305;s&#305;</i> vard&#305;r. Patofizyolojisi tam
bilinmemektedir ve migren ve trigeminotonomik sefaljiler aras&#305; ge�i&#351;
formu kabul edilmektedir. Fonksiyonel MRG kontrlateral posterior hipotalamus
aktivasyonu ve ipsilateral mezensefalona uzanan dorsal pons aktivasyonu
g�stermi&#351;tir. &#304;ndometazine yan&#305;tl&#305; bir
a&#287;r&#305;d&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�apraz bir �al&#305;&#351;mada oksipital sinir stim�lasyonu 6 hasta
�zerinde ba&#351;ar&#305;l&#305; bulunmu&#351;tur. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hipnik ba&#351;a&#287;r&#305;s&#305;</span></i></b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>:</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> Tipik olarak gece uykuya
dald&#305;ktan birka� saat sonra ortaya �&#305;kan orta &#351;iddette
ba&#351;a&#287;r&#305;lar&#305;d&#305;r ve 30 dakika kadar s�rer. �ok seyrek ve
50 ya&#351; �st�nde g�r�l�r. A&#287;r&#305; genellikle zonklama &#351;eklindedir,
birden ba&#351;lar ve t�m ba&#351;a yay&#305;l&#305;r. Birlikte g�r�len
herhangi bir organik etken yoktur. Genellikle uykunun REM d�neminde ortaya
�&#305;kar ve ki&#351;iyi uyand&#305;r&#305;r. 15 ile 60 dakika aras&#305;nda
de&#287;i&#351;en s�relerde g�r�l�r, gecede birka� kez tekrarlayabilir. Tek
tarafl&#305; olabilse de bu a&#287;r&#305;lar genellikle yayg&#305;nd&#305;r.
Bu t�r ba&#351; a&#287;r&#305;lar&#305; bulunan hastalar genellikle yatarken
al&#305;nan 200-600 mg lityum karbonata cevapl&#305;d&#305;r.<sup> </sup></span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Primer saplan&#305;c&#305;
ba&#351;a&#287;r&#305;s&#305;:</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> Alt&#305;ndaki yap&#305;lar veya kranyal
sinirlerin organik bir bozuklu&#287;u olmaks&#305;z&#305;n kafada
kendili&#287;inden ortaya �&#305;kan ge�ici ve yerel a&#287;r&#305;
saplanmalar&#305;d&#305;r. Genelde trigeminal alandad&#305;r ama ba&#351;ka
b�lgelerde de olabilir ve yer de&#287;i&#351;tirebilir. Saplanmalar&#305;n
birka� saniye i�inde (%80�i 3 saniye veya daha k&#305;sa s�rede) sonlanarak g�n
i�inde pek �ok kez de&#287;i&#351;en s&#305;kl&#305;kta yeniden ortaya
�&#305;kmas&#305; olas&#305;d&#305;r. Seyrek olgularda b&#305;�ak saplan&#305;r
tarzda a&#287;r&#305;lar g�nler boyunca tekrarlar. Saplanmalar ayn&#305;
ba&#351; yar&#305;s&#305; veya kar&#351;&#305; yar&#305;da bir alandan
di&#287;erine hareket edebilir. Saplanma a&#287;r&#305;lar&#305;, genellikle
a&#287;r&#305; hissetmeye al&#305;&#351;&#305;lm&#305;&#351; olan ba&#351;
b�lgesinde hissedilmek �zere, s&#305;kl&#305;kla migren (yakla&#351;&#305;k
%40) veya k�me ba&#351;a&#287;r&#305;s&#305; (yakla&#351;&#305;k %30)
tan&#305;s&#305; alan hastalar taraf&#305;ndan bildirilmektedir. Baz&#305;
kontrols�z �al&#305;&#351;malarda indometazine olumlu yan&#305;t
al&#305;nm&#305;&#351; di&#287;er baz&#305;lar&#305;nda ise k&#305;smi
yan&#305;t veya yan&#305;ts&#305;zl&#305;k bildirilmi&#351;tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>�ks�r�k ba&#351;a&#287;r&#305;s&#305;:</span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> �ks�r�kle,
hap&#351;&#305;r&#305;kla ortaya �&#305;kan, eskiden Valsalva manevras&#305;
ba&#351;a&#287;r&#305;s&#305; denen nadir bir
ba&#351;a&#287;r&#305;s&#305;d&#305;r. <i>Benign �ks�r�k
ba&#351;a&#287;r&#305;s&#305; </i>yani bu tablonun primer &#351;ekli �ok nadir
bir durumdur. Ortalama ba&#351;lang&#305;� ya&#351;&#305; 55�tir ve erkeklerde
kad&#305;nlara oranla daha s&#305;k g�r�l�r. Ba&#351;a&#287;r&#305;s&#305;
�ks�r�k, hap&#351;&#305;r&#305;k veya bir Valsalva manevras&#305;ndan
(a&#287;&#305;rl&#305;k kald&#305;rma, zorlanma, d&#305;&#351;k&#305;larken
&#305;k&#305;nma, s�mk�rme, a&#287;lama veya &#351;ark&#305; s�yleme) hemen
sonra veya birka� saniye i�inde ortaya �&#305;kar.
Ba&#351;a&#287;r&#305;s&#305; �ok &#351;iddetlidir ve patlay&#305;c&#305; veya
yar&#305;lma gibi bir nitelik g�sterir, saniyeler veya dakikalar (1
saniye-30dakika) s�rer, genellikle iki yanl&#305;d&#305;r, en yo&#287;un
a&#287;r&#305; vertekste veya oksipital, frontal veya temporal b�lgede
hissedilir. Ba&#351;&#305;n �ne e&#287;ilmesi veya yatmak m�mk�n olmayabilir,
�ks�r�&#287;�n �nlenmesi ile ba&#351;a&#287;r&#305;s&#305; engellenebilir.<sup>
</sup>N�rolojik muayene genellikle normaldir. Kusman&#305;n bulunmas&#305;,
ba&#351;a&#287;r&#305;s&#305;n&#305;n alt&#305;nda organik bir neden
oldu&#287;unu d�&#351;�nd�r�r.<sup> </sup>�nc�l bir solunum yolu infeksiyonu
bazen bulunur.<sup> </sup>Hastalar&#305;n �o&#287;u atak aralar&#305;nda
a&#287;r&#305;s&#305;zd&#305;r, ancak baz&#305; olgularda ataklar&#305;n
ard&#305;ndan k�nt bir a&#287;r&#305; birka� saat boyunca s�rebilir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�ks�r�k ba&#351;a&#287;r&#305;lar&#305;n&#305;n
yakla&#351;&#305;k %40�&#305; semptomatiktir ve bu olgular&#305;n
�o&#287;unlu&#287;unda Arnold Chiari Tip I malformasyonu bildirilmi&#351;tir.
�ks�r�k ba&#351;a&#287;r&#305;s&#305;n&#305;n di&#287;er yay&#305;mlanm&#305;&#351;
nedenleri aras&#305;nda karotid veya vertebrobaziler hastal&#305;klar ve beyin
anevrizmalar&#305; yer almaktad&#305;r. Ba&#351;lang&#305;� ya&#351;&#305; <i>semptomatik
�ks�r�k ba&#351;a&#287;r&#305;s&#305;</i> hastalar&#305;nda benign �ks�r�k
ba&#351;a&#287;r&#305;s&#305; hastalar&#305;na oranla daha gen�tir. &nbsp;<i>Bu
nedenle bu tip ba&#351;a&#287;r&#305;lar&#305;nda MRG mutlaka
yap&#305;lmal&#305;d&#305;r. </i>Semptomatik �ks�r�k
ba&#351;a&#287;r&#305;s&#305;, benign �ks�r�k
ba&#351;a&#287;r&#305;s&#305;n&#305;n aksine indometazine cevaps&#305;z da
olabilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Egzersiz
ba&#351;a&#287;r&#305;s&#305;:</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> Egzersizin herhangi bir �e&#351;idi ile alevlenen
ba&#351;a&#287;r&#305;lar&#305;d&#305;r. �Halterci
ba&#351;a&#287;r&#305;s&#305;� gibi alt bi�imleri bilinmektedir. Genelde migren
tipi ba&#351;a&#287;r&#305;s&#305; g�r�l�r, zonklay&#305;c&#305;d&#305;r, 5
dakika-48 saat s�rer. Bu tipte ba&#351;a&#287;r&#305;s&#305; ilk kez ortaya
�&#305;kt&#305;&#287;&#305;nda subaraknoid kanama ve arteryel diseksiyonun d&#305;&#351;lanmas&#305;
zorunludur. Primer egzersiz ba&#351;a&#287;r&#305;lar&#305; �zellikle
s&#305;cak hava veya y�ksek irtifada ortaya �&#305;kar. Ergotamin
al&#305;m&#305; ile baz&#305; olgularda ba&#351;a&#287;r&#305;lar&#305;n&#305;n
�nlenebildi&#287;i bildirilmi&#351;tir. Olgular&#305;n pek �o&#287;unda
indometazin etkili bulunmu&#351;tur. Tedavide spordan yar&#305;m saat �nce
NSA&#304; verilmesi sorunu ��zebilir. �ks�r�k ba&#351;a&#287;r&#305;s&#305;ndan
daha erken ya&#351;ta ba&#351;layan bir tablodur. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>S<i>emptomatik efor ba&#351;a&#287;r&#305;s&#305;</i>
genellikle daha &#351;iddetlidir, iki tarafl&#305;d&#305;r ve
ba&#351;lang&#305;c&#305; patlay&#305;c&#305; niteliktedir. �e&#351;itli
etyolojik nedenler aras&#305;nda subaraknoid kanama, sin�zit ve beyin kitleleri
say&#305;labilir. Di&#287;er ba&#351;a&#287;r&#305;s&#305; tipleri de eforla
tetiklenebilir. Migren, lomber ponksiyon sonras&#305;
ba&#351;a&#287;r&#305;s&#305; ve intrakranyal hipertansiyona ba&#287;l&#305;
a&#287;r&#305; da �ks�r�kle &#351;iddetlenebilir. Ayr&#305;ca Monro
forameninden BOS ak&#305;m&#305;n&#305; engelleyen III. ventrik�l kolloid kisti
bulunan hastalarda da kafa i�i bas&#305;nc&#305;n ani y�kselmelerine
ba&#287;l&#305; olarak paroksizmal ba&#351;a&#287;r&#305;s&#305; bulunabilir.
Yan ventrik�l t�m�rleri, kranyofaringioma, pinealoma, serebral ve serebellar
t�m�rleri bulunan hastalarda da benzer ba&#351; a&#287;r&#305;lar&#305;
g�r�lebilir. Feokromasitomalar da �zellikle egzersiz s&#305;ras&#305;nda
paroksizmal ba&#351; a&#287;r&#305;lar&#305;na yol a�abilirler.<sup> </sup>&nbsp;Bu
nedenle bu ba&#351;a&#287;r&#305;s&#305; tipinde de mutlaka
ayr&#305;nt&#305;l&#305; incelemeler yap&#305;lmal&#305;d&#305;r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Cinsel ili&#351;ki ile ili&#351;kili ba&#351;a&#287;r&#305;s&#305;:</span></i></b><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Cinsel etkinlik
s&#305;ras&#305;nda ortaya �&#305;kan ve cinsel uyar&#305;lma ile artan
a&#287;r&#305; genellikle iki yanl&#305; �ok &#351;iddetli ve patlar gibi
ortaya �&#305;kar, nadiren zonklay&#305;c&#305; veya saplan&#305;c&#305;
�zellik g�sterebilir. Erkeklerde daha s&#305;kt&#305;r ve hastan&#305;n
ya&#351;am kalitesini olumsuz etkiler. S�resi de&#287;i&#351;kendir ve 1
dakikadan k&#305;sa s�rebildi&#287;i gibi, 3 saati a&#351;abilir,
s&#305;kl&#305;&#287;&#305; do&#287;rudan cinsel ili&#351;ki veya mast�rbasyon
s&#305;kl&#305;&#287;&#305;na ba&#287;l&#305;d&#305;r. Hastalar&#305;n
yakla&#351;&#305;k ��te birinde fiziksel egzersizle benzer ba&#351;
a&#287;r&#305;lar&#305; ortaya �&#305;kar. Koitus s&#305;ras&#305;nda ortaya
�&#305;kan patlay&#305;c&#305; ba&#351; a&#287;r&#305;s&#305; bir subaraknoid
kanamaya ba&#287;l&#305; olabilece&#287;i gibi, primer bir
ba&#351;a&#287;r&#305;s&#305; da olabilir. Bu hastalar&#305;n uzun vadeli
prognozu olumludur. Ba&#351;a&#287;r&#305;lar&#305; s&#305;k ve &#351;iddetli
ise, ataklar&#305;n k&#305;sa s�reli olmas&#305; atak tedavisini anlams&#305;z
k&#305;laca&#287;&#305;ndan, profilaktik tedavi gerekebilir. Baz&#305; hastalar
indometazine veya naproksene iyi bir cevap verirler. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tan&#305;mlanan farkl&#305; tipler aras&#305;nda <i>preorgazmik
ba&#351;a&#287;r&#305;s&#305;</i> boyun ve/veya �ene
kas&#305;lmalar&#305;n&#305;n e&#351;lik etti&#287;i k�nt tipte, ba&#351; ve
boyunda yerle&#351;en, cinsel heyecan d�zeyi artt&#305;k�a &#351;iddetlenen bir
ba&#351;a&#287;r&#305;s&#305;d&#305;r. <i>Orgazmik
ba&#351;a&#287;r&#305;s&#305;,</i> orgazm s&#305;ras&#305;nda ortaya �&#305;kan
ani ba&#351;lang&#305;�l&#305; ve &#351;iddetli (�patlay&#305;c&#305;�) bir
ba&#351; a&#287;r&#305;s&#305;d&#305;r. <i>Post�ral tip</i> ise koitus
sonras&#305;nda d�&#351;�k BOS bas&#305;nc&#305; ba&#351;
a&#287;r&#305;s&#305;n&#305; and&#305;ran bir post�ral ba&#351;
a&#287;r&#305;s&#305;d&#305;r. Kafai�i bozukluk olmaks&#305;z&#305;n cinsel
etkinlik ile tetiklenen ba&#351;a&#287;r&#305;s&#305;, genellikle cinsel
uyar&#305;lma ile k�nt iki yanl&#305; a&#287;r&#305; olarak ba&#351;lar ve
orgazm s&#305;ras&#305;nda aniden yo&#287;un hale gelir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Yeni g�nl�k s�re&#287;en
ba&#351;a&#287;r&#305;s&#305;:</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> Gerilim tipi ba&#351;a&#287;r&#305;s&#305; ile
pek �ok benzerli&#287;i olmas&#305;na kar&#351;&#305;n yeni
s&#305;n&#305;flamada farkl&#305; tan&#305;mlanm&#305;&#351;t&#305;r. G�nl�k
s&#305;kl&#305;kta ortaya �&#305;kmas&#305; ve daha �nce
ba&#351;a&#287;r&#305;s&#305; �yk�s� olmayan ki&#351;ilerde
ba&#351;lang&#305;�tan (ya da hemen hemen ba&#351;lang&#305;�tan) itibaren hi�
ataks&#305;z olmas&#305; �zelli&#287;i ile benzeri olmayan bir tablodur.
D�&#351;�k BOS hacmi ba&#351;a&#287;r&#305;s&#305;, y�ksek BOS
bas&#305;nc&#305; ba&#351;a&#287;r&#305;s&#305;, posttravmatik
ba&#351;a&#287;r&#305;s&#305;, infeksiyonlara ba&#287;l&#305; (�zellikle viral)
ba&#351;a&#287;r&#305;s&#305; ve ila� a&#351;&#305;r&#305; kullan&#305;m
ba&#351;a&#287;r&#305;s&#305; gibi ikincil ba&#351;a&#287;r&#305;lar&#305;
uygun ara&#351;t&#305;rma y�ntemleri ile d&#305;&#351;lanmal&#305;d&#305;r.
Tipik olarak aylar i�inde tedavisiz d�zelen kendini s&#305;n&#305;rlayan bir
formu ve yo&#287;un tedavi program&#305;na ra&#287;men devam eden diren�li
&#351;ekli vard&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Atipik y�z
a&#287;r&#305;s&#305;:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Muayenede ve incelemelerde bir bulgu saptanmayan
devaml&#305; idyopatik y�z a&#287;r&#305;s&#305;d&#305;r. Derin veya y�zeyel,
genelde tek yanl&#305; periferik n�roanatomik s&#305;n&#305;rlara uymayan,
yay&#305;lan ve hafif subjektif duyusal yak&#305;nmalar&#305;n eklendi&#287;i
ve iyi anla&#351;&#305;lmam&#305;&#351; bir durumdur. Altta yatan bir n�ropatik
durum oldu&#287;u, hafif hasarlar&#305;n tetikledi&#287;i uzun s�reli
n�roplastik de&#287;i&#351;iklikler ve deaferantasyona ba&#287;l&#305;
oldu&#287;u d�&#351;�n�lmektedir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kranyal Akut Nevraljiler:</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> Ba&#351; ve boyun a&#287;r&#305;s&#305;
trigeminal, intermedial, glossofaringeal, vagal, oksipital sinirler
arac&#305;l&#305;&#287;&#305; ile ve �st servikal k�klerin afferent lifleri
taraf&#305;ndan ta&#351;&#305;n&#305;r. Bu sinirlerin bas&#305;ya, distorsiyona,
so&#287;uk veya di&#287;er zararl&#305; uyar&#305;lara maruz kalmas&#305; veya
santral yollarda ortaya �&#305;kan bir lezyonla uyar&#305;lmas&#305; sonucunda
semptomatik olarak ya da s&#305;k olarak da idyopatik olarak ilgili sinirin
innerve etti&#287;i alanda akut saplan&#305;c&#305; veya sabit bir
a&#287;r&#305; ortaya �&#305;kar. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>En s&#305;k g�r�len <i>trigeminal nevralji </i>iyi tan&#305;nan bir
tablodur ve ay&#305;r&#305;c&#305; tan&#305;da genelde problem yaratmaz.
Trigeminal nevralji tek tarafl&#305;, k&#305;sa &#351;im&#351;ekvari
a&#287;r&#305;lar ile karakterize, ani ba&#351;lay&#305;p ani sonlanan ve
trigeminal sinirin ikinci veya ���nc� dal&#305;n&#305;n da&#287;&#305;l&#305;m
alan&#305; ile s&#305;n&#305;rl&#305; (birinci dalda %5) bir durumdur.
A&#287;r&#305; genelde y�z y&#305;kama, tra&#351; olma, sigara i�me,
konu&#351;ma ve/veya di&#351; f&#305;r�alama (tetik fakt�rler) gibi uyaranlarla
ortaya �&#305;kabildi&#287;i gibi, s&#305;kl&#305;kla spontan da olabilir.
Nazolabial oluk ve/veya �enedeki k���k alanlar (tetik alanlar&#305;)
a&#287;r&#305;n&#305;n tetiklenmesine e&#287;ilimli b�lgelerdir. Tetik
noktalar&#305;n&#305;n daha �ok idyopatik tipte oldu&#287;u
d�&#351;�n�lmektedir. A&#287;r&#305;lar de&#287;i&#351;ik d�nemler boyunca
durabilir. Bazen zeminde k�nt bir a&#287;r&#305; devam edebilir. Nevraljiler
idyopatik veya nadiren semptomatik&nbsp; (herpes zoster infeksiyonu veya MRG
ile g�sterilmi&#351; yap&#305;sal bir lezyon g�r�lmesi &#351;eklinde) olabilir.
Giderek artan g�r�nt�leme incelemeleri sonucunda bu tabloda y�ksek oranda
trigeminal sinir k�k�n�n geni&#351; ve k&#305;vr&#305;ml&#305; damarlar taraf&#305;ndan
bas&#305;ya u&#287;rad&#305;&#287;&#305; g�sterilmi&#351;tir. Olgularda ince
kesitli bir MRG incelemesi mutlaka yap&#305;lmal&#305;d&#305;r. A&#287;r&#305;
asla kar&#351;&#305;ya ge�mez, bilateral g�r�ld�&#287;�nde multipl skleroz gibi
bir tablodan ku&#351;kulan&#305;lmal&#305;d&#305;r. A&#287;r&#305;
s&#305;ras&#305;nda o taraf y�z kaslar&#305;nda spazm geli&#351;ebilir
(a&#287;r&#305;l&#305; tik). Di&#287;er s�z� edilen sinir alanlar&#305;na ait
nevraljiler de tan&#305;mlanm&#305;&#351;t&#305;r ama �ok seyrektir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tedavide analjezikler etkisizdir, alt&#305;n standart olarak kabul g�ren
karbamazepin (200-1200 mg yava&#351;�a yan&#305;t al&#305;nana dek titre
edilerek ve l�kosit, elektrolit ile transaminazlar izlenerek) veya benzer
etkide oldu&#287;u bildirilen okskarbazepin ilk se�enek ila�lard&#305;r.
Gabapentin, pregabalin gibi di&#287;er baz&#305; epilepsi ila�lar&#305; da
yan&#305;ts&#305;z olgularda veya yan etki varl&#305;&#287;&#305;nda ek olarak
kullan&#305;l&#305;r. Tedavi baz&#305; hastalarda d�&#351;�k dozlarla da
sa&#287;lanabilece&#287;i i�in d�&#351;�k dozla ba&#351;lan&#305;p klinik
duruma g�re yan etkiler a�&#305;s&#305;ndan takip edilerek
artt&#305;r&#305;lmal&#305;d&#305;r. �ok az say&#305;da diren�li olguda sinirin
s&#305;k&#305;&#351;t&#305;&#287;&#305; b�lgeyi rahatlatmaya y�nelik cerrahi
giri&#351;im yap&#305;labilir. </span><span class=MsoCommentReference><span
lang=TR style='font-size:8.0pt;font-family:Tahoma;display:none;mso-hide:all;
mso-ansi-language:TR'>&nbsp;</span></span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tolosa-Hunt sendromu: </span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>���nc�, d�rd�nc�, ve/veya alt&#305;nc&#305; kranyal
sinirlerin paralizisi ile giden, genellikle kendili&#287;inden d�zelen, ancak
alevlenme ve yat&#305;&#351;ma e&#287;ilimleri sergileyen epizodik bir
tablodur. Bazen trigeminal birinci dal ve optik, fasyal veya akustik sinir tutulumu
da eklenebilir. Tedavi edilmezse haftalarca devam eden tek yanl&#305; orbital
a&#287;r&#305; s�z konusudur. Bu sendromda kavern�z sin�s, superior orbital
fiss�r ve/veya orbitada MR (kontrast verilmesi genellikle gerekmektedir) ve
biyopsi ile gran�lomat�z bir lezyonun varl&#305;&#287;&#305; g�sterilebilir.
Kortikosterodilerle genellikle 3 g�n i�inde d�zelme g�zlenir. Di&#287;er
a&#287;r&#305;l&#305; oftalmopleji nedenleri �rne&#287;in t�m�rler, vask�lit,
bazal menenjit, sarkoidoz, diyabet ve oftalmoplejik migren uygun y�ntemlerle
d&#305;&#351;lanmal&#305;d&#305;r</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Oftalmoplejik migren</span></i></b><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>:</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Eskiden migren diye gruplan&#305;rken art&#305;k kranyal
n�ropatilerin aras&#305;na al&#305;nm&#305;&#351;t&#305;r. Ok�ler sinirlerin
genellikle 3. sinirin tutulumunun e&#351;lik etti&#287;i, MRG�de sinirde
de&#287;i&#351;iklikler d&#305;&#351;&#305;nda neden g�sterilemeyen
tekrarlay&#305;c&#305;, migren benzeri ba&#351;a&#287;r&#305;lar&#305;n&#305;n
oldu&#287;u bir tablodur ve olduk�a nadirdir. MRG�de sinirde kontrast tutulumu
olmas&#305; nedeniyle demiyelinizan bir n�ropati olarak kabul edilmektedir.
Migren tipi a&#287;r&#305; 1 hafta veya daha uzun s�rer.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BAZI SEKONDER BA&#350;A&#286;RILARI</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Hipertansif Ensefalopati</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Akut hipertansiyon da akut ba&#351;a&#287;r&#305;s&#305;nda �ok �nemli bir
ay&#305;r&#305;c&#305; tan&#305; olas&#305;l&#305;&#287;&#305;d&#305;r. MRG�ye
dek bir�ok ileri inceleme ve �ok say&#305;da tedavi uygulamas&#305; ile kontrol
edilemeyen bir ba&#351;a&#287;r&#305;s&#305;n&#305;n nedeni hipertansiyon olabilir,
bu nedenle her hastada mutlaka arteryel tansiyon �l��lmelidir. G�z dibi bozuklu&#287;u,
n�betler, mental de&#287;i&#351;iklik tabloya e&#351;lik edebilir. Yeni
ba&#351;layan hipertansiyon veya malign hipertansiyonun dekompansasyonlar&#305;
bu tabloya neden olabilir. Ancak hipertansiyonun tan&#305;s&#305; konmu&#351;
ve tedavisi d�zenlenmi&#351; oldu&#287;u durumlarda
ba&#351;a&#287;r&#305;s&#305;n&#305; hipertansiyona ba&#287;lamak
yanl&#305;&#351; bir yakla&#351;&#305;md&#305;r</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<h2 style='page-break-after:auto;text-autospace:none'><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></h2>

<h2 style='page-break-after:auto;text-autospace:none'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;s&#305;
gerek artm&#305;&#351; gerekse azalm&#305;&#351; kafa i�i
bas&#305;nc&#305;n&#305;n s&#305;k g�r�len bir klinik belirtisidir</span></i><span
lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>
(Bak&#305;n&#305;z: <u><span style='color:blue'>Kafa i�i bas&#305;n�
de&#287;i&#351;iklikleri</span></u>).</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></h2>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Akut Sin�zit</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Seyrek g�r�len bir ba&#351;a&#287;r&#305;s&#305; nedeni olan akut sin�zit genellikle
nazal yollarda p�r�lan ak&#305;nt&#305; ve infeksiyon b�lgesine g�re
de&#287;i&#351;en bir a&#287;r&#305; profili ile karakterizedir. <i>Sin�sler
�zerindeki a&#287;r&#305;n&#305;n mutlaka sin�zite ba&#287;l&#305; olmas&#305;
gerekti&#287;i &#351;eklindeki yanl&#305;&#351; inan� nedeni ile
ba&#351;a&#287;r&#305;s&#305; nedeni olarak sin�zit tan&#305;s&#305; a&#351;&#305;r&#305;
s&#305;k konmaktad&#305;r.</i> Asl&#305;nda frontal ba&#351;
a&#287;r&#305;s&#305; en s&#305;k migren ve gerilim tipi ba&#351;
a&#287;r&#305;s&#305; nedeniyle g�r�l�r. Burun
t&#305;kan&#305;kl&#305;&#287;&#305;n&#305;n ba&#351; a&#287;r&#305;s&#305;na
yol a�&#305;p a�mad&#305;&#287;&#305; da tart&#305;&#351;mal&#305; bir konudur.
Sfenoid sin�zit hem klinik �zellikler hem tedavi a�&#305;s&#305;ndan
farkl&#305;l&#305;klar g�sterir ve s&#305;k atlan&#305;r. B�t�n sin�zit
olgular&#305;n&#305;n sadece %3��n� olu&#351;turmas&#305;na kar&#351;&#305;n,
ya&#351;am&#305; tehdit edebilen bir durum olmas&#305; nedeniyle �nem
ta&#351;&#305;maktad&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Temporal Arterit </span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Di&#287;er ad&#305;yla <i>dev h�creli arterit, </i>&nbsp;ba&#351;l&#305;ca
orta boy arterleri etkileyen bir sistemik vask�littir. Belirti ve
bulgular&#305; aras&#305;nda ba&#351;a&#287;r&#305;s&#305;
d&#305;&#351;&#305;nda, g�rme kayb&#305;, halsizlik, kilo kayb&#305; ve
miyaljiler yer al&#305;r. 50 ya&#351;&#305;ndan �nce g�r�lmesi �ok nadirdir,
kad&#305;nlarda erkeklere g�re �� kat daha s&#305;k g�r�l�r.<sup> </sup>Yeni
ortaya �&#305;kan ba&#351;a&#287;r&#305;s&#305; bulunan veya
ba&#351;a&#287;r&#305;s&#305; paterninde belirgin bir de&#287;i&#351;iklik
tan&#305;mlayan ya&#351;l&#305; bir hastada mutlaka bu tan&#305; akla
gelmelidir. En belirgin bulgusu olan ba&#351;a&#287;r&#305;s&#305;, olgular&#305;n
%70-90�&#305;nda mevcuttur ve ��te birinde de ilk belirtidir.
Aral&#305;kl&#305; veya s�rekli olabilir; tipik olarak &#351;akaklarda
lokalize, zonklay&#305;c&#305; bir a&#287;r&#305;d&#305;r. S&#305;kl&#305;kla
beraberinde kafa derisi hassasiyeti ve tutulan damarlar&#305;n �zerinde cilt
hassasiyeti bulunur. Kas a&#287;r&#305;s&#305; ve eklem kat&#305;l&#305;&#287;&#305;
gibi belirtileri olan �<i>polimiyalji romatika�</i> ate&#351;, kilo kayb&#305;,
gece terlemeleri, �ene (masseter) klodikasyosu (�zellikle �i&#287;nerken),
amorozis fugaks (hastalar&#305;n yar&#305;s&#305;nda iki yanl&#305; olabilir),
kal&#305;c&#305; k�rl�k (s&#305;kl&#305;kla herhangi bir uyar&#305;
olmaks&#305;z&#305;n) veya k&#305;smi g�rme kayb&#305; (s&#305;kl&#305;kla
anterior iskemik optik n�ropatiye ba&#287;l&#305; olarak) g�r�lebilir. Diplopi
ve kranyal sinir felci nadir g�r�l�r. Ayr&#305;ca seyrinde koroner, mezenterik,
hepatik ve renal arter iskemisi, aort r�pt�r�, inme ve ge�ici iskemik ataklar
(G&#304;A) da g�r�lebilir. En tutarl&#305; laboratuvar bulgusu eritrosit
sedimentasyon h&#305;z&#305;ndaki art&#305;&#351;t&#305;r. Bunun
d&#305;&#351;&#305;nda, C-reaktif protein art&#305;&#351;&#305; ve
karaci&#287;er enzimlerinde hafif bir y�kselme ile hafif bir anemi de s&#305;k
g�r�l�r. �ok nadiren eritrosit sedimentasyon h&#305;z&#305; normal bulunabilir.
Baz&#305; olgularda, ba&#351;lang&#305;�ta normal olan eritrosit sedimentasyon
h&#305;z&#305;n&#305;n daha sonra y�kselmesi, hastal&#305;k progresyonu ile
ili&#351;kili bulunmu&#351;tur.<sup> </sup>Aspirin, NSA&#304; veya sistemik
steroid kullanan hastalarda eritrosit sedimentasyon h&#305;z&#305; d�&#351;erek
yalanc&#305; negatif sonu� verebilir. Temporal arter biyopsisi tan&#305;da alt&#305;n
standartt&#305;r ve m�mk�nse steroid tedavisinin ba&#351;lanmas&#305;ndan sonra
en ge� 48 saat i�inde yap&#305;lmal&#305;d&#305;r. Biyopside klinik olarak
etkilenmi&#351; (hassasiyet, endurasyon veya nab&#305;z
zay&#305;fl&#305;&#287;&#305; bulunan) bir arter se�ilir. Biyopsi negatifse
(hastal&#305;k yama tarz&#305; lezyonlar olu&#351;turdu&#287;u i�in bu
m�mk�nd�r), pozitiflik oran&#305;n&#305; artt&#305;rmak i�in birden fazla kesit
incelenmelidir. Biyopsi negatifse ve tan&#305; olas&#305;l&#305;&#287;&#305;
y�ksekse, di&#287;er temporal arterden tekrarlanmal&#305;d&#305;r. Bazen teknik
nedenlerle biyopsi tekrar&#305; da negatif kalabilir, klinik &#351;�phe netse
ve sedimentasyon y�ksekse temporal arterit tan&#305;s&#305;ndan
vazge�ilmemelidir. Tipik bulgular ve eritrosit sedimentasyon h&#305;z&#305;nda
art&#305;&#351; g�r�len bir hastada, temporal arter biyopsi sonucu beklenirken
hemen tedaviye ba&#351;lanmal&#305;d&#305;r. Tedavinin ba&#351;l&#305;ca hedefi
ani geli&#351;en ve geri d�n�&#351;�ms�z g�rme kayb&#305;n&#305;n �nlenmesidir.
Ba&#351;lang&#305;�taki prednizon dozu g�nl�k 60-80 mg�d&#305;r; baz&#305;
uzmanlar ilk dozlar&#305; intraven�z yolla vermeyi tercih etmektedir. E&#287;er
hasta akut bir n�rolojik sendromla veya h&#305;zla k�t�le&#351;en bir n�rolojik
tabloyla ba&#351;vurmu&#351;sa, intraven�z pulse steroid (1000 mg/g�n) ile veya
�ok y�ksek doz oral steroidle (120 mg/g�n prednizon) tedaviye
ba&#351;lanmal&#305;d&#305;r.<sup> </sup>Ba&#351;a&#287;r&#305;s&#305; ve
sistemik belirtiler tipik olarak steroid ba&#351;land&#305;ktan k&#305;sa bir
s�re sonra d�zelme g�sterir. Hasta belirtilerin kontrol� i�in en az 6 ay-1
y&#305;l s�re ile bir idame dozu almal&#305;d&#305;r. Eldeki
s&#305;n&#305;rl&#305; veriler, steroidlerin d&#305;&#351;&#305;nda en
tutarl&#305; bi�imde etkili immunsupresif ilac&#305;n siklofosfamid oldu&#287;unu
ve bir relaps sonras&#305;nda verildi&#287;inde steroidin daha h&#305;zl&#305;
azalt&#305;larak kesilebilmesini sa&#287;layabildi&#287;ini
d�&#351;�nd�rmektedir. Ayr&#305;ca azotiopurin kullan&#305;m&#305;n&#305; da
savunan klinisyenler vard&#305;r.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:200%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<b><span lang=TR style='font-size:12.0pt;line-height:200%;font-family:Tahoma;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:TR;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:200%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 6: Akut &#351;iddetli
ba&#351;a&#287;r&#305;s&#305;nda ay&#305;r&#305;c&#305; tan&#305; listesi </span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Subaraknoidal kanama </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Di&#287;er kanay&#305;c&#305; serebrovask�ler
hastal&#305;klar </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
9.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>subdural</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
9.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>ekstradural</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=TR style='font-size:
9.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>intraserebral
hematom</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Serebral ven�z sin�s trombozu (Beh�et
Hastal&#305;&#287;&#305; veya di&#287;er etyolojilere ba&#287;l&#305;)</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kafa travmas&#305; sonras&#305; �e&#351;itli sekonder
nedenler</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ge�ici iskemik atak ve inmede ek bir semptom olarak</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Hipofizer apopleksi</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Spontan intrakranyal hipotansiyon</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&#304;ntermittan hidrosefali</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Arnold-Chiari malformasyonu</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&#304;dyopatik intrakranyal hipertansiyon</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Hipertansif ensefalopati</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Servikosefalik arteryel disseksiyon</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>MSS ve di&#287;er akut infeksiyonlar</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
menengoensefalit (bakteryel, viral, fungal)</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
serebral abse</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Optik n�rit, akut glokom gibi g�z hastal&#305;klar&#305;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Temporal arterit ve di&#287;er vask�litler</span><span
lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Feokromasitoma</span><span lang=DA style='mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tiroid hastal&#305;klar&#305;</span><span lang=DA
style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Hiperkarbi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Preeklampsi</span><span lang=DA style='mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Yer kaplay&#305;c&#305; lezyonlar </span><span lang=DA
style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&#304;ntoksikasyon (�rne&#287;in karbonmonoksid)</span><span
lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&#304;la� k�t�ye kullan&#305;m&#305;</span><span lang=DA
style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&#304;dyopatik g�kg�r�lt�s� ba&#351;a&#287;r&#305;s&#305;</span><span
lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>K�me ba&#351;a&#287;r&#305;s&#305; ve benzer tablolar</span><span
lang=DA style='mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut migren</span><span lang=DA style='mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Benin efor, �ks�r�k ve orgazm
ba&#351;a&#287;r&#305;s&#305;</span><span lang=DA style='mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut sin�zit ve dental infeksiyonlar</span></p>

</div>

<h2 style='page-break-after:auto;text-autospace:none'><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></h2>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>KAYNAKLAR</span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;s&#305;
     s&#305;n&#305;flama komitesi. Ba&#351;a&#287;r&#305;s&#305; bozukluklar&#305;n&#305;n
     uluslararas&#305; s&#305;n&#305;flamas&#305; 2. Bas&#305;m. T�rk N�roloji
     Derne&#287;i yay&#305;nlar&#305;; 2005 say&#305;:2 Denizli</span></li>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Baykan B, Ertas M,
     Karli N, Akat-Aktas S, Uzunkaya O, Zarifoglu M, Siva A,Saip S;
     MIRA-Neurology Study Group. The burden of headache in neurology outpatient
     clinics in Turkey. Pain Pract 2007; 7:313-23.</span></li>
 <li class=MsoNormal style='color:black;mso-list:l4 level1 lfo6;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;color:windowtext;
     mso-ansi-language:TR'>Ducros A, Tournier-Lasserve E, Bousser MG. The
     genetics of migraine. <i>Lancet Neurol </i>2002;1: 285-93.</span><o:p></o:p></li>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Erta&#351; M,
     Baykan B. Ba&#351;a&#287;r&#305;lar&#305;na yakla&#351;&#305;m ve Akut
     Ba&#351;a&#287;r&#305;lar&#305;. Ekspres Bask&#305;, &#304;stanbul 2007.</span></li>
 <li class=MsoNormal style='color:black;mso-list:l4 level1 lfo6;tab-stops:list 36.0pt;
     text-autospace:none'><span lang=TR style='font-family:Tahoma;color:windowtext;
     mso-ansi-language:TR'>Evans RW, Mathew NT. Handbook of Headache.
     &#304;kinci Bask&#305;; Lippincott Williams Wilkins, Philadelphia 2005. </span><o:p></o:p></li>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Headache
     classification committee of the IHS. Classification and diagnostic
     criteria for pain disorders, cranial neuralgias and facial pain.
     Cephalagia 1988; Sup. 7:&nbsp; 1-96 </span></li>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Headache
     classification committee of the International Headache Society.
     Classification of the headache disorders 2.edition. Cephalagia 2004; 24;
     Sup.1:&nbsp; 1-156</span></li>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>M.Sandler,
     G.M.Collins (Ed): Ara&#351;t&#305;rmalar I&#351;&#305;&#287;&#305;nda
     Migren. �evirenler: H.A.&#304;driso&#287;lu, R.T&#305;naz. Bilimsel ve
     Teknik �eviri Vakf&#305;. &#304;stanbul, 1993.</span></li>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Olesen J,
     Tfelt-Hensen P, Welch KMA: The Headache. Raven Press, New York. 1993; pp:
     255-403. </span></li>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>S.D.Silberstein,
     J.R. Saper, F.G.Freitay (Eds),&nbsp; Wolff�s Headache and other head pain.
     Oxford University Press, New York, Toronto, 2001; pp: 121-237. </span></li>
 <li class=MsoNormal style='mso-list:l4 level1 lfo6;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Silberstein SD,
     Lipton RB, Goadsby P. Edit�rler T�rk�e �eviri: Erta&#351; M, Akman-Demir
     G. Klinik Uygulamada Ba&#351;a&#287;r&#305;s&#305; &#304;kinci Bask&#305;,
     Yelkovan yay&#305;nc&#305;l&#305;k, &#304;stanbul, 2004.</span></li>
</ol>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Te&#351;ekk�r:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Prof Dr Mustafa Erta&#351;�a katk&#305;lar&#305;ndan
dolay&#305; te&#351;ekk�r ederiz.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

</div>

</body>

</html>
